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Abstract
Changes in the lipid metabolism are known to mediate several diseases (e.g. atheroscle-
rosis, coronary artery disease). The potential of lipidomics is increasingly recognized as
clinical tool to assess pathomechanisms and biomarkers for several of these diseases.
The purpose of this study was first, to evaluate canine lipoprotein separation and
second, to characterize the canine lipidome using an untargeted lipidomic approach.
After ultracentrifugation or precipitation of plasma and serum, fractions were ana-
lyzed by SDS–PAGES, indicating associated apoproteins. No accurate separation of the
different lipoproteins was possible.
Lipidome analysis revealed a total amount of 561 different lipids from eight of eight
categories in plasma and serum; 246 of them were identified in both matrices. The relative
mean abundance was different in 11/246 lipids between the two matrices. Prednisolone
treatment induced a significant increase of seven and a significant decrease of three lipids
in plasma and a significant increase of two and a significant decrease of one lipid in the
serum.
In conclusion, complete lipoprotein separation is still not possible in dogs, presumably
due to their overlapping densities. Untargeted lipidomic analysis revealed marginal differ-
ences between lipids found in both, serum and plasma. Prednisolone treatment induced
significant changes in the plasma lipidome, which should be evaluated in further studies.
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Zusammenfassung
Vera¨nderungen im Lipidmetabolismus spielen bei verschiedenen Erkrankungen eine Rolle
(z.B. Atherosklerose, Herzkranzgefa¨sserkrankungen). Untersuchungen des gesamten Lipi-
doms gewinnen daher zunehmend an Bedeutung, da damit die Pathomechanismen dieser
Erkrankungen untersucht und neue Biomarker erforscht werden ko¨nnen.
Das Ziel dieser Studie war es, die Lipoproteine beim Hund zu separieren und das
canine Lipidom mittels einer ungerichteten Lipidomanalyse zu untersuchen.
Nach Ultrazentrifugation oder Pra¨zipitation von Plasma und Serum, wurden alle ge-
wonnenen Fraktionen mit SDS–PAGES auf zugeho¨rige Apoproteine untersucht. Eine ex-
akte Auftrennung der Lipoproteine war nicht mo¨glich. Bei der Lipidomanalyse wurden
561 Lipide aus acht von acht Lipidkategorien nachgewiesen. In beiden Materialien wur-
den 246 Lipide identifiziert, wovon bei elf ein signifikanter Unterschied in der mittleren,
relativen Menge zwischen den zwei Medien bestand. Die Prednisolonbehandlung fu¨hrte
im Plasma zu einem signifikanten Anstieg von sieben, im Serum von zwei Lipiden und im
Plasma zu einem signifikanten Abfall von drei, im Serum von einem Lipid.
Eine exakte Auftrennung der Lipoproteine beim Hund war, vermutlich wegen Dich-
teu¨berlappungen, nicht mo¨glich. Die ungerichtete Lipidomanalyse ergab lediglich gering-
fu¨gige Unterschiede zwischen Plasma und Serum. Die Prednisolonbehandlung fu¨hrte zu
signifikanten Vera¨nderungen einiger Lipide, die in weiteren Studien genauer untersucht
werden sollten.
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Chapter1
Introduction
1.1 Canine Lipoproteins and Lipid Metabolism
Lipids, including triglycerides and cholesterols, are essential for a normal physiological
function of the organism. Triglycerides are the most common and efficient source of chem-
ical energy, while cholesterol, the main sterol in animal tissue, is a structural component
of cell membranes and an essential precursor in steroid hormone and bile acid synthesis
(Camus et al., 2011; Xenoulis and Steiner, 2010). Because of their water–insolubility,
transportation of lipids through plasma to their sites of utilization is provided by lipopro-
teins (LPs). LPs are composed of a surface coat, containing phospholipids, free cholesterol
and apoproteins (apos), surrounding a hydrophobic lipid center containing triglycerides
(TGs) and cholesteryl esters (CEs), Fig. 1.1. The apoproteins, also called apolipopro-
teins, are specific proteins which direct the lipoproteins to their sites of metabolism and
act as cofactors in enzymatic reactions (Camus et al., 2011; Bauer, 2004).
1.1.1 Canine Lipoproteins
There are four discrete populations of canine lipoproteins, classified on the basis of their
size, density, lipid and apoprotein content, and electrophoretic mobility, with lipoproteins
being larger and less dense if the fat to protein ratio is increased. Each lipoprotein
species has specific functions. The classes recognized in the dog are: chylomicrons (CMs),
very low density lipoproteins (VLDLs), low density lipoproteins (LDLs) and high density
lipoproteins (HDLs), which is a heterogeneous group of lipoproteins, displaying several
subfractions such as HDL1, HDL2 and HDL3 as the most important ones (Camus et al.,
2011).
CMs and VLDLs predominantly transport triglycerides, LDLs while HDLs predom-
inantly transport cholesterol (Camus et al., 2011). As an exception, non–esterified free
fatty acids form complexes with albumin in the circulation and do not require incorpora-
tion into lipoproteins for transportation (Johnson, 2005).
In contrast to humans, whose LDLs are the major lipoproteins and cholesterol carriers,
the dog is a species with very few LDLs and predominantly HDLs. Hence, the majority of
7
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Figure 1.1: Lipoprotein model
circulating cholesterol is carried by HDLs as well, with HDL2 being the main cholesterol
carrier in dogs (Mahley and Weisgraber, 1974). Canine HDL and LDL contribute with
nearly 87% and 11%, respectively, to the total cholesterol concentration of plasma in dogs
(Maldonado et al., 2001). In addition to the higher percentage of HDL in canine blood,
LDLs have a higher content of triglycerides than has been reported for the LDL class in
humans (Mahley and Weisgraber, 1974).
There is no general consensus on the exact lipoprotein classes in dogs regarding size,
density ranges and major apoproteins. The most popular canine lipoprotein studies are
those of Mahley and Weisgraber (1974), Bauer (2004) and Xenoulis and Steiner (2010)
as described in table 1.1.
CMs are similar to human CMs, consisting mainly of dietary triglycerides (TGs),
75–1200 nm in size, with a density of <0.96 g/mL and tending to be at the origin of
electrophoretic mobility. Apoprotein (apo) B–48 functions as the major apoprotein for
CMs (Mahley and Weisgraber, 1974).
VLDLs consist primarily of endogenous triglycerides, measure 30–80 nm in size, pos-
sess a density of 0.093–1.006 g/mL and a pre–β electrophoretic mobility. Their major
apoproteins are B–48 and B–100, but apo E and C were found as minor apoproteins in
the dog as well (Mahley and Weisgraber, 1974).
LDLs contain phospholipids and cholesteryl esters, are 18–25 nm in size, have a density
of 1.019–1.087 g/mL, show β mobility on electrophoresis and have B–48 as well as B–100
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Table 1.1: Characteristics of lipoproteins in dogs (Bauer, 2004; Xenoulis and Steiner, 2010).
Lipoprotein Main Consistency Size
(nm)
Hydrated
Density
(g/mL)
Electro–
phoretic
Mobility
Major
Apopro–
teins
Chylomicrons Dietary
Triglycerides
75–1200 <0.96 Origin B–48, (C)
VLDL Endogenous
Triglycerides
30–80 0.093–1.006 Pre–β B–100, B–48,
E, C
LDL Phospholipids,
Cholesteryl esters
18–25 1.019–1087 β B–100, B–48
HDL1 Phospholipids,
Cholesteryl esters
10–35 1.025–1.100 α2 E, A, C
HDL2 Phospholipids 9–12 1.063–1.100 α1 E, A, C
HDL3 Phospholipids 5–9 1.100–1.210 α1 A, C
as major apoproteins (Mahley and Weisgraber, 1974).
The last lipoprotein fraction, HDLs, is divided into three subfractions in dogs, whereas
in humans up to 14 subfractions are known. Canine HDL1 is a unique canine lipoprotein,
unlike any of the commonly described lipoproteins in humans, containing phospholipids
and nearly as much cholesterol as the LDL class. With 10–35 nm, they overlap in size
with LDLs. Further they possess a density range of 1.025–1.100 g/mL, also overlapping
with LDLs, and an α2 electrophoretic mobility. Major apoproteins are apo E, A and
C (Maldonado et al., 2002). The canine HDL2 consists mainly of phospholipids but also
carries most of the total plasma cholesterol, is 9–12 nm in size, has a density range of 1.063–
1.100 g/mL, an α1 mobility on electrophoresis and apo E, A and C as major apoproteins.
Finally, the canine HDL3 consists mainly of phospholipids as well, measures 5–9 nm in
size and has also the highest density range with 1.100–1.210g/mL, an α1 mobility on
electrophoresis and apo A and C as major apoproteins (Mahley and Weisgraber, 1974).
Several apoproteins can further be divided into subfractions, such as apo A–I, apo A–II
and so on, similar to apo B–48 or apo B–100.
1.1.2 Canine Lipid Metabolism
Canine lipoproteins are formed either during exogenous or endogenous lipid metabolism;
both mechanisms are graphically illustrated in figure 1.2.
Exogenous Lipid Metabolism
The exogenous lipid metabolism consists mainly of CMs, which are formed of triglycerides
absorbed from the small intestine in combination with a small amount of cholesterol, phos-
pholipids and apo B–48. Afterwards CMs enter the intestinal lacteal and are transferred
through the lymphatic system into the blood circulation (Camus et al., 2011; Mooney
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et al., 2004). Therefore, CMs may be detected in the blood if samples are taken post-
prandially. During transport through circulation, CMs acquire several other apoproteins,
such as apo Cs and apo E from interaction with HDLs. (Bauer, 2004) Apo C–II acts
as a co–factor to activate the enzyme lipoprotein lipase (LPL), which is attached to tis-
sue endothelium such as the capillary beds of adipose and skeletal muscle tissue. LPL
hydrolyzes TGs in the core of CMs into free fatty acids (FFA), mono– and diglycerides,
and glycerol. FFAs become re–esterified within the tissue into TGs for storage, which are
the main energy source for cells (Camus et al., 2011; Xenoulis and Steiner, 2010). After
activation of LPL, the remaining chylomicron remnants are relatively deficient in TGs
and enriched in cholesteryl ester (Mooney et al., 2004). CM remnants return their apo
C–II to HDLs and are then removed from circulation by uptake into the liver through
their remaining apo E (Bauer, 2004; Xenoulis and Steiner, 2010).
The activity of LPL can be modified not only by apoproteins, but also by a variety
of hormones, including insulin, glucagon and catecholamines. Hence, the activity of LPL
of the adipose tissue correlates positively with plasma insulin concentrations, ensuring
delivery of fatty acids to the adipose tissue during the postprandial period (Camus et al.,
2011).
Endogenous Lipid Metabolism
The endogenous lipid metabolism involves VLDLs, LDLs and HDLs. VLDLs and HDLs
are synthesized continuously in the liver, with secretion being influenced by nutritional
and metabolic changes, whereas LDLs are formed by transformation of VLDLs (Camus
et al., 2011).
VLDLs are large macromolecules, although smaller than CMs, containing predom-
inantly triglycerides (TGs) and in lesser amounts cholesterol, cholesteryl ester (CEs),
phospholipids and apo B–100 as well as apo B–48 (Bauer, 2004). Most of the parts used
for formation of VLDLs in the liver are either synthesized by the liver itself or redistributed
after hepatic uptake of other lipoproteins (Mooney et al., 2004).
Upon entering the circulation, the metabolism of VLDLs resembles that of CMs. They
acquire apo C and apo E from HDLs, with apo C–II activating the LPL, starting hy-
drolyzation of TGs identically to the metabolism of CMs (Xenoulis and Steiner, 2010).
The resulting remnants of VLDLs are then also relatively deficient in TGs and enriched
in CEs and can be removed from the circulation by hepatic uptake or they may be further
modified to LDLs by hepatic lipase (HL), an enzyme bound to the hepatic endothelium
(Mooney et al., 2004).
LDLs contain mainly cholesteryl esters (CEs), phospholipids and apo B–100, circulate
in the blood and bind to specific receptors in order to deliver cholesterol to the peripheral
tissues for further usage, such as synthesis of steroid hormones and cell membranes (Bauer,
1996).
In so–called reverse cholesterol transport, HDLs are responsible for the transport of
cholesterol from peripheral tissues back to the liver. HDLs are primarily synthesized
in the liver and intestines in the form of dense disc–shaped particles, so–called HDL3,
containing mainly phospholipids and apo A–I (Camus et al., 2011). These HDL3 particles
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Figure 1.2: Canine lipid metabolism. LPL = lipoprotein lipase; FFA = free fatty acids; VLDL
= very low density lipoproteins; HL = hepatic lipase; LDL = low density lipoproteins; CHOL =
cholesterol; HDL = high density lipoproteins, LCAT = lecithin cholesterol acyltransferase.
draw cholesterol from peripheral tissue onto their surface, where free cholesterol is then
continuously esterified into cholesteryl ester (CE) by the action of lecithin cholesterol
acyltransferase (LCAT), activated by apo A–I (Mooney et al., 2004; Xenoulis and Steiner,
2010; Bauer, 2004). CEs move consecutively into the core of HDL3, resulting in the
formation of larger HDL2 particles, allowing even more free cholesterol to be absorbed
onto their surface. The final particles formed through the drawing of cholesterol and
activity of LCAT are HDL1, which are unique cholesteryl ester–rich particles. Finally,
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CEs in the core of HDL1 or HDL2 are not transferred to other lipoproteins, but are
directed to the liver for disposal or reuse, representing the last step of reverse cholesterol
transport. Additionally, TGs of HDLs can be hydrolyzed in the liver, resulting in the
conversion of HDL2 back into HDL3, the latter recirculating to the periphery, restarting
the reverse cholesterol transport (Bauer, 2004; Li et al., 2014).
1.1.3 Difference of Canine and Human Lipid Metabolism
Although humane exogenous lipid metabolism functions similarly to that in dogs, some
differences occur in the endogenous pathway.
Major Cholesterol Carrier
In humans, LDL is the main cholesterol carrier and is considered to be the major partic-
ipating lipoprotein in the development of atherosclerosis (Camus et al., 2011). This is in
contrast to dogs, where HDLs have a higher concentration within the blood than LDLs,
rendering the reverse cholesterol transport more efficient in general by allowing more free
cholesterol from peripheral tissue to be taken up into HDLs. This feature may be involved
in the natural resistance to developing atherosclerosis in some mammals with enhanced
HDL concentrations in the blood, such as the dog, since enhancement of cholesterol ef-
flux and reverse cholesterol transport capacity is potentially antiatherogenic (Maldonado
et al., 2002).
Intermediate Density Lipoprotein (IDL)
In humans, a further lipoprotein class has been described, the so–called intermediate den-
sity lipoproteins (IDLs). They might exist in dogs, as there is a gap between canine LDL
and HDL density ranges, but they have only been described rarely. Further differences
regarding canine and human lipoproteins and their composition are shown in table 1.2.
Reverse Cholesterol Transport
HDL1, as described above in the canine endogenous lipid metabolism, is only known
in mammals lacking a certain protein called cholesteryl ester transfer protein (CETP).
In humans, CETP allows CEs to be transferred from HDL2 back to apo–B containing
lipoproteins such as LDLs or VLDLs in exchange for triglycerides (Johnson, 2005). This
prohibits the formation of HDL1 particles and furthermore enhances the percentage of
LDL in the blood, allowing it to be the main cholesterol carrier in humans (Mooney
et al., 2004).
The clearance of cholesteryl ester through HDL1 in the dog, due to the absence or
very low amount of CETP, is therefore considered to contribute to the cardioprotective
role of HDL. Another presumed protective role of HDL is a higher resistance to oxidation
than LDL (Warnick et al., 2001; Tsutsumi et al., 2001).
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Table 1.2: Comparison of lipoproteins in dogs and humans. Table is composed of three different
sources: Bauer (2004), Xenoulis and Steiner (2010) and Wasan et al. (2001).
Lipoprotein Species Size (nm) Hydrated
Density
(g/mL)
Electro–
phoretic
Mobility
Major
Apoproteins
Chylomicrons Dogs 75–1200 <0.96 Origin B–48, C
Humans 75–1200 <0.95 Origin B–48, A, C, E
VLDL Dogs 30–80 0.093–1.006 Pre–β B–100, B–48, E,
C
Humans 30–80 0.95–1.006 Pre–β B–100, E, C
IDL Humans 25–35 1.006–1.019 B–100, C, E
LDL Dogs 18–25 1.019–1087 β B–100, B–48
Humans 18–25 1.019–1063 β B–100
Lp (a) Humans
HDL1 Dogs 10–35 1.025–1.100 α2 E, A, C
HDL2 Dogs 9–12 1.063–1.100 α1 E, A, C
Humans 9–12 1.063–1.125 α1 A, E, C
HDL3 Dogs 5–9 1.100–1.210 α1 A, C
Humans 5–9 1.125–1.210 α1 A, E, C
Lipoprotein a
Lipoprotein (a), Lp (a), is a specific lipoprotein not fully described in dogs and of un-
known physiological function. There are occasional reports of an unusual lipoprotein
in the canine plasma, presumably Lp (a), occurring together with marked hypercholes-
terolemia and hypothyroidism (Camus et al., 2011). Human Lp (a) is believed to be an
LDL particle containing additional apo (a) next to apo B–100. Hence it is not known
if Lp (a) acts independently from LDL regarding the development of coronary vascular
diseases, although studies have suggested that increased levels of Lp(a) in the plasma
have been correlated positively with increased risk of coronary artery disease (Kronen-
berg, 2014; Danesh et al., 2000). Although pro–inflammatory oxidized phospholipids have
been strongly associated with Lp (a) in human plasma, the underlying mechanisms by
which Lp (a) contributes to the pathogenesis of atherosclerosis are not well understood
(Tsimikas et al., 2004).
Apoproteins
Because of the large number of studies performed on human lipoproteins, more apopro-
teins and related metabolic functions are known in humans compared to canine lipopro-
teins (Table 1.3).
The majority of apoproteins have been found on HDLs, as they not only possess apo
A–I and apo A–II as major apoproteins, but also minute amounts of apo C–I, apo C–II,
apo C–III, apo E, apo A–IV and apo D. The sole apoprotein not found on HDL is apo B,
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Table 1.3: Classification and properties of major human apoproteins with metabolic functions
being mostly similar in humans and dogs (Jonas, 2002; Xenoulis and Steiner, 2010; Breslow, 1989).
CM = chylomicron, VLDL = very low density lipoprotein, LDL = low density lipoprotein, IDL
= intermediate density lipoprotein, HDL = high density lipoprotein, LCAT = lecithin cholesterol
acyltransferase, CHD = coronary heart disease, LP = lipoprotein, LPL = lipoprotein lipase, TG =
triglyceride, CE = cholesteryl ester.
Apolipoportein Molecular
Weight (kDa)
Lipoproteins Major Metabolic Function
Apo A–I 28–29 HDL, CM Activates LCAT; high levels associated
with reduced risk of CHD
Apo A–II 17–18 HDL, CM Enhances hepatic lipase activity
Apo A–IV 44–46 HDL, CM Present in fat enriched LPs
Apo B–48 241–264 CM (plus
VLDL & LDL
in Dogs)
Secretion of CMs into lacteals; en-
hances hepatic uptake
Apo B–100 513–540 LDL, VLDL,
IDL
Secretion of VLDLs from liver; hepatic
uptake; high levels associated with in-
creased risk of CHD
Apo C–I 6–7 CM, VLDL,
IDL, HDL
Involved in activation of LPL
Apo C–II 8–9 CM, VLDL,
IDL, HDL
Activation of LPL; deficiency results
in accumulation of CMs and TGs
Apo C–III 8–9 CM, VLDL,
IDL, HDL
Inhibition of LPL
Apo D 33 HDL Closely associated with LCAT
Apo E 34–35 CM, VLDL,
IDL, HDL
Uptake of CM remnants; binding to
LDL–receptor; may inhibit develop-
ment of atherosclerosis
Apo (a) 250–800 Lp (a) Unknown
which is restricted to CMs, VLDLs, IDLs and LDLs (Warnick et al., 2001).
Regarding the subfractions of apo B, dogs possess apo B–48 not just on CMs, as in
humans, but also on VLDLs and LDLs as well (Bauer, 1996). The inclusion of apo B–
48 into VLDLs and LDLs in dogs may further explain their low concentrations of apo
B–containing lipoproteins in the blood next to the occurrence of HDL1, because of the
possible rapid recognition and hepatic–receptor binding of apo B–48 together with apo
B–100. Hence, more efficient clearance of particles containing both apoproteins may occur
in the dog (Bauer, 1996).
1.1.4 Canine Dyslipidemia
As a general term, dyslipidemia involves all kinds of disturbances with lipids and lipopro-
teins (Xenoulis and Steiner, 2015). Hyperlipidemia is more specific and describes an in-
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creased concentration of lipids in the blood, including cholesterol (hypercholesterolemia)
or triglycerides (hypertriglyceridemia) or both (Jerico´ et al., 2009; Xenoulis and Steiner,
2015). In humans, hyperlipidemia, especially enhancement of LDLs, has long been known
as one of the main risk factors for the development of atherosclerosis (Liu et al., 1986).
The importance of specific forms of hyperlipidemia in dogs has come up only recently, as
it was considered a relatively benign condition before (Xenoulis and Steiner, 2015).
A characteristic lipoprotein profile for healthy dogs is represented by low concentra-
tions of VLDL and LDL and high concentrations of HDL (Mahley and Weisgraber, 1974).
Therefore it was suggested that the higher concentration of HDL, supposedly due to the
absence or minimal amount of CETP in dogs, decreases the risk of developing atheroscle-
rosis (Jerico´ et al., 2009).
Nevertheless, hyperlipidemia in dogs has also been associated with several complica-
tions such as pancreatitis, liver disease, ocular disease, seizure and atherosclerosis (Xe-
noulis and Steiner, 2015).
It is important here to differentiate between pathological and physiological hyper-
lipidemia. The latter represents the most common form and occurs in non–fasted dogs
through accumulation of chylomicrons (Johnson, 2005). Accordingly, any determination
of blood lipid concentrations should always follow a fast of at least 12 hours.
Regarding pathological lipid disorders, primary hyperlipidemia may arise as a result of
a defect in lipoprotein metabolism or, secondary hyperlipidemia, as a consequence of an
underlying systemic disease (Camus et al., 2011; Jerico´ et al., 2009; Xenoulis and Steiner,
2015).
Table 1.4: Primary and secondary lipid disorders in the dog. Slightly modified and shortened table
by author, original by Xenoulis and Steiner (2010, 2015). HTG = hypertriglyceridemia, HCH =
hypercholesterolemia
Examples of Hyperlipidemia Type of Lipid Abnormality Increased Lipoproteins
Postprandial Hyperlipidemia HTG (rarely HCH) CM
High–fat Diets HTG and/or HCH HDL1
Secondary Hyperlipidemia
Diabetes mellitus HTG (mainly) and/or HCH VLDL
Hypothyroidism HTG and/or HCH HDL1, VLDL, LDL
Hyperadrenocorticism HTG and/or HCH VLDL, LDL
Pancreatitis HTG and/or HCH VLDL, CM, LDL, HDL1
Obesity HTG and/or HCH VLDL, LDL, HDL
Protein–losing Nephropathy HCH unknown
Cholestasis HTG and/or HCH LDL
Hepatic Insufficiency HTG and/or HCH unknown
Drugs (e.g. Glucocorticoids) HTG and/or HCH probably VLDL, LDL
Primary hyperlipidemia
Miniature Schnauzer HTG with or without HCH VLDL, CM
Beagle HTG and/or HCH HDL1, LDL
Shetland Sheepdog HCH with or without HTG HDL1, LDL
16 Chapter 1. Introduction
Primary hyperlipidemia appears infrequently and is mostly associated with certain
breeds and geographic regions, the most common being a hypertriglyceridemia mainly
due to enhanced VLDLs, familial in breeds such as the Miniature Schnauzer, Shetland
sheepdogs or Beagles (Watson and Barrie, 1993; Xenoulis and Steiner, 2015).
Secondary hyperlipidemia, the most common form of hyperlipidemia in dogs, is mainly
associated with endocrine disorders such hypothyroidism, diabetes mellitus or hypera-
drenocorticism (Xenoulis and Steiner, 2010, 2015). The main primary and secondary
lipid disorders in dogs and respective lipoprotein abnormalities are summarized in table
1.4.
In spite of elevated LDL concentrations in the plasma of several of these secondary
hyperlipidemias, the development of atherosclerosis still remains rare in dogs (Hess et al.,
2003). It has been documented only in association with extremely high plasma cholesterol
(>20 mmol/L or 750 mg/dL) and triglyceride concentrations (Kagawa et al., 1998). If
occurring spontaneously, atherosclerosis has been reported mainly in dogs with hypothy-
roidism, a disease that often is associated with extreme levels of hypercholesterolemia
(Liu et al., 1986; Hess et al., 2003). Further, atherosclerosis has also been reported to
occur in dogs with diabetes mellitus, however this is less common and controlled studies
to prove these associations have not been performed so far (Hess et al., 2003). Interest-
ingly, dogs with hyperadrenocorticism do not seem to have enhanced risk of developing
atherosclerosis (Hess et al., 2003).
Hyperadrenocorticism
Canine hyperadrenocorticism (HAC) can occur spontaneously or iatrogenically. If oc-
curring spontaneously, HAC results most often from an increased secretion of adreno-
corticotropic hormone (ACTH) due to an anterior pituitary neoplasia or less often from
autonomous cortisol production from a functional adrenocortical neoplasia (Mooney et al.,
2004). Either way, enhanced cortisol levels can be found within the blood as the normal
feedback mechanism can no longer function (Mooney et al., 2004). In contrast, iatrogenic
HAC is caused by administration of glucocorticoids.
Both naturally occurring and iatrogenic HAC have been associated with hyperlipi-
demia, especially increased concentrations of LDLs and VLDLs or increased total plasma
cholesterol concentrations within these lipoproteins (Bauer, 2004; Jerico´ et al., 2009).
This increase may be explained by a reduced clearance rate of VLDL, caused by
lower LPL activity and be the consequence of glucocorticoid antagonism on insulin action
(Barrie et al., 1993a). In addition, HDL concentrations were lower compared to those of
healthy dogs, probably due to a decreased activity of LPL as well, because HDL originates
partly from surface components released from chylomicrons or VLDL during LPL activity
(Shaw et al., 2005). Hypertriglyceridemia has also been shown in dogs with HAC. But
both cholesterol and triglyceride concentrations are only mildly to moderately increased
(Johnson, 2005).
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Glucocorticoids
The administration of glucocorticoids (GCs) in dogs can lead to hypertriglyceridemia,
probably due to increased hepatic synthesis of triglycerides and increased secretion of
VLDL, similar to naturally occurring HAC (Mooney et al., 2004). Generally, GCs have
various effects on the organism, influencing carbohydrate, protein and fat metabolism
as well as acting as anti–inflammatory agents. The effects of GCs on carbohydrate
metabolism can be summarized as an increase in the gluconeogenesis rate, which leads to
an increase in the blood glucose concentration, and this hyperglycemia, in turn, leads to a
secondary hyperinsulinemia (Mooney et al., 2004). The enzymes activated by GCs in pro-
tein metabolism, enhancing blood amino acid concentrations through muscle catabolism,
affect the lipid metabolism indirectly by increased conversion of amino acids to glucose
and increased formation of plasma proteins in the liver (Mooney et al., 2004).
Further, GCs activate several enzymes involved in the fatty acid synthesis, promoting
the secretion of lipoproteins (Wang et al., 1995). This is caused by increased body fat
mass, lipolysis and lipid oxidation, which leads to peripheral insulin resistance, inhibit-
ing the effect of insulin on stopping lipolysis and stimulating lipogenesis (Kaur, 2014).
Finally, lipolysis results in the release of free fatty acids and glycerol from adipose tis-
sue, stimulating an overproduction of VLDLs and consequently also enhanced LDL levels
(Barrie et al., 1993a).
1.1.5 Atherosclerosis
Arteriosclerosis is a general term for thickening and hardening of arterial walls, whilst
atherosclerosis is a specific form of arteriosclerosis defined as plaques building up inside
arteries. The pathogenesis of this latter process is characterized by a chronic inflammation
of the arterial walls, probably initiated by endothelial dysfunction, followed by structural
alterations which in turn permit the accumulation of LDLs within the arterial walls (Kwon
et al., 2008).
Risk Factors for Atherosclerosis
There are several classic risk factors for the development of atherosclerosis in humans,
including so called first class and second class risk factors. First class risk factors are the
following: hypertension, causing endothelial damage; hyperlipidemia with increased LDL
or VLDL but reduced HDL concentrations; nicotine; diabetes mellitus; progressing age
and gender (related to the protective effect of estrogen). Second class factors rely more
on environmental factors such as high fat diets, obesity, stress or lack of physical exercise
(Bo¨cker et al., 2008).
In contrast to other factors, dyslipidemia is a prerequisite for the initiation and pro-
gression of about half of all arterial lesions (Simionescu and Sima, 2012) with increased
lipoprotein (a) and small dense LDL concentrations. The latter are LDLs that are smaller
after hydrolysis, mainly of triglycerides (Kullo et al., 2000; Lammert and Zeeb, 2014).
Other studies have strongly associated mainly oxidized LDL with atherosclerosis (Ekroos
et al., 2010). As they invoke inflammatory response in the artery wall, unleashing many
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of the processes involved in atherosclerosis, detection of oxidized LDL may represent a
good tool as a disease biomarker (Packard and Libby, 2008). Generally, inflammation
has recently gained in importance, as it represents a key contributor to all stages of
atherosclerosis, decreasing the importance of oxidized lipoproteins and further revealing
the complexity of the process (Libby et al., 2009).
However in general, dyslipidemia including elevated small dense LDLs, total blood
cholesterol levels and decreased HDL concentrations still seem to be the most potent risk
factors for coronary heart disease (Grundy, 2011; Yin et al., 2012; Sniderman et al., 2001).
As small dense LDLs are supposed to increase the risk for atherosclerosis independently
of LDL–cholesterol, this may explain some resistance to cholesterol lowering therapies.
Small dense LDLs hold various pro–atherogenic features such as the ability to penetrate
the subintimal space, greater susceptibility to oxidation (Warnick et al., 2006), increased
binding to the arterial wall, increased toxicity to endothelial cells and activation of further
atherogenic processes contributing to the formation of foam cells (Sniderman et al., 2001).
Stages of Atheroma Formation
The accumulation of atherogenic lipoproteins involves the initial influx of particles into
the intima following endothelial injury, known as the ”Response to Injury” hypothesis,
and creating an atheroma, which is defined as hardening of the arteries. Although LDL
is the main lipoprotein involved in the process, VLDL and IDL may also accumulate in
arteries (Bauer, 2004). After lipoproteins are retained by the intima of the arterial walls,
the formation of the atheroma continues, involving several stages illustrated in figure 1.3.
− Stage I: The formation of an atheroma can be summarized as a chronic inflamma-
tory process, started by a dysfunction of the endothelial cells. This is caused by
altered haemodynamic factors such as hypertension. Due to the following structural
alterations, proteoglycans of endothelial cells are exposed to the blood. LDLs can
bind to these proteoglycans through their apo B–100, permitting subendothelial
accumulation of LDL particles in the intima (Weber and Noels, 2011).
− Stage II: After LDLs are trapped within the intima and if cholesterol is not brought
back to the liver through reverse cholesterol transport by HDLs at this point, LDLs
are susceptible to oxidative modifications by reactive oxygen species or enzymes,
mostly released from inflammatory cells (Weber and Noels, 2011). Oxidative mod-
ification of LDLs involves lipid peroxidation, which in turn enhances recognition
and uptake of LDLs by macrophages (Bauer, 2004). Recent studies also associated
glycation of lipoproteins (bonding with a sugar molecule) as a process potentially
contributing to atherosclerosis (Soran and Durrington, 2011) as glycated LDLs are
more likely to be oxidized than non–glycated LDLs (Ravandi et al., 2000).
− Stage III: Oxidized LDLs induce further endothelial cell dysfunctions, expressed by
the appearance of new cell adhesion molecules and chemotactic factors (Wick and
Grundtman, 2011). Triggered by these attracted cells, a robust inflammatory reac-
tion takes place in which blood monocytes, platelets, T–lymphocytes and dendritic
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Figure 1.3: Diagrammatic Representation of stages I–VI of atheroma formation. Definitions: EC =
endothelial cells; LDL = low density lipoproteins; MLP = modified lipoproteins; MON = monocytes;
PL = platelets; TLY = T–lymphocytes; MAC = macrophages; FC = foam cells; SMC = smooth
muscle cells; CHOL = cholesterol; CA = calcification cores; THROMBUS = thrombus. Figure
adapted by author from Wick and Grundtman (2011).
cells adhere and enter the arterial intima (Wick and Grundtman, 2011). During this
process, monocytes migrate to the sub–endothelial space where they differentiate
into macrophages (Xiangdong et al., 2011). Once activated, macrophages express
scavenger receptors, take up oxidized LDLs through these receptors and progres-
sively turn into characteristic macrophage–derived foam cells (Wick and Grundt-
man, 2011). Under normal conditions, LDLs would be phagocytized through apo
B–receptors, working with a feedback mechanism to stop cells from taking up too
much cholesterol. This mechanism is lacking with scavenger receptors, allowing for
the formation of large foam cells (Bo¨cker et al., 2008). Ultimately, the accumula-
tion of foam cells loaded with lipids and T–lymphocytes results in the formation of
fatty streaks within the vessel walls, narrowing the arterial lumen (Xiangdong et al.,
2011).
− Stage IV: Changes within the intima and influx of lymphocytes, interacting with
macrophages, stimulates further production of IFN–γ. This enhances the ongoing
inflammatory reaction and promotes immigration of smooth muscle cells from the
media into the intima or sub–endothelial space. Immigrated smooth muscle cells
may ingest modified lipoproteins, forming a fibrous cap or plaque (Ross, 1999; Bo¨cker
et al., 2008).
− Stage V: After formation of a fibroid plaque, more extracellular lipids, foam cells,
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apoptotic cells and cholesterol crystals accumulate (Weber and Noels, 2011). Hence
calcification centers develop. Moreover, free cholesterol is a potent inducer of the
apoptosis of macrophage–derived foam cells, inducing a lipid rich necrotic core (Wick
and Grundtman, 2011). Also, the smooth muscle cells and collagen which cover the
fibrous cap are replaced by macrophages, thinning the cap and turning the fibroid
plaque into a vulnerable structure whilst attracting more inflammatory cytokines
(Wick and Grundtman, 2011).
− Stage VI: The last stage is characterized by the rupture of the vulnerable plaque,
which allows blood components such as platelets to come into contact with exposed
matrix, plaque lipids or tissue factors, resulting in the formation of a thrombus.
Subsequent ischemic symptoms such as myocardial infarction may occur, depending
on the location and magnitude of the process (Libby et al., 2009).
The Role of HDL
Conventionally, HDL is known to have several anti-atherogenic properties due to its role
in the reverse cholesterol transport bringing cholesterol from peripheral tissue, including
artery walls, back to the circulation and the liver. Therefore, high concentrations of
HDL are traditionally believed to assist in lowering the risk of developing cardiovascular
diseases. However, there is accumulating evidence that it is the molecular structure
of HDL rather than circulating HDL–cholesterol levels which determine their functional
properties (Yan et al., 2014).
Newer studies suggest that HDL acts as a reservoir of preformed hydroperoxides,
which can be donated to VLDL by CETP via apo A–I and LCAT. Therefore both en-
zymes seem to have pro–oxidative activity during VLDL oxidation (McPherson et al.,
2007). Despite LCAT acting as a pro–oxidant during VLDL oxidation, it also acts as an
antoxidant during LDL oxidation. Thus HDL plays a double–edged role in the pathogen-
esis of atherosclerosis, attributable to both CETP and LCAT (McPherson et al., 2007).
Further, the antioxidative activity of HDL depends on its subfraction, with small HDL3
having significantly higher activity than large HDL2, the antioxidative action being mostly
associated with inactivation of LDL lipid hydroperoxides (Kontush et al., 2003).
HDL also seems to have anti–inflammatory and antithrombotic effects (Frohlich and
Pritchard, 1989) and particularly HDL3 has been linked to the down–regulation of cell ad-
hesion molecules on vascular endothelial cells, thus blocking the progression of atheroscle-
rosis. Additionally, it prevents to some extent the chemotaxis of monocytes and may
inhibit platelet aggregation (McPherson et al., 2007).
However, the protective activities of HDL may vary between individuals in humans and
under different disease states (Ekroos et al., 2010). In patients with coronary heart disease,
several recent studies have provided evidence that HDL can also exert pro–inflammatory
properties and loses its protective functions under certain circumstances such as enhanced
serum amyloid A levels, which are present during inflammation. (Natarajan et al., 2010;
Artl et al., 2000).
Further evidence for the double role of HDL is given by pharmacological interventions
that increase HDL blood levels. This did not reduce the risk of cardiovascular disease,
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pointing to the importance of determining HDL composition and its functional properties
rather than only circulating HDL concentrations (Li et al., 2014).
Canine Atherosclerosis
It has been suggested that canine atherosclerosis differs from human atherosclerosis in
that lipids are primarily present in the media and adventitia of atherosclerotic canine
arteries (Jubb, 2007). Nevertheless, some similarities are observed, e.g. lipids are also
deposited in the tunica intima, as described in humans and the infiltration of monocytes
into subendothelial space can take place (Kagawa et al., 1998). Further, among all do-
mestic animals, only dogs show a deposition of cholesterol and other lipids in the arteries
in measurable amounts (Jubb, 2007).
As discussed in section 1.1.3, several reasons may contribute to the atherosclerotic
resistance of dogs. First, the naturally high concentration of HDLs, being the major
cholesterol carrier even in obese dogs (Jeusette et al., 2005), may lead to a more efficient
reverse cholesterol transport from peripheral tissue known as an anti–atherogenic feature.
Second, the low or absent activity of CETP in dogs contributes to their resistance, as
more total cholesterol remains in HDLs, leading to the formation of unique HDL1 particles
(Maldonado et al., 2001).
1.2 Lipoprotein Separation
Separation of serum or plasma fractions can be useful for investigating lipoprotein changes
in different diseases. Due to lipoproteins differing in size, density, electrical charge,
lipid and apoprotein composition, there are different techniques for separating lipoprotein
classes within the blood.
1.2.1 Sequential Preparative Ultracentrifugation
Ultracentrifugation depends on different densities of particles with two traditionally used
approaches: analytical or preparative ultracentrifugation.
In analytical ultracentrifugation, a sample is centrifuged at high speed without split-
ting it up into different fractions, rendering this technique unsuitable for further analytical
procedures where separated lipoprotein fractions are needed. (Xenoulis et al., 2013).
Using preparative ultracentrifugation, different salt solutions are added stepwise to
separate the lipoprotein classes in multiple centrifugation steps, allowing sequential flota-
tion of lipoprotein classes dependent on their density, size and shape (Mills et al., 1984).
However, the disadvantage of this conventional ultracentrifugation procedure is the rela-
tively long total spin time, where the complete fractionation of all lipoproteins may take
up to five days.
Thus, a new technique called very fast ultracentrifugation was investigated, using
rapid rotation speeds of up to 120’000 rpm and thereby lowering the total run time (Piet-
zsch et al., 1995). To further minimize processing artifacts, an ultracentrifugal sequential
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flotation method was developed that used only small sample volumes and short centrifu-
gation times at low temperatures but with high rotation speeds (Brousseau et al., 1993).
Low temperatures are a prerequisite when processing lipoproteins, to minimize enzymatic
transformation and autoxidation (Tong et al., 1998). However, in contrast to conventional
protocols, when the temperature is lowered to 4◦C, prolonged centrifugation time is re-
quired for lipoprotein separation due to the increased viscosity of the density gradients at
the lower temperature (Mills et al., 1984).
1.2.2 Precipitation
There are two approaches to the precipitation of lipoproteins. Either precipitation is
performed alone or triglyceride–rich lipoproteins such as VLDLs are eliminated before
precipitation by a short ultracentrifugation step. The precipitation of lipoproteins without
a previous ultracentrifugation step may cause incomplete precipitation due to the large
amount of triglycerides. If HDL–cholesterol is measured afterwards, it may be slightly
overestimated (Warnick et al., 1985).
Typically, a combination of polyanions (heparin or dextran sulfate) with divalent
cations (magnesium or manganese) is used for precipitation of apo B–containing lipopro-
teins (Warnick et al., 1985). Both methods, the heparin manganese chloride and the
dextran sulfate magnesium chloride, leave small amounts of apo B in the HDL super-
natant, while some parts of HDL precipitate unplanned (Warnick et al., 2001). However,
the heparin manganese chloride method is recommended by several authors and with this
method, small dense LDL, known to be even more atherogenic than normal LDLs, may
also precipitate (Hirano et al., 2005).
Precipitated lipoproteins in humans are commonly contaminated with other plasma
proteins and their lipid composition may differ from the analogous fractions obtained by
ultracentrifugation alone (Mills et al., 1984). A more precise technique for precipitation
would be achieved using antibodies directed against apoproteins, called immunoprecipi-
tation. Unfortunately, the availability of suitable antibodies can be challenging.
In the dog, a combined ultracentrifugation–precipitation (0.09M MnCl2) technique
has been evaluated, resulting in trace contaminations of the LDL precipitate with HDL
apoproteins (apo A–I) analyzed on SDS–PAGE. Further, it was suggested that an apo E–
rich subfraction of HDL in dogs may co–precipitate with LDL when a manganese chloride
method is used (Barrie et al., 1993a).
1.2.3 Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS–PAGE)
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) is a form of pro-
tein electrophoresis in which the movement of charged proteins within an electrical field
results in their separation; it is illustrated in figure 1.4. Therefore it can be used to evalu-
ate apoprotein distribution among lipoprotein fractions separated by the above–mentioned
methods such as ultracentrifugation or precipitation.
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Figure 1.4: Mechanism of SDS–PAGE. Figure adapted by author from Raff et al. (2002).
Proteins can be negatively or positively charged, depending on their composition.
Transferred into an electrical field, the proteins will migrate at a rate depending on their
net charge, size and shape. Because of these different net charges, SDS–PAGE uses a
powerful negatively charged detergent added to the protein solution called sodium dodecyl
sulfate (SDS), which causes unfolding of proteins into extended polypeptide chains. In
addition, β–mercapto–ethanol is added to the protein solution to break any disulfide
bonds and separate all protein fragments from each other (Raff et al., 2002). This results
in apoproteins released from other proteins or lipids becoming available to be studied alone
in the different fractions of their assigned lipoproteins. Further, proteins of the same size
will move at similar speed, because their native structure is completely unfolded and they
possess the same amount of negative charge. Hence, large molecules are slower than small
ones, resulting in a fractionation of proteins arranged by molecular weight with large
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weight molecules at the beginning of the gel and small weight molecules further down the
field (Raff et al., 2002).
Molecular weights of proteins detected on SDS–PAGEs can further be roughly es-
timated using the relative migration distance (Rf ) of proteins; the migration rate of a
protein on SDS–PAGE is inversely proportional to the logarithm of its molecular weight
(Raff et al., 2002).
1.3 Lipidomics
By definition, lipidomics characterizes the composition of intact lipids in biological systems
by identifying and quantifying intact molecular species of lipids (Ekroos et al., 2010;
Postle, 2012).
Recently, there has been a dramatic increase in lipidomic research due to technical
improvements such as the application of electrospray ionization to mass spectrometry
(Postle, 2012). Lipidomics can be used not only for researching consecutive lipid changes
during diseases, but also to map the entire spectrum of cellular lipids in biological systems,
including metabolic pathways as well as lipid–lipid and lipid–protein interactions (Li et al.,
2014).
There has already been an effort to identify the oxidation products of lipid species such
as phospholipids, sterols and apoproteins formed in vivo and probably contributing to the
development of atherosclerosis (Tong et al., 1998). In regard to dogs and their natural
resistance to developing atherosclerotic plaques (Hess et al., 2003) lipidomic research on
canine LDL, HDL and specific lipids and apoproteins seems promising. However, to our
knowledge, the canine lipidome has not been characterized up to now.
1.3.1 Lipid Classification (Lipid Maps)
Lipids can be classified into eight major categories according to the Lipid Maps consortium
(www.lipidmaps.org), where more than 500 distinct lipid species have been quantified so
far from human samples, but many more have been identified (Postle, 2012). However, to
define all lipid molecular species is challenging due to the extraordinary number of possible
combinations. It has been recently postulated that the theoretical number of possible
identifiable lipids in the human organism may approach 200’000 distinct molecular species,
if all isoforms are included (Bou Khalil et al., 2010).
Further, lipids consist of a number of structurally and functionally distinct molecular
species that extend from apolar (e.g. sterol esters) via neutral (e.g. triglycerides) to
polar (e.g. phospholipids). Therefore it is challenging to carry out suitable identification
techniques for each lipid and to integrate lipid data from different laboratories that have
used different techniques (Hu et al., 2009).
Lipid Maps has gathered all this information and announced a lipid biology–approach
system, whereby lipids can be classified according to their chemical structure: fatty acyls
(FAs), glycerolipids (GLs), glycerophospholipids (GPs), sphingolipids (SPs), sterol lipids
(STs), prenol lipids (PRs), saccharolipids (SLs) and polyketides (PKs).
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The first group of lipids, fatty acyls (FAs), form the basic element of all lipids. They
have either saturated or unsaturated straight hydrocarbon chains varying in lengths and
amount of double bonds. Functionally, FAs are precursors of other lipid molecules, such
as arachidonic acid, the precursor of eicosanoids (Hu et al., 2009).
Glycerophospholipids (GPs) represent the major group of lipids in the human or-
ganism and cover all sorts of mixtures of glycerol with a functional polar head group
at the sn-3 position. Similar to glycerolipids, GPs are constituted of a glycerol back-
bone but with a phosphate esterified to one fo the glycerol hydroxyl groups (Fahy et al.,
2005). They can be divided into subgroups based on these different polar head groups as
follows: glycerophosphatidic acids (PAs), glycerophosphocholines (PCs), glycerophospho-
ethanolamines (PEs), glycerophosphoserines (PSs), glycerophosphoglycerols (PGs) and
glycerophosphoinositols (PIs) (Hu et al., 2009).
Despite the diversity in their structure, all of these GPs are main components of cell
membranes as parts of phospholipid bilayers and participate in cell signaling, membrane
anchoring and substrate transport (Hu et al., 2009). In addition, some lipid molecular
species (Lyso–PCs, PEs, PCs and PIs) have been found as potential biomarkers in various
diseases such as pancreatic and ovarian cancer (Kolak et al., 2007).
Sterol lipids (STs), compromised of a four–ring core structure, consist of cholesterols
and their derivatives, such as cholesteryl esters (CE). STs act as important components
of membrane lipids, have regulatory functions related to cell signaling and contribute to
the production of bile acids, mainly in the from of cholesterols. Steroid hormones, formed
from STs, are separated into groups depending on their number of carbon atoms, for
example C21 including progestagenes, glucocorticoids and mineralocorticoids (Tsai and
O’Malley, 1994).
Glycerolipids (GLs), relatively simple lipids, mainly include monoacylglycerols (MGs),
diacylglycerols (DGs) and triacylglycerols (TGs), synonymous with triglycerides. GLs
consist of a glycerol backbone, varying only in the number of FAs esterified to the hydroxyl
groups of this backbone. In nature, TGs are the main constituent of animal fats and
therefore play an essential role in cellular energy storage. They have also been associated
with the development of atherosclerosis (Goldberg, 1996; Hu et al., 2009).
Sphingolipids (SPs) together with glycerophospholipids (GPs) and cholesteryl esters
(CEs) play an important role in the development of atherosclerosis, as they may alter
lipoprotein functions. Ceramide (Cer), a main class of sphingolipids, affects this pro-
cess through its role as second–messenger. Further, the concentration of sphingomyelin
(SM), another class of sphingolipids, was positively correlated with the development of
atherosclerosis in previous studies (Bismuth et al., 2008; Fahy et al., 2005).
1.3.2 Human Lipidome
The most detailed quantitative characterization of the human plasma lipidome was done
by Quehenberger et al. in 2010, quantifying over 500 distinct lipid molecular species
within the human plasma.
In that study, glycerolipids (GLs), mainly TGs, were found to be the most abundant
lipids in human plasma, detected in CMs, VLDLs and IDLs. Next to TGs, cholesteryl
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esters (CEs) were identified to be one of the most abundant lipid classes in human blood.
Further, a large number of glycerophospholipids (GPs) were identified, with the majority
of GPs being glycerophosphocholines (PCs) and glycerophosphoethanolamines (PEs).
In the group of sphingolipids (SPs), over 200 individual lipid species were assessed
in which sphingomyelins (SMs) accounted for the largest fraction. Specific lipids such as
ceramides (Cers) were mainly detected in VLDL and LDL fractions, whereas Lyso–PCs
and ether–linked PCs were found in all lipoprotein fractions but were most abundant
within HDL2, HDL3 and LDL. As this was a human study, no informations is available
for HDL1 (Quehenberger et al., 2010).
The observations of Quehenberger et al. were similar to those of other human lipidome
studies, where major human lipoprotein components consisted of free cholesterol, chole–
steryl esters (CEs), triglycerides (TGs) and phospholipids (PLs), particularly phosphatidyl-
cholines (PCs) and sphingomyelins (SMs) (Wiesner et al., 2009). However, the abundance
of different lipids varies between the studies because lipid profiles are affected by factors
such as gender, age, race, current diet and the analytical approach used (Hyo¨tyla¨inen and
Oresˇicˇ, 2015).
1.3.3 Lipidomics and Atherosclerosis
Lipidomics is an essential tool used to determine lipid molecular species as potential
biomarkers in lipid–related diseases (Hu et al., 2009). As one of the first studies, atheroscle-
rotic plaques were investigated, revealing that different (oxidized) lipids were enhanced
exclusively within these plaques (Waddington et al., 2001).
Several lipids or lipid categories have been associated with atherosclerosis so far, for ex-
ample oxidized phospholipids (ox PLs) (Berliner et al., 2009) with oxidized phosphatidyl-
cholines specifically (Stu¨biger et al., 2012), sphingolipids (SPs) (Bismuth et al., 2008) and
Lyso–PLs (Schmitz and Ruebsaamen, 2010). Further, cholesteryl esters, ceramides and
lactosylceramide species were also associated with atherosclerotic plaques (Cheng et al.,
2015), representing important lipid biomarkers for further investigations.
Regarding the antiatherogenic potential of HDL, lipidomic analyses are also important
in characterizing HDL subfractions. The human HDL lipidome has been evaluated in
various studies, e.g. revealing negatively charged PS and PA enriched in small, dense
HDL3, their content positively associated with anti–atherogenic functions (Berliner et al.,
2009).
However, despite the great number of lipidomic studies performed in atherosclerotic
research so far, we are still at the beginning of understanding lipid abnormalities in
atherosclerosis. Most lipids identified and reported to be associated with atherosclerosis
have not been investigated until now and their metabolic activity often remains unclear.
Nevertheless, identification of these lipids would be an important step in moving forward.
1.3.4 Analytical Methods in Lipidomics
As lipidomic procedures consist of several different steps and every step has an effect on
the measured lipid species, it is mandatory to consider several analytical factors.
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Sample Matrices
Plasma and serum are known to be lipid–rich biofluids, containing many thousands of
distinct lipid molecular species (Quehenberger et al., 2010). Proteins are the main class
of interfering compounds in serum lipid analysis and their removal in advance of analysis
is therefore important (Teo et al., 2015). Further, as plasma and serum differ in their
composition, both matrices should be examined for their complete lipidome.
As no consensus on an optimal matrix for lipidomics in general has been reached, the
type of matrix should always be chosen according to the targeted lipids (Ishikawa et al.,
2014).
Storage and Handling
This is a critical point, as samples should always be stored immediately at −80◦C or kept
on ice during handling. Such conditions inhibit enzymatic activity and peroxidation as
well as hydrolytic degradation of lipids. Hence, repeated freeze–thaw cycles should be
avoided, which may lead to possible loss of metabolites such as PCs (Teo et al., 2015).
Lysophospholipids (Lyso–PLs), one of the biomarkers for atherosclerosis, were found to
be highly sensitive to higher temperatures. Even plasma samples kept at 4◦C for 24h
showed increased concentrations of Lyso–PCs, a subgroup of GPs (Yang et al., 2013).
Lipid Extraction
Generally, lipidomic analysis requires some form of lipid extraction. As lipids consist of
hydrophobic and hydrophilic parts in varying amounts, the organic solvent needs to have
a solubility specific to targeting the desired lipid. TGs and CEs are neutral lipids without
any polar head groups and thus dissolve readily in nonpolar solvents such as hexane and
also in moderately polar solvents such as chloroform, used in the traditional Folch lipid
extraction (Hyo¨tyla¨inen and Oresˇicˇ, 2015; Folch et al., 1957). More polar lipids, such as
phospholipids and sphingolipids are only slightly soluble in nonpolar solvents but have
good solubility in polar solvents such as methanol. Hence, sample preparation always
affects the detected metabolite profile and a single extraction method will therefore never
represent all lipid subclasses adequately.
Currently there are two protocols that are used most commonly. One is a classic
protocol based on a modified extraction using chloroform and methanol (2:1 v/v) invented
by Folch et al. (1957). The other, newer protocol proposed by Matyash et al. (2008) uses
methyl tert–butyl ether (MTBE), methanol and water (10:3:2.5 v/v/v). Results from
Matyash et al. indicate that with the MTBE extraction protocol the recovery of most
lipids is comparable to or in some lipid classes even more efficient than the traditional
Folch method.
Internal Standards
Internal standard lipids can be added to the sample to correct differences in recoveries
between lipids. However, even class–specific standards cannot fully account for the dif-
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ferent extraction behaviors within lipid subclasses. For accurate quantification, targeted
lipidomics with internal standards for each individual lipid is required (Cajka and Fiehn,
2014).
Liquid chromatography mass spectrometry (LC–MS) or Shotgun Lipidomics
Shotgun lipidomics and LC–MS based lipidomics are the two most widely used approaches
(Ekroos et al., 2010).
Shotgun lipidomics is able to give a good overview of the lipids within a sample by
detecting hundreds of molecular lipid species in non–separated lipid extracts. However,
this often happens at the cost of less reliable lipid identification, as lipids are not separated
before mass spectrometry, enhancing the rate of structural isomers. Isomers are different
molecules but with the same molecular weight (Ekroos et al., 2010; Yang et al., 2015).
If already focused onto a specific lipid class or subclass, LC–MS based lipidomic analy-
sis allows absolute quantification, often controlled by appropriate lipid standards (Ekroos
et al., 2010). Further separation of isomers is partly achieved by previous LC (Watson,
2006). The drawback of this approach is the narrow time window when using LC, resulting
in a limited number of identified lipids (Ekroos et al., 2010).
In both approaches, molecules usually undergo electrospray ionization (ESI), produc-
ing ions followed by the detection of mass–to–charge ratios for each charged particle by
a mass analyzer. Together with characteristic fragmentation patterns resulting from tan-
dem mass spectrometers, this allows a reliable identification of the lipid species (Ivanova
et al., 2007; Carrasco-Pancorbo et al., 2009). However, the detection of lipid species with
a very low abundance remains a major challenge regardless of the lipidomic approach
(Wenk, 2010).
Data Processing and Lipid Identification
There are several tools available for data processing and identification with the core
functions peak detection, filtering, artefact removal, alignment (for LC–MS data) and
normalization. Common fragments (e.g.H+, COO−,...) possibly added to lipid molecules
during analysis have to be supplemented to data for enhanced identification of lipids.
Software tools have been developed for further identification of lipids using MS/MS in
both positive and negative mode, adopting the lipid classification system introduced by
Lipid Maps (Hyo¨tyla¨inen and Oresˇicˇ, 2015).
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1.4 Objectives of the Study
Based on the information outlined above, two major objectives were addressed in the
present study.
1. Firstly, to determine whether canine lipoproteins can be separated satisfactorily
using ultracentrifugation or precipitation.
2. Secondly, to characterize the canine lipidome and to give an overview of the different
lipid categories present in dogs. In the first part, we wanted to investigate a suitable matrix
for the lipid extraction by comparing mean abundances of lipids in plasma and serum. In
the second part, we wanted to evaluate the influence of short–term prednisolone treatment
in healthy beagle dogs on the lipidome.
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Material and Methods
2.1 Lipoprotein Separation
Canine lipoprotein fractions were isolated from lithium heparin plasma or serum and
were separated using two different techniques. A detailed description of each protocol is
described in this section and an overview of the two protocols is depicted in figure 2.1.
Protocol A used ultracentrifugation at densities known to separate human lipoproteins
and resulted in separation of the samples into five fractions (lipoproteins with density
(d) <1.006 g/mL, d 1.006–1.019 g/mL, d 1.019–1.063 g/mL, d 1.063–1.210 g/mL and d
>1.210 g/mL). The physiological arrangement of lipoproteins after ultracentrifugation is
illustrated in figure 2.2.
Protocol B used heparin manganese chloride for precipitation and resulted in separa-
tion of the samples into two fractions (apo B–containing precipitate and supernatant).
Blood Samples
Lithium heparin and serum samples were collected from a healthy dog by puncture of
jugular vein after 12 hours’ fasting. Informed consent was obtained from the owner of the
dog and its use was in accordance with the guidelines and directives established by the
Animal Welfare Act of Switzerland (TVB NR 133/2013).
After separation of plasma or serum by centrifugation at 1500 × g for 10 minutes,
samples were kept on ice at 4◦C during analytical procedures or stored at −80◦C. All
samples were analyzed within 48 hours of collection.
Reagents
Sodium chloride (NaCl), ethylenediaminetetraacetic acid (EDTA), potassium bromide
(KBr), manganese chloride solution (manganese(II) chloride tetrahydrate), tris hydrochlo-
ride (tris–HCl), sodium dodecyl sulfate (SDS), glycerol, bromophenol blue (BPB) and
β–mercaptoethanol were purchased from Sigma–Aldrich Chemie GmbH (Buchs, Switzer-
land); Precision Plus ProteinTM All Blue Marker was purchased from Bio–Rad, Switzer-
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Figure 2.1: Different lipid separation techniques used in section 2.1.
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land and heparin–sodium injection (5,000 I.U./mL) was purchased from B. Braun Medical
AG (Sempach, Switzerland).
2.1.1 Protocol A: Ultracentrifugation
Canine lipoproteins were separated into five fractions from lithium heparin plasma or
serum, using a protocol working strictly according to human lipoprotein densities and
shorter run times, called protocol A, a modified protocol of Brousseau et al. (1993).
For ultracentrifugation, a benchtop ultracentrifuge (Beckman Optima TLX) with fixed
angle rotor (TLA 120.2) operating at 120,000 rpm and maintained at 4◦C was used with
Quick–Seal R© tubes (Beckman Coulter, Nyon, Switzerland).
All density solutions used for this protocol were made of potassium bromide (KBr)
and distilled water, containing 1 mM EDTA and adjusted and verified by measurement
on a digital density meter (Automatic Density Meter DS7800 from A. Kru¨ss Optronic).
Proportions were calculated according to a formula invented by Radding and Steinberg
(1960).
Isolation of lipoproteins with d <1.006 g/mL: 0.8 mL of lithium heparin plasma or
serum was placed in a Quick–Seal R© tube, overlaid with 1.2 mL of a d = 1.006 g/mL
potassium bromide solution and submitted to ultracentrifugation for 2 hours and 12 min-
utes under the conditions described above. The upper layer was harvested by tube slicing
at 11.5 mm and stored at −80◦C until further analysis.
Isolation of lipoproteins with d = 1.006–1.019 g/mL: The remaining lower fraction of
1.2 mL was transferred to a new tube, adjusted to d = 1.019 g/mL by adding 48.6 µL
of a d = 1.34 g/mL potassium bromide solution and made up to a final volume of 2 mL
with a d = 1.019 g/mL potassium bromide solution. Centrifugation for 2 hours and 12
minutes was performed as described above and 0.8 mL of the supernatant was collected
by tube slicing at 11.5 mm.
Isolation of lipoproteins with d = 1.019–1.063 g/mL: The remaining lower fraction
of 1.2 mL was transferred to a new tube and mixed with 190.6 µL of a d = 1.34 g/mL
potassium bromide solution and 609.4 µL of a d = 1.063 g/mL potassium bromide solution.
The tube was heat–sealed and submitted to ultracentrifugation for 2 hours and 45 minutes
under the same conditions as before. After centrifugation, 0.8 mL of the supernatant was
collected by tube slicing at 11.5 mm.
Isolation of lipoproteins with d = 1.063–1.210 g/mL: The remaining lower fraction of
1.2 mL was transferred to a new tube and adjusted to d = 1.210 g/mL by adding 1’357
µL of a d = 1.34 g/mL potassium bromide solution. The sample was brought to a final
volume of 2.6 mL with 43 µL of a d = 1.210 g/mL potassium bromide solution. Of this
mixture, only 2 mL were submitted to ultracentrifugation for 2 hours and 12 minutes
under similar conditions as before. 0.8 mL of the supernatant was collected by tube
slicing, again at 11.5 mm.
Isolation of the lipoproteins with d >1.210 g/mL: The remaining lower fraction of 1.2
mL gained from the step above was collected.
All fractions were stored at −80◦C until further analysis.
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Figure 2.2: Hypothetical arrangement of lipoprotein fractions after ultracentrifugation.
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2.1.2 Protocol B: Precipitation
A precipitation technique was applied to aliquots of the lithium heparin plasma and
serum for separation of apoprotein B–containing lipoproteins, using a modified technique
obtained by combining two protocols from Warnick et al. (1985) and Barrie et al. (1993a).
As evaluated by previous studies, a heparin concentration of 1–5 mg/mL was used in the
presence of 0.092M Mn2+ for optimal precipitation of apo B–containing lipoproteins.
Isolation of “Supernatant”: 0.8 mL of plasma or serum was mixed with 80 µL of a
heparin manganese chloride solution obtained by mixing 2.5 mL heparin–sodium injec-
tion solution (5,000 I.U./mL) with a 1.012 M manganese chloride solution, made up to
5 mL (resulting in a final Mn2+ concentration of 92 mM). After mixture, the sample
was incubated at room temperature for 20 minutes and submitted to centrifugation at
4◦C and 1500 g for 30 minutes with the supernatant being immediately removed after
centrifugation.
Isolation of “Apo B–containing Precipitate”: The remaining precipitate was dissolved
in 0.25 mL of a 0.5 M sodium citrate and 1 mL of a 0.15 M sodium chloride solution.
All fractions were stored at −80◦C until further analysis.
2.1.3 Estimation of Molecular Weights of Proteins
Sodium dodecyl sulphate polyacrylamide gel electrophoresis 10% (SDS–PAGE; Criterion
TGX Stain–Free any kD, Bio–Rad, Switzerland) was used to identify protein–containing
lipoprotein constituents of all fractions obtained as described in protocols A and B.
Before analysis, all fractions were desalted and concentrated by 10 kDa Amicon Ultra
centrifugal filters (Sigma–Aldrich Chemie GmbH, Buchs, Switzerland) at 12,000 g and
4◦C. The dialysis buffer consisted of 0.2 M sodium chloride and 0.3 mM EDTA.
After dialysis, all fractions showed pH values within normal limits (7–7.5) and protein
concentration measurement was performed using NanoDrop (NanoDrop 1000, Thermo
Scientific, Switzerland). If required, additional diluting steps were performed to adjust
the protein amount to 5 µg protein per separated fraction before application to SDS–
PAGE. Only lipoproteins with d = 1.006–1.019 g/mL obtained in protocol A had a lower
protein amount with 2.5 µg protein per sample.
After adaption of protein amounts, all samples were diluted with ”2x” Laemmli SDS–
PAGE sample buffer (containing 62.5 mM Tris–HCl at pH 6.8, 2% SDS, 25% glycerol,
0.01% bromophenol blue and 5% β–mercaptoethanol) in a proportion of 1:1 (v:v) and
samples were heated at 95◦C for 5 minutes. Appropriate volumes of samples were loaded
on the gel together with a protein marker (Precision Plus ProteinTM All Blue Marker,
Bio–Rad, Switzerland) and electrophoresis was performed using 200 V and 35 minutes
run time. Afterwards, gels were activated and imaged through a ChemiDocTM System
(Bio–Rad Clinical Diagnostics, Switzerland).
The relative migration distances (Rf ) of the protein standards used and of the unknown
proteins were calculated using the mobility of a protein (band), divided by the mobility
of the ion front (Rf = distance to band / distance to dye front). Because the ion front
was difficult to locate, mobilities were normalized to the tracking dye that migrates only
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slightly behind the ion front, a technique proposed by Rodbard and Chrambach (1971).
The molecular weights of the unknown protein bands were then generated by the
function y = c × ln(x) + b, using the logarithm of the molecular weights as a function of
Rf (see graph plots in figures 3.2 and 3.4).
2.2 Lipidomics
The lipidomic study was performed between 2014–2015 at the Vetsuisse Faculty of the Uni-
versity of Zurich in collaboration with the Functional Genomics Center Zurich (FGCZ).
Blood samples (lithium heparin plasma and serum) were taken from healthy Beagles be-
fore and after treatment with prednisolone. Lipid extraction was conducted using an
MTBE (methyl tert–butyl ether) extraction protocol while analytical studies were per-
formed by liquid chromatography (LC)–tandem mass spectrometry (MS/MS) followed by
data processing with Progenesis QI and statistical analyses by R.
Blood Samples
Six healthy Beagles, aged between 1 and 5 years (median 4) were included in this study.
Gender was equally distributed with three dogs being male and three dogs being female
(one spayed). All dogs were fed the same constant diet (Josera R© Sensitive) at least one
month before and during the study.
Before treatment with prednisolone, blood was collected into lithium heparin and
serum tubes after at least 12 hours of fasting. Informed consent was obtained from
the owners of the dogs. Their use was in accordance with the guidelines and directives
established by the Animal Welfare Act of Switzerland (TVB NR 133/2013).
The dogs were treated on three consecutive days with prednisolone 50 mg once daily
(Prednisolone 50 mg, Streuli Pharma AG, Uznach, Switzerland), administered orally.
Immediately after treatment, blood from fasted dogs was collected again into lithium
heparin and serum tubes. All samples were centrifuged at 1500 × g for 10 minutes and
stored at −80◦C until further analysis.
Reagents
Methanol (>99.9%), BHT (2,6–di–tert–butyl–4–methylphenol), MTBE (methyl tert–butyl
ether, >99.8%), ammonium acetate (>98%) and LC–MS–grade water were purchased
from Sigma–Aldrich Chemie GmbH (Buchs, Switzerland).
Lipid Extraction
Lipid extraction was performed using a protocol developed by Matyash et al. (2008).
Methanol (1.5 mL) was added to a 200 µL sample aliquot and the tube was vortexed. Then
the sample was mixed with 5 mL of MTBE, including 500 µg/mL BHT as antioxidant,
and the mixture was incubated for 1 hour at room temperature, gently shaking at 450
rpm.
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Phase separation was induced by adding 1.25 mL of MS–grade water, sample was
briefly vortexed and incubated 10 minutes at room temperature. After centrifugation
at 1’000 g for 10 minutes, the upper (organic) phase (4.5 mL, MTBE/methanol/water
10:3:2.5, v/v/v) was collected, transferred into a new glass tube and dried under slow
nitrogen flow on a thermoblock set at 37◦C.
The dried sample was then dissolved in 500 µL of methanol (suitable for liquid chro-
matography) by shaking the glass tube at 300 rpm for 20 minutes, transferred into a
specific glass vial and stored at −20◦C until further analysis.
Liquid Chromatography – Mass Spectrometry
After storage, the dissolved lipid sample was vortexed briefly and 20 µL of the sample was
diluted with 80 µL of a running buffer solution containing methanol (80%) and ammo-
nium acetate (10 mM). From this mixture, 1 µL was injected into a LC–MS/MS system
consisting of a Q–Exactive Hybrid Quadrupole–Orbitrap Mass Spectrometer (Thermo
Scientific) combined with an in house packed tip column (C18 HSST Waters). Samples
were run in randomized order.
Data Processing and Lipid Identification
Data processing was performed by importing raw files from LC–MS/MS into Progenesis–
QI (Nonlinear Dynamics, Newcastle upon Tyne, U.K.), used for automatic alignment,
denoising, deconvolution and extraction of ion peaks. Fragments (such as H+, Na+,
NH4
+, HCOO−, CH3COO−) commonly added to lipid molecules during analysis were
taken into consideration.
Every feature found during mass spectrometry was attached to the best fitting lipid
molecular species available on the Lipid Maps database with lipid ions being first identified
by their mass to charge ratio (m/z) by Lipid Maps (Sud et al., 2007), currently the most
detailed lipid database available. Second, due to multiple identifications of specific lipid
molecular species, further lipid identification was performed on an in–house built Pyton
script (Dr. Jeremy Deuel, University Hospital, Zurich) to enhance the accuracy of lipid
identification by setting the fragmentation score to >0, the overall score of every feature
was set to >2 × standard deviation (SD) and isotope similarity to >2 × SD.
Taking these precautions, lipids were considered to be securely identified and the
common standard lipid language described by Lipid Maps was applied.
Statistical Analysis
Data was normalized by logarithmic transformation of raw data (relative abundance of
lipid ions), indicating normal distribution of lipids within dogs (QQ–plots).
Lipids from dogs before prednisolone treatment were analyzed by paired Student’s
t–test to compare lithium heparin plasma with serum.
All identified lipids were further analyzed using the paired Student’s t-test for compar-
ison between before and after prednisolone treatment, separately performed for lithium
heparin plasma and serum.
38 Chapter 2. Material and Methods
The statistical analyses and graphics were performed using the open source program R
(R Core Team, 2015) and all p values were corrected for multiple testing (false discovery
rate). Differences were considered significant at values of p ≤ 0.05.
Chapter3
Results
3.1 Lipoprotein Separation
3.1.1 Protocol A: Ultracentrifugation
SDS–PAGE analysis of the five fractions (d <1.006 g/mL, d 1.006–1.019 g/mL, d 1.019–
1.063 g/mL, d 1.063–1.210 g/mL, d >1.210 g/mL) from lithium heparin plasma revealed
five bands in fraction 1, two bands in fraction 2, two bands in fraction 3, one band in
fraction 4 and five bands in fraction 5 as the most intense protein stains (figure 3.1,
Plasma).
SDS–PAGE analysis of the five fractions (d <1.006 g/mL, d 1.006–1.019 g/mL, d
1.019–1.063 g/mL, d 1.063–1.210 g/mL, d >1.210 g/mL) from serum revealed four bands
in fraction 1, two bands in fraction 2, two bands in fraction 3, one band in fraction 4 and
five bands in fraction 5 as the most intense protein stains (figure 3.1, Serum).
The estimated molecular weights of protein bands found on SDS–PAGEs produced
by protocol A from lithium heparin plasma and serum are shown in Fig. 3.2. A plot of
migration versus logarithmic molecular weight shows logarithmic function for all proteins
found.
Further, all estimated molecular weights found in lithium heparin plasma and serum
are summarized in table 3.1. Possible relations with apoproteins will be discussed in the
next chapter.
Table 3.1: Estimated molecular weights of isolated lipoprotein fractions from lithium heparin
plasma and serum using protocol A as described in subsection 2.1.1.
Lane Density Fraction Molecular Weights (kDa)
in Plasma
Molecular Weights (kDa)
in Serum
1 <1.006 g/mL 67, 52, 33, 30, 23 58, 34, 31, 23
2 1.006–1.019 g/mL 250, 23 298, 23
3 1.019–1.063 g/mL 23, 14 23, 15
4 1.063–1.210 g/mL 23 23
5 >1.210 g/mL 75, 60, 44, 31, 26 75, 56, 51, 31, 26
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Figure 3.1: SDS–PAGEs of canine lithium heparin plasma and serum, lipoproteins were separated
by protocol A. Description of lanes: 1) d <1.006 g/mL; 2) d 1.006–1.019 g/mL; 3) d 1.019–1.063
g/mL; 4) d 1.063–1.210 g/mL; 5) d >1.210 g/mL. Protein marker with defined standard molecular
weights ranging from 10 to 250 kDa was applied (Marker), each lane consists of 5 µg total protein,
except lane 2 (2.5 µg).
3.1. Lipoprotein Separation 41
250kDa 
45kDa 
67kDa 
14kDa 
33kDa 
23kDa 
30kDa 
1
1.5
2
2.5
3
0 0.2 0.4 0.6 0.8 1
lo
g(
kD
a)
 
Rf 
Protocol A: Estimated Molecular Weights in Plasma 
Protein Marker
Molecular Weights found on
SDS-PAGE
Log. (Protein Marker)
(a) Plasma
298kDa 
51kDa 
75kDa 
23kDa 
31kDa 
34kDa 
15kDa 
56kDa 
1
1.5
2
2.5
3
0 0.2 0.4 0.6 0.8 1
lo
g(
kD
a)
 
Rf 
Protocol A: Estimated Molecular Weights  in Serum  
Protein Marker
Molecular Weights found on
SDS-PAGE
Log. (Protein Marker)
(b) Serum
Figure 3.2: Molecular weight estimations of major protein bands observed on SDS–PAGEs after
lipoprotein separation according to protocol A.
42 Chapter 3. Results
3.1.2 Protocol B: Precipitation
Serum samples precipitated more quickly during analytical procedures and in greater
amounts than lithium heparin plasma. However, no obvious turbidity was seen in the
supernatant of either blood sample as an indication for incomplete precipitation.
SDS–PAGE analysis of the two fractions from lithium heparin plasma revealed six
bands in the precipitate and six bands in the supernatant as the most intense protein
stains (figure 3.3, Plasma).
SDS–PAGE analysis of the two fractions from serum revealed six bands in the pre-
cipitate and six bands in the supernatant as the most intense protein stains(figure 3.3,
Serum).
The estimated molecular weights of protein bands detected on both SDS–PAGEs are
shown in Fig. 3.4. A plot of migration versus logarithmic molecular weight shows a
logarithmic function for all proteins.
All estimated molecular weights found on SDS–PAGEs from lithium heparin plasma
and serum are summarized in table 3.2. Possible relations with apoproteins will be dis-
cussed in the next chapter.
Table 3.2: Estimated molecular weights of isolated precipitate and supernatant from lithium he–
parin plasma and serum using protocol B.
Fraction Molecular Weights (kDa)
in Plasma
Molecular Weights (kDa)
in Serum
Precipitate 255, 63, 56, 49, 33, 23 266, 75, 61, 49, 35, 25
Supernatant 75, 63, 49, 33, 26, 23 75, 61, 49, 35, 26, 25
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Figure 3.3: SDS–PAGEs of canine lithium heparin plasma and serum, lipoproteins were separated
by protocol B. Description of lanes: Precip. = Precipitate; Supernat. = Supernatant. Protein
marker with defined standard molecular weights ranging from 10 to 250 kDa was applied (Marker),
each lane consists of 5 µg total protein.
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Figure 3.4: Molecular weight estimations of major protein bands observed on SDS–PAGEs after
lipoprotein separation according to protocol B.
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3.2 Lipidomics
3.2.1 Lipid Identification and Distribution
Canine Plasma
408 different lipids were identified in the canine lithium heparin plasma and categorized
into seven categories as shown in table 3.3.
The highest amount of identified lipid molecular species found was the fatty acyls
(FAs), at 44.6%, followed by glycerophospholipids (GPs, 19.4%), sterol lipids (STs, 10.5%),
glycerolipids (GLs, 8.8%), sphingolipids (SPs, 7.1%), prenol lipids (PRs, 6.9%) and
polyketides (PKs, 2.7%). Of the eight main lipid categories as categorized by Lipid
Maps, only saccharolipids (SLs) were missing.
Canine Serum
In all, 399 different lipids were identified in the canine serum and categorized into eight
categories of lipids, as shown in table 3.3.
The highest amount of identified lipid molecular species found was the fatty acyls
(FAs), at 47.4%, followed by the glycerophospholipids (GPs, 19.3%), sterol lipids (STs,
10.3%), sphingolipids (SPs, 7.8%), glycerolipids (GLs, 7.0%), prenol lipids (PRs, 5.8%),
polyketides (PKs, 2.3%) and one saccharolipid (SL, 0.3%).
A complete data set of the canine lipidome (561 molecular lipid species) found in
plasma and serum during this study is presented in table A.1 in the appendix, with further
details on all identified lipids available on the Lipid Maps homepage (www.lipidmaps.org).
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Table 3.3: Lipid categories and classes analyzed in canine plasma and serum.
Lipid Category Main Class Lipid
Species
Plasma
Lipid
Species
Serum
Fatty Acyls (FAs) 182 189
Other Fatty Acyls 1 0
Fatty Acids and Conjugates 94 80
Octadecanoids 19 16
Eicosanoids 8 15
Docosanoids 3 3
Fatty Alcohols 7 9
Fatty Aldehydes 5 8
Fatty Esters 25 34
Fatty Amides 12 12
Hydrocarbons 2 3
Oxygenated Hydrocarbons 6 8
Glycerophospholipids
(GPs)
79 77
Other Glycerophospholipids 1 0
Glycerophosphocholines (PCs) 29 26
Glycerophosphoethanolamines (PEs) 17 18
Glycerophosphoserines (PSs) 10 14
Glycerophosphoglycerols (PGs) 1 1
Glycerophosphoinositols (PIs) 8 8
Glycerophosphates (PAs) 10 8
Oxidized Glycerophospholipids 3 2
Sterol Lipids (STs) 43 41
Sterols 18 17
Steroids 3 5
Secosteroids 8 10
Bile Acids and Derivates 12 7
Steroid Conjugates 2 2
Glycerolipids (GLs) 36 28
Monoradylglycerols 6 5
Diradylglycerols 22 20
Triradylglycerols 8 3
Sphingolipids (SPs) 29 31
Sphingoid Bases 5 9
Ceramides 9 11
Phosphosphingolipids 8 6
Neutral Glycosphingolipids 4 2
Acidic Glycosphingolipids 3 3
Prenol Lipids (PRs) 28 23
Isoprenoids 26 20
Quinones and Hydroquinones 2 2
Hopanoids 0 1
Polyketides (PKs) 11 9
Linear Polyketides 0 1
Macrolides and Lactone Polyketides 2 2
Flavonoids 8 6
Aromatic Polyketides 1 0
Saccharolipids (SLs) 0 1
Other Acyl Sugars 0 1
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3.2.2 Plasma vs. Serum
246 molecular lipid species were identified in both plasma and serum in all six dogs.
When these individual lipids are compared across the matrices, out of the 246, eleven
lipids (4.5%) were significantly altered in their relative mean abundances between plasma
and serum as analyzed by the paired Student’s t–test, graphically illustrated by a volcano
plot (figure 3.5) and summarized in table 3.4.
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Figure 3.5: Volcano plot showing eleven statistically significant different lipids (green strokes)
between canine lithium heparin plasma and serum.
Q–Q–plots for plasma and serum are shown in section A.2 in the appendix. To sum-
marize, seven fatty acyls (FAs) were found to be significantly altered, followed by two
prenol lipids (PRs), one glycerophospholipid (GP) and one polyketide (PK). Ratios were
calculated for all significantly changed lipids, comparing plasma with serum to express
the magnitude of variation. Four lipids were increased in plasma, with ratios between
1.3 to 3.4, and seven lipids were increased in serum, with ratios between – 0.6 to – 1.2
(plasma / serum).
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Table 3.4: Eleven significantly different lipids comparing lithium heparin plasma to serum by paired
Student’s t–test.
Nr. Cat. Main Class Sub Class Common Name Systematic Name Log2
Ratio
Plasma
/Serum
p
1 FA Fatty Acids
and Conju-
gates
Dicarboxylic
acids
– 2E,4E,8E,10E–
Dodecatetraenedioic
acid
– 1.2 0.014
2 FA ” ” Hydroxy fatty
acids
3–hydroxy–
isoheptanoic
acid
3–hydroxy–6–methyl–
hexanoic acid
– 1.2 0.049
3 FA ” ” ” ” – 11S–hydroxy–
tetradecanoic acid
– 0.8 0.049
4 FA ” ” Oxo fatty acids 14–keto pen-
tadecanoic
acid
14–oxo–
pentadecanoicacid
2.8 0.003
5 FA ” ” or Do–
cosanoids
Unsaturated
fatty acids or –
Adrenic Acid 7Z,10Z,13Z,16Z–
docosatetraenoic acid
– 0.6 0.004
6 FA Fatty amides N–acyl amines N–palmitoyl
glycine
N–hexadecanoyl–glycine – 1.4 0.046
7 FA Fatty esters Wax monoesters – formyl 7–oxo–11E–tetra–
decenoate
– 0.4 0.034
8 GP Glycerophos–
phoserines
1–(1Z–
alkenyl),2–
acylglycero–
phosphoserines
PS(P–
16:0/18:0)
1–(1Z–hexadecenyl)–2–
octadecanoyl–glycero–3–
phosphoserine
1.3 0.034
9 PK Flavonoids Chalcones and
dihydrochal-
cones
– 1–(2,5–dihydro–6,8–
dihydroxy–3–methyl–
1–benzoxepin–7–yl)–3–
phenyl–1–propanone
3.4 0.026
10 PR Isoprenoids C15 isoprenoids
(sesquiterpenes)
(+)–Blennin D – 2.9 0.004
11 PR Isoprenoids Retinoids 9–cis–retinol 9Z–retinol – 0.7 0.049
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3.2.3 Prednisolone Treatment
Canine Plasma
Ten different lipids turned out to be significantly decreased or increased in canine plasma
after treatment with prednisolone (figure 3.6 and table 3.5).
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Figure 3.6: Volcano plot showing statistically significant lipids (green strokes) in plasma after
prednisolone treatment.
Ratios were calculated for all significantly changed lipids after prednisolone treatment
to express the magnitude of variation. In summary, three lipids were decreased after
prednisolone treatment, with ratios between – 0.6 to – 3.2, and seven lipids were enhanced
after treatment, with ratios between 0.6 to 3.9.
All significantly altered lipids after prednisolone treatment are illustrated in figure
3.7, showing their abundances within each dog according to color intensity, with blue
indicating a decreased amount and red indicating an increased amount of the lipid in
question. Q–Q–plots for plasma are shown in section A.3 in the appendix at the end of
this manuscript.
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Table 3.5: Ten statistically significant lipids in plasma after prednisolone treatment.
Nr. Cat. Main Class Sub Class Common Name Systematic Name Log2
Ratio
After/
Before
p
1 FA Fatty Acids
and Conju-
gates
Branched fatty
acids
Hydroxyphthio–
ceranic acid
(C39)
2S,4S,6S,8S,10R,12R,
14R–heptamethyl–15–
hydroxy–dotriacontanoic
acid
– 3.2 0.034
2 FA ” ” Hydroxy fatty
acids
– 3–hydroxy–hexadecanoic
acid
2.3 0.017
3 FA ” ” Unsaturated
fatty acids
– 10,13,16–Docosatriynoic
acid
3.9 0.029
4 FA ” ” ” ” – 8,11–Eicosadiynoic acid 1.7 0.044
5 FA ” ” ” ” – 11Z–octadecen–9–ynoic
acid
– 0.8 0.029
6 FA Docosanoids – DPA 7Z,10Z,13Z,16Z,19Z–
docosapentaenoic acid
3.2 0.016
7 FA Octadeca–
noids
Other Octade–
canoids
– 9R–hydroxy–octadecanoic
acid
2.3 0.003
8 FA ” ” Other Octade–
canoids
– 3R–hydroxy–octadecanoic
acid
2.1 0.008
9 GP Glycerophos–
phoethanol–
amines
1–(1Z–
alkenyl),2–acyl–
glycerophospho–
ethanolamines
PE(P–
16:0/22:4)
1–(1Z–hexadecenyl)–
2–(7Z,10Z,13Z,16Z–
docosatetraenoyl)–
glycero–3–
phosphoethanolamine
0.6 0.039
10 GL Monoradyl–
glycerols
Monoacyl–
glycerols
MG(18:1(11E)/
0:0/0:0)[rac]
1–(11E–octadecenoyl)–
rac–glycerol
– 0.6 0.019
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Figure 3.7: Heatmap of statistically significant lipids in canine lithium heparin plasma compared
before (A) and after (B) prednisolone treatment. Blue indicates a decreased amount and red and
increased amount of this lipid.
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Canine Serum
Three different lipids turned out to be significantly decreased or increased in canine serum
after treatment with prednisolone (figure 3.8 and table 3.6).
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Figure 3.8: Volcano plot showing statistically significant lipids (green strokes) in serum after
prednisolone treatment.
Ratios were calculated for all significantly changed lipids after prednisolone treatment
to express the magnitude of variation. To summarize, one lipid was decreased after
prednisolone treatment, by a ratio of –1.2, and two lipids were increased after treatment,
by ratios of 0.8 to 0.9. Q–Q–plots for serum are shown in section A.3 in the appendix at
the end of this manuscript.
In addition, all significantly altered lipids after prednisolone treatment are illustrated
in figure 3.9, which their abundances within each dog by means of color intensity, with
blue indicating a decreased amount and red indicating an increased amount of a lipid.
Interestingly, 9R–hydroxy–octadecanoic acid was found to be significantly altered after
prednisolone treatment in both serum and plasma. It was 0.9 times higher in serum and
2.3 times higher in plasma.
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Table 3.6: Statistically significant lipids in serum after prednisolone treatment.
Nr.Cat. Main Class Sub Class Common
Name
Systematic Name Log2
Ratio
After/
Before
p
1 FA Octadeca–
noids
Other Octade–
canoids
– 9R–hydroxy–octadecanoic
acid
0.9 0.047
2 FA Fatty Acids
and Con–
jugates or
Docosanoids
Unsaturated
fatty acids or –
Adrenic acid 7,10,13,16–
docosatetraenoic acid
0.8 0.019
3 GP Glycerophos–
phoethanol–
amines
Diacylglycero–
phosphoethanol–
amines
PE(20:4/20:0)1–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–2–
eicosanoyl–glycero–3–
phosphoethanolamine
–1.2 0.038
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Figure 3.9: Heatmap of statistically significant lipids in canine serum before (A) and after (B)
prednisolone treatment.
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Discussion
4.1 Lipoprotein Separation
4.1.1 Protocol A: Ultracentrifugation
Lipoprotein separation with Protocol A was performed according to human lipoprotein
density classes, with density (d) fraction <1.006 g/mL representing human VLDLs, d =
1.006–1.019 g/mL human IDLs, d = 1.019–1.063 g/mL human LDLs, d = 1.063–1.210
g/mL human HDLs and d >1.210 g/mL no specific fraction.
Separation of lipoprotein fractions was evaluated according to the estimated molecular
weights from SDS–PAGEs, which were assumed to represent related apoproteins. For
protocol A, the most suitable apoproteins in the dogs are shown in table 4.1 for plasma
and in table 4.2 for serum. However, as SDS–PAGEs show not only apoproteins but all
proteins within a fraction, the estimated molecular weights could also be indicative of
various other proteins.
Table 4.1: Assumed apoproteins isolated from plasma using protocol A.
Density Fraction Molecular Weights
(kDa) in Plasma
Indicated Apoproteins
<1.006 g/mL 67, 52, 33, 30, 23 Albumin, ?, E, D, A–I
1.006–1.019 g/mL 250, 23 B–48, A–I
1.019–1.063 g/mL 23, 14 A–I, A–II
1.063–1.210 g/mL 23 A–I
>1.210 g/mL 75, 60, 44, 31, 26 ?, Albumin, A–IV, D/E, ?
An intense protein band with an estimated molecular weight of ≈ 23 kDa, indicative
of apo A–I, was found in both canine plasma and serum. This is in agreement to another
study with canine apoproteins, where a protein band of 25 kDa was identified as apo A–I
by LC–MS (Asuka et al., 2013). This protein band was most intense and broad in the two
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Table 4.2: Assumed apoproteins isolated from serum using protocol A.
Density Fraction Molecular Weights
(kDa) in Serum
Indicated Apoproteins
<1.006 g/mL 58, 34, 31, 23 Albumin, E, D, A–I
1.006–1.019 g/mL 298, 23 B–48, A–I
1.019–1.063 g/mL 23, 15 A–I, A–II
1.063–1.210 g/mL 23 A–I
>1.210 g/mL 75, 56, 51, 31, 26 ?, Albumin, A–IV, D/E, ?
fractions covering d 1.019–1.210 g/mL, which most closely represent the density range of
canine HDL (Xenoulis and Steiner, 2010; Bauer, 2004), verifying apo A–I as the major
apoprotein of HDL.
However, the suspected apo A–I was also found in fractions with lower densities from d
<1.006 g/mL up to 1.019 g/mL, where no canine HDL was expected. Therefore either the
separation of lipoprotein fractions was inaccurate, possibly due to an insufficient run time,
or another protein has similar molecular weights to apo A–I. Apo A–I could also occur
separated from HDL due to ultracentrifugal forces (Munroe et al., 2015), however labile
apoproteins, such as Apo A–I and apo E, have been reported to be found at the bottom
of the tube after centrifugation, hence in a fraction above HDL, such as d >1.210g/mL
(Brousseau et al., 1993; Kunitake and Kane, 1982).
Overlapping densities of canine LDL, d 1.019–1.087 g/mL, and HDL, d 1.025–1.210
g/mL (Mahley and Weisgraber, 1974), can best be seen in the fraction of d 1.019–1.063
g/mL, with strong protein bands indicative of apo A–I and faint bands assumed to repre-
sent apo B–48 with molecular weights >250 kDa. The faint bands may be due to technical
aspects, as only 5µg protein per lane was applied on our SDS–PAGEs, and apo A–I occurs
at a higher percentage than apo B–48 and possibly apo B–100.
Apo B–48 was also assumed to occur in the fraction of d 1.006–1.019 g/mL, which
represents human IDLs (Jonas, 2002) and has only occasionally been reported for dogs
(Bauer, 2004). However, lipoproteins have been found in this fraction and the occurrence
of apo B–48 was previously reported for canine CMs, VLDLs and LDLs, (Xenoulis and
Steiner, 2010). Therefore, either canine IDL does exist or VLDLs and LDLs are not
separated as accurately as previously reported (Mahley and Weisgraber, 1974), which
seems plausible regarding the ongoing exchange of molecules in lipoprotein metabolism.
However, in contrast to human studies, we report a protein band indicative of apo B–48
instead of apo B–100 within the IDL fraction.
Protein bands of 30–31 kDa and 33–34 kDa, indicative of apo D and E, were found
in the first fraction (d <1.006 g/mL)L. However, mainly apo E has been mentioned so
far in dogs, and then especially in a cholesteryl ester–rich subfraction of HDL that shows
a similar density to LDL (Barrie et al., 1993a). However, we did not find protein bands
indicative of apo E in fractions representing canine HDL. But looking at the last fraction
with d >1.210 g/mL, the protein band of ≈ 31 kDa was found, indicative of either apo
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D or E. This could either represent a separated apoprotein from HDL or no apoprotein
at all. Instead, another protein could represent this band, e.g. haptoglobin, identified
at a molecular weight of 35 kDa in another study with canine lipoproteins (Asuka et al.,
2013).
Further, an established apoprotein of HDL, apo A–IV, may correspond to protein
bands of 44–51 kDa. Apo A–IV was detected in humans at a weight of 44–46 kDa
(Jonas, 2002). However, in our study, they were primarily detected at d >1.210 g/mL,
when the expected density for canine HDL lies lower at d 1.025–1.210 g/mL (Mahley
and Weisgraber, 1974). This may be due to a false identification of this protein band or
the disconnection from HDL and therefore occurring in a higher density class because of
ultracentrifugal forces, although apo E and A–I would then be expected to be found in
the same fraction. It is also possible that apo A–IV is associated with heavier HDLs as
reported for various species including the dog in another study (Hollanders et al., 1986).
However, that study hypothesized that apo E and apo A–IV do not coexist on the same
HDL, which would be different to our findings. Additionally, the protein bands of 44–51
kDa were also detected as faint bands at the fraction with d <1.006 g/mL, indicative of
CMs. As apo A–IV was already reported for CMs in humans (Jonas, 2002), this could be
true for dogs as well. However, CMs were thought to be limited due to fasting.
Apo A–II was interpreted into faint protein bands of 14-15 kDa, occurring in two
fractions in our study: d <1.006 g/mL and d 1.019-1.063 g/mL. The latter seems rea-
sonable, as apo A–II is related to HDL in humans, making it plausible to have the same
characteristics in dogs. But apo A–II appearing in the fraction related to canine VLDL
was not reported before, which may be due to the newer imaging techniques for SDS–
PAGEs, which are more sensitive than the traditional staining methods. However, false
identification could always have occurred and this molecular weight could also represent
another protein, e.g. serum amyloid A, an acute phase protein found at 13 kDa within
canine plasma (Chikamune et al., 1998). Although apo A–II is considered to be one of
the major apoproteins of HDL in humans, it was only reported once before for canine
lipoproteins by Puppione et al. (2008). That study confirmed its presence and indicated
a possible connection with canine HDL1. This would match our results with a protein
band of 14–15 kDa in the fraction of d 1.019–1.063 g/mL.
Further, lithium heparin plasma as well as serum showed several proteins strongly
visible in the last fraction of d >1.210 g/mL, assumed to represent contamination with
other proteins as previously reported (Chikamune et al., 1998). One of these proteins has
a strong band of ≈ 75 kDa, occurring in the density fraction >1.210 g/mL, not currently
related to any known apoprotein in dogs. Hypothetically, it may represent clusterin (70
kDa), a complement lysis inhibitor and also known as apoprotein J, reported as forming
complexes with apo A–I in human HDLs (Jenne et al., 1991). However, apo A–I does not
seem to be present in this fraction. Another explanation for a protein of ≈ 75 kDa would
be the occurrence of hemoglobin (≈ 65 kDa), because an orange band was visible during
the analytical procedure at the very bottom of the ultracentrifugation tube, previously
reported from the hemoglobin of rats (Rodriguez-Sureda et al., 2002). Transferrin has
also been reported to have a molecular weight of ≈ 80 kDa and was shown to be enriched
in small and dense subfractions of HDL (HDL3), which means it could also represent the
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Table 4.3: Isolated fractions, expected lipoproteins and indicated apoproteins on SDS–PAGEs.
Isolated Fraction Human
Lipo–
proteins
Expected
Canine
Lipoproteins
Expected
Canine
Apoproteins
Aporoteins indi-
cated on SDS–
PAGEs
<1.006 g/mL VLDL VLDL B–100, B–48,
E, C
(B–48), A–I, (A–
II), E, D
1.006–1.019 g/mL IDL - – B–48, A–I
1.019–1.063 g/mL LDL LDL, HDL1 B–48, A, E,
C
(B–48), A–I, A–II
1.063–1.210 g/mL HDL Rest of LDL
and HDL1−3
B–100, B–48,
A, E, C
A–I
>1.210 g/mL >HDL - – A–IV, D/E
protein band at ≈ 75 kDa (McPherson et al., 2007).
No apo C (7–9 kDa) was indicated in our study, probably due to the dialysis of samples
with 10 kDa filters, and thus losing proteins with molecular weights <10 kDa.
In conclusion, canine lipoprotein separation probably needs longer ultracentrifugal run
times than used in this study, but such an increase may further contribute to the lability
of apoproteins and allow more time for oxidation. Further, slightly different molecular
weights than those reported previously for canine apoproteins as well as small differences
between plasma and serum occurred with this protocol, possibly due to analytical proce-
dures and manual estimation of molecular weights. Nevertheless, our results in this study
were similar to those reported previously for canine lipoproteins (Mahley and Weisgraber,
1974; Bauer, 2004), verifying different density ranges for canine lipoproteins compared
with human lipoproteins and indicating overlapping lipoprotein densities. Most apopro-
teins assumed to be found in this protocol were comparable to those found in another
study investigating canine lipoproteins and analyzing apoproteins either by SDS–PAGE
(Chikamune et al., 1998) or mass spectrometry (Asuka et al., 2013).
4.1.2 Protocol B: Precipitation
Similar to the overlapping lipoprotein densities in dogs, lipoprotein (a) in humans, an
LDL–like lipoprotein containing apo B and apo (a), has a density range overlapping
with HDL (Warnick and Albers, 1978), requiring different separation techniques, such as
precipitation.
The protocol we used here consisted of 92 mM heparin manganese chloride, which
was reported to precipitate apoprotein B–containing lipoproteins (Warnick et al., 1985)
in a human study, and similarly to another study with canine lipoproteins (Barrie et al.,
1993a). The heparin manganese chloride technique is also the method recommended by
the International Federation of Clinical Chemistry, although an ultracentrifugation step
is generally a precondition for excluding VLDLs for cholesterol measurements of LDLs
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and HDLs. During our study, we evaluated precipitation with and without a previous
ultracentrifugation step for removal of VLDLs (d <1.006 g/mL), resulting in only minor
differences. Because the same protocol for removal of VLDLs was used as described above
(4.1.1) in protocol A, removal of VLDLs seemed to either be incomplete or contaminated
with other proteins. For this reason, we only present precipitation without previous
ultracentrifugation in this study.
Table 4.4: Estimated molecular weights and assumed related proteins using protocol B in plasma.
Fraction Molecular Weights (kDa)
in Plasma
Indicated Apoproteins
Precipitate 255, 63, 56, 49, 33, 23 B–48, (Albumin), ?, A–IV,
E/D, A–I
Supernatant 75, 63, 49, 33, 26, 23 ?, (Albumin), A–IV, E/D, ?,
A–I
Table 4.5: Estimated molecular weights and assumed related proteins using protocol B in serum.
Fraction Molecular Weights (kDa)
in Serum
Indicated Apoproteins
Precipitate 266, 75, 61, 49, 35, 25 B–48, ?, (Albumin), A–IV,
E/D, A–I
Supernatant 75, 61, 49, 35, 26, 25 ?, (Albumin), A–IV, E/D, ?,
A–I
The precipitated fractions showed strong protein bands around ≈ 260 kDa, indicative
of apo B–48 in both lithium heparin plasma and serum. However, the same protein band
was very faintly visible in the remaining supernatant as well. This is in contrast to two
previous studies with canine lipoproteins (Barrie et al., 1993a; Asuka et al., 2013), which
both reported almost complete precipitation, although the latter used a higher amount
of manganese chloride.
In our study, incomplete precipitation could have occurred due to absent removal of
triglyceride–rich VLDLs as hypothesized by Warnick et al. (1985). Otherwise, protein
bands interpreted as apo B in the supernatant could represent other proteins.
Next to the protein band indicative of apo B–48, a second and fainter one of ≈ 330
kDa was also visible in both samples, not necessarily corresponding to apoproteins known
in the dog. Apo B–100 would be expected to have a higher molecular weight of ≈ 500
kDa (Xenoulis and Steiner, 2010; Mahley and Weisgraber, 1974).
A strong protein band of ≈ 49 kDa was visible in both fractions, and was suspected
of representing apo A–IV. As apo A–IV is only known as being associated with HDL in
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dogs (Xenoulis and Steiner, 2010), a contamination of the precipitated fraction with HDL
is suspected.
Similarly to apo A–IV, a protein band of 23–25 kDa, assumed to represent apo A–I,
was observed in both fractions with stronger visibility in the supernatant. Thus apo A–I
and apo A–IV were found within the dissolved precipitate, which is in agreement with
previous studies involving canine lipoproteins (Barrie et al., 1993a; Asuka et al., 2013),
where traces of contamination were found in the precipitate. As an explanation, small
amounts of apo A–I could still have been attached to the precipitate or enclosed in its
complex, despite washing the precipitated fractions before dissolving them. Or it may
indicate that certain lipoproteins containing apo A–I precipitate together with canine apo
B–containing lipoproteins, represented by CMs, VLDLs, and LDLs (Xenoulis and Steiner,
2010). A third possibility could be that some canine LDLs possess both apo B and apo
A–I, however this property has only been investigated in humans, and showed LDL to
have apo B–100 and certain amounts of apo A–I and apo E (Collins et al., 2010).
A faint protein band of 33–35 kDa was seen in both fractions, appearing slightly
stronger in the supernatant. As apo E is associated with VLDLs and HDLs (Xenoulis
and Steiner, 2010), this protein band probably represents apo E.
Furthermore, a protein band of 61–63 kDa, suspected to be albumin, appeared al-
most equally strong in both fractions and matrices. This suggests that albumin can also
be complexed by heparin manganese chloride which was reported previously for human
lipoproteins (Warnick and Albers, 1978).
Protein bands indicative of apo C (7–9 kDa) were not apparent in either fraction, as
expected, due to previous dialysis against 10 kDa–sized filters.
Regarding the comparison of plasma and serum, a difference between suspected apo
A–I and apo A–IV protein bands occurred, indicating matrix–associated differences. This
could possibly be due to the use of lithium heparin plasma, adding additional heparin
to the precipitation protocol. Alternatively, heparin could have activated the lipoprotein
lipase and modified the lipoprotein structures in the tube, as already hypothesized by
others (Moffatt and Stamford, 2005).
Generally, numerous protein bands were seen in both fractions, revealing difficulties
in lipoprotein separation and identification of apoproteins. Moreover, the lipid composi-
tion of precipitated lipoproteins may differ from that of analogous lipoproteins obtained
by flotation techniques. Therefore, precipitation with heparin manganese chloride may
be generally effective for a rough and time–saving separation of lipoproteins but may
not accurately separate canine LDLs from HDLs. Further, potential alterations of lipid
structures render this technique unsuitable for subsequent lipidomic analyses.
4.1.3 Other Lipoprotein Separation Techniques
The traditional approaches such as ultracentrifugation and precipitation did not result
in satisfactory separation of canine lipoproteins. Separation according to electrophoretic
mobilities has so far been most successful according to Pasquini et al. (2008), however its
suitability for subsequent lipidomic analyses is doubtful.
As a different approach, several studies with canine lipoproteins have already used fast
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protein liquid chromatography (FPLC) for separation of lipoproteins into three fractions:
VLDL, LDL and HDL, accelerating the process of identifying apoproteins (Jerico´ et al.,
2009; Bailhache et al., 2003). It has also been also reported that gel permeation–high
performance liquid chromatography (GP–HPLC) is an efficient method in separating ca-
nine lipoproteins by size (Mizutani et al., 2010), however GP–HPLC was compared with
the ultracentrifugation–precipitation technique and did not achieve better results (Asuka
et al., 2013).
Nevertheless, using FPLC in combination with tandem mass spectrometry (MS/MS)
to study lipoprotein fractions separated according to their (apo–) proteins would represent
an ideal combination and has been achieved in human lipoproteins in a pioneering study
by Wiesner et al. (2009). A similar approach with canine lipoproteins should be evaluated
for future studies.
4.2 Lipidomics
4.2.1 Lipid Distribution
Fatty Acyls
When compared with all identified lipids (561 identified lipids), fatty acyls (FAs) account
for the most diverse lipid category and the specific FAs identified differ greatly between
serum and plasma. This is probably due to FAs being a very diverse group of molecules
that only have a repeating series of methylene groups in common, (Li et al., 2014). Fur-
ther, the first subclass of fatty acyls in the canine lipidome (”fatty acids and conjugates”)
is most diversified, constituting half of all fatty acyls in plasma and serum, similar to
what has been found human studies (Fahy et al., 2005).
The predominant fatty acids in animals have been reported to be C16 (palmitic acid)
and C18 species, such as stearic (saturated), oleic (mono–unsaturated) and linoleic acids
(poly–unsaturated). Unsaturated fatty acids consist of one (mono–) or more (poly–)
unsaturated double bonds that are prone to oxidation. Due to biosynthesis from C2
units, most fatty acids have been reported to possess an even number of carbon atoms
(Voet et al., 2012). In our study, we found FAs with almost any number of carbon atoms,
varying from C5 to C42, with no definite predominance of even–numbered fatty acyls
identified.
However, we did find an oelic acid (appendix A.1, FA01 No 48), the number one
constituent of human plasma (Quehenberger et al., 2010). Palmitic acid, the second most
commonly measured lipid in human plasma (Quehenberger et al., 2010), was not found
in its original form in our study, but as a dihydroxy-palmitic-acid instead (appendix A.1,
FA01 No 74).
Two polyunsaturated fatty acids (PUFA) were further found to be most abundant
in the human plasma lipidome: linoleic acid and arachidonic acid (Quehenberger et al.,
2010). Of these, only linoleic acid was found in our study, albeit in a slightly different
chemical structure. As for arachidonic acids, only derivates were found in this study.
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Of the major fatty acids found in human plasma, comprising about 78% of all free
fatty acids in the circulation (Quehenberger et al., 2010), none was found in identical
form in the canine lipidome. Although free fatty acids represent only a small fraction of
all fatty acids, they are highly active lipids. Their low identification rate in our study
may be due to the analytical procedures used, as free fatty acids are better extracted by
different lipid extraction techniques followed by gas chromatography instead of by liquid
chromatography. Further, adipose tissue is the main source of free fatty acids in plasma
(Quehenberger et al., 2010) and the distribution of free fatty acids is potentially related to
dietary factors, which differ between humans and dogs. Additionally, the non–occurence
of major human lipids in the canine lipidome could be due to susceptibility of PUFAs
to oxidation processes (Watson, 2006), despite the addition of an antioxidant (BHT)
during the analytical procedures. Especially if looking for lipids involved in atherosclerotic
processes, the prevention of further oxidation is essential, as oxidation may continue
indefinitely (Malle et al., 2006). As we did not include the identification of oxidative
lipids, we missed these lipids in our study.
An important lipid class is the eicosanoids, involved in inflammatory processes and as-
sociated with atherosclerosis, where they often function as signaling molecules (Fahy et al.,
2005). They are further found to play an important role on cholesterol regulation and
seem therefore promising in the therapy of high plasma LDL–cholesterol levels as proposed
by Demetz et al. (2014). In our study, eicosanoids were represented by eight identified
lipids in plasma and 15 in serum. In comparison, 143 metabolites were found associated
with the eicosanoid pathway in the study of Quehenberger et al. (2010), although not all
of them were categorized as eicosanoids. Two subclasses of eicosanoids were specifically
found to be related to oxygenic processes: hydroxy / hydroperoxy–eicosatetraenoic acids
and isoprostanes. In our study, we found five of these lipids. Especially F2-isoprostanes
were mentioned as risk factors, which are prostaglandin–like compounds derived from the
peroxidation of arachidonic acid (Morrow, 2005). Further, one of the prostaglandins found
in this study (appendix A.1, FA03 No 140) was previously reported to be associated with
atherosclerosis (Berliner et al., 2009).
Glycerophospholipids
In our study, glycerophospholipids (GPs) were the second largest category of all identi-
fied lipids. The majority of all GPs identified in our study are glycerophosphocholines
(PCs) and glycerophosphoethanolamines (PEs), similar to those found in human studies
(Quehenberger et al., 2010).
As GPs are most widely known as key components of cell membranes, e.g. in lipopro-
teins, and are expected to represent a high percentage of lipids in the blood. Especially
PCs, PEs and PIs (Fahy et al., 2005; Li et al., 2014) represent the most numerous mem-
brane lipids with 50% of all PCs, lysophosphatidylcholines (LPCs) and PEs to be con-
tained within HDLs (Gallego et al., 2010). This percentage is assumed to be even higher
in dogs due to their different amount and composition of their HDLs.
Lysophosphatidylcholines (LPCs) are characterized as having a single carbon chain
(e.g. 0:0/16:0) and a polar head group, derived from PCs through the action of phospho-
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lipase A2. Due to their structure, they are more hydrophilic than similar phospholipids
(Fahy et al., 2005). Specifically, LPC 16:0 was reported to be enriched in human HDL,
whereas LPC 18:0 was predominantly associated with VLDL and LDL in humans (Wies-
ner et al., 2009). Further LPCs have been reported to be a major component of oxidized
LDLs in humans and therefore implicated as important factors in their atherogenic activ-
ity (Schmitz and Ruebsaamen, 2010). This is in agreement with other studies, where LPCs
have been found to generate inflammatory effects, enhancing the process of atheroscle-
rosis (Kita et al., 1999). In this study, we identified 17 LPCs in total, of which at least
two (LPC 18:0 and LPC 18:1) have been described as inducing reactive oxygen species in
aortic endothelial cells (Li et al., 2016).
Further, we identified one oxidized glycerophosphocholine (oxPC 16:0/9:0(CHO)) de-
spite not focusing on oxidized lipids in our identification program. Oxidized lipids were
previously associated with the formation of foam cells in atherosclerotic lesions in mice
and humans (Podrez et al., 2002; Tsimikas et al., 2004; Watson, 2006). Therefore, they
would represent an interesting group of lipids for future studies regarding atherosclerotic
processes in the dog. However, a different lipid extraction protocol would be needed in
that case, as GPs are a more hydrophilic group of lipids and our lipid extraction protocol
with following research on the organic phase focused on more hydrophobic lipids.
Sterol Lipids
We did find four main classes of sterol lipids (STs) in our study, including sterols (mainly
cholesterol and cholesterol esters) as the most numerous group of identified lipids. They
have long been mentioned as being involved in human cardiovascular diseases if appearing
at highly elevated levels (Hu et al., 2009; Han et al., 2007). Cholesterol is also the most
abundant sterol in animals in terms of lipid concentrations, as verified by other studies
(Li et al., 2014), which is similar to humans, where cholesterol and cholesterol esters were
found to be among the most abundant metabolites in serum (Psychogios et al., 2011) and
plasma (Quehenberger et al., 2010). As no internal standards were included in our study,
no comparison of lipid concentrations to other studies can be carried out.
The occurrence of cholesterol and cholesteryl esters (CEs) in the blood is closely linked
to lipoproteins, as explained in the introduction. Neutral CEs represent the most abun-
dant lipid class in humans with CE 18:2 accounting for over half of it, followed by eicos-
apentaeonic acid (CE 20:4) (Quehenberger et al., 2010). Both of them were found in our
study, among five other CEs. Three of these CEs (18:3, CE 20:4, CE 20:5) were also found
to be associated with fatal cardiovascular outcome in human studies (Tarasov et al., 2014;
Stegemann et al., 2011).
Another CE identified in our study (CE18:1) was investigated in a study by Degirolamo
et al. (2009), revealing human LDLs enriched in mono–unsaturated cholesteryl oleate (CE
18:1) to be more active in binding to arterial proteoglycans than other LDLs, favoring the
formation of atherosclerotic lesions. This underlines the importance of lipidomic analyses
of lipoprotein compositions rather than focusing on the concentration of lipoproteins only.
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Glycerolipids
In humans, glycerolipids (GLs) represent a high proportion of the total lipids in plasma
(McAnoy et al., 2005). This is expected to be similar in dogs, as triglycerides are one
of the most numerous lipids occurring in CMs and VLDLs. However, as no quantitative
study was performed, we can only compare the identification of specific lipids and not
their concentration within the blood.
Distinguishing between isomeric species was a challenge. This is due to the varying
number of FAs that are esterified to the hydroxyl groups attached to the glycerol backbone.
As those FAs can permute at various positions, stereochemical composites (isomers) are
formed (Fahy et al., 2005). Therefore, similar to human studies (Fahy et al., 2005), we
found the majority of GLs as isomeric forms with each diglyceride having two isomeric
species and each triglyceride, with its three different radyl groups, resulting in six possible
isomers.
In most studies, natural FAs found in TGs from plants or animals have been reported
to consist of long hydrocarbon chains with an even number of carbon atoms (Hu et al.,
2009). This is in line with our results; however we only identified nine TGs in our study,
of which seven were even–numbered. Within the blood, TGs are distributed between
CMs and VLDLs and are therefore highly dependent on food intake (Quehenberger and
Dennis, 2011), potentially differing between humans and dogs.
Considering all isobaric species, over 200 individual molecular species of TGs were
detected in human plasma with TG 50:2, 52:2 and 52:4 being the most abundant GLs
(Quehenberger et al., 2010) of which only TG 52:3 was identified in our study and further
in plasma only.
DGs were present at substantially lower levels in human blood than TGs, with 1,2–
DGs being about three times more abundant than 1,3–DGs (Quehenberger et al., 2010).
In our study, we found 1,2–DGs to be the vast majority of DGs identified, however we
did not quantitatively assess them.
Sphingolipids
Sphingolipids (SPs) are usually found in cell membranes and composed of a sphingoid
backbone with various fatty acids attached to it (Watson, 2006). They are categorized
into sphingoid bases, ceramides (sphingoid bases with amide–linked fatty acids), phos-
phosphingolipids, including sphingomyelins, and glycosphingolipids such as cerebrosides
and gangliosides (Fahy et al., 2005). Of these, ceramides (Cer) and sphingomyelins (SMs)
are biologically most important (Hu et al., 2009).
In our study, we identified 39 different SPs, of which Cers were the most numerous
class, followed by SMs. This distribution differs from that in human plasma, where SMs
accounted for the largest fraction of SPs (Quehenberger et al., 2010). However, as we used
a different lipid extraction method than Quehenberger et al. (2010) and only identified a
small number of SPs, distribution may vary.
SPs, especially Cers and SMs, have been reported to influence the atherogenic process
by affecting the lipoprotein metabolism and are therefore associated with the development
of atherosclerotic lesions (Bismuth et al., 2008; Alewijnse and Peters, 2008). Cers were
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also found in a 10 to 50–fold higher content in LDLs within an atherosclerotic lesion in
human patients than in plasma LDLs (Schissel et al., 1996). However, the interaction of
Cers, oxidized LDLs, inflammatory cytokines and endothelial cells is not entirely clear so
far (Bismuth et al., 2008).
Further, ratios of several Cers have been associated with fatal cardiovascular outcome
in a human study, including the ratio of Cer(d18:1/24:1) to Cer(d18:1/24:0) (Tarasov
et al., 2014), both of which occurred in our study.
Sphingomyelins (SMs) consist of ceramides with either an additional phosphocholine or
phosphoethanolamine head group. They are found most frequently as membrane lipids in
myelin sheaths (Voet et al., 2012) but also contribute to the major lipoprotein membrane
lipids in the human blood (Wiesner et al., 2009). This explains why the different SMs are
found in such a high number within canine blood.
To summarize, CEs, PCs including LPCs, Cers and SMs are the main interesting
lipid classes associated with atherosclerosis and were also significantly altered comparing
atherosclerotic plaques to plasma samples (Stegemann et al., 2011).
Regarding the distribution of SMs within lipoproteins, different studies revealed dif-
ferent results. A study by Li et al. (2014) revealed SMs to account for half of the lipids
contributing to the total HDL mass in humans, together with phospholipids, cholesteryl
esters, TGs and free cholesterol. In contrast, the study of Wiesner et al. (2009) reported
that SMs only account for 5–10% of all lipids in HDLs, whereas LDLs contain the largest
amount of the plasma SMs.
Prenol Lipids
Prenol lipids (PRs) and their main group of isoprenoids are synthesized from five carbon
precursors (C5), therefore they consist of multiplicities of this unit such as C10 isoprenoids,
C15 and so on (Fahy et al., 2005).
We identified a total number of 37 prenol lipids in our study, the majority being
isoprenoids (34 lipids) of which most consisted of C15 molecules.
Polyketides
Most of the polyketides identified in our study were flavonoids, mostly known to originate
from plants or microbial sources (Fahy et al., 2005), and therefore assumed to arise from
the diet that our dogs had received during the study. Furthermore, the occurrence of
flavonoids may prove that some amphiphilic lipids were recovered in the organic phase of
our lipid extraction.
4.2.2 Plasma vs. Serum
Amounts of lipids identified in both matrices were expected to differ only slightly between
plasma and serum, with plasma being obtained from whole blood in the presence of
anticoagulants and serum being harvested after a clotting process. However, many of
the 561 lipids identified in total were only found in either plasma or serum in our study,
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similar to humans were the lipidomic profiles of the two matrices were found to differ as
well (Ishikawa et al., 2013).
In our study, comparing the 246 lipids identified in both plasma and serum, we did
find eleven lipids to be significantly altered in their mean abundances between plasma
and serum, analyzed by a paired Student’s t–test and corrected with a false discovery
rate (fdr). However, usage of fdr gives 5% of significant results by default. As we have
≈ 4.5% significant results, log2 ratios of mean abundances in plasma versus serum were
also taken into consideration.
Lipids with ratios >2 or <–2 were interpreted to represent important differences,
resulting in the three lipids further discussed here: 14–keto pentadecanoic acid, an oxida-
tive fatty acid; 1–(2,5–dihydro–6,8–dihydroxy–3–methyl–1–benzoxepin–7–yl)–3–phenyl–
1–propanone, a flavonoid categorized into the polyketides; and (+)–Blennin D, an iso-
prenoid categorized into the prenol lipids.
Oxidative fatty acids were previously reported to be associated with the clotting pro-
cess of serum, as they may be derived from arachidonic acid, which in turn is released from
membrane phospholipids in platelets during blood coagulation (Ishikawa et al., 2013).
But the ratio of the oxo fatty acid found here is enhanced in plasma compared to
serum. Hence, there are probably other reasons than the clotting process for this specific
lipid to differ greatly between plasma and serum.
Similarly, eicosanoids are thought to differ greatly between serum and plasma, due to
release from activated platelets, as they are derivates of arachidonic acid (Ishikawa et al.,
2014). However, no significant eicosanoids were found in our study, probably due to their
distribution within the matrices. Of 19 different eicosanoids found within the dog, only
four were found in both matrices and could therefore be compared. Eleven eicosanoids
were found in serum exclusively, supporting the theory of enhanced eicosanoids in serum
due to the clotting process (Liu et al., 2010).
Similar to eicosanoids, 21 sphingolipids were identified in serum only, whereas eight
occurred in plasma only and ten were found in both matrices. This supports serum as
the matrix of choice for eicosanoids and sphingolipids. Further, sphingolipids were also
reported as potential biomarkers for atherosclerotic processes (Liu et al., 2010), which is
in agreement to other studies, revealing serum to include more potential biomarkers than
plasma (Yu et al., 2011).
In addition, and possibly related to the clotting process, may be the second lipid, a
flavonoid, which was highly enhanced in plasma. Nothing is known so far on that specific
lipid, but flavonoids in general are widely distributed plant polyphenols (Dangles et al.,
2000). Due to their ability to inhibit several enzymes, they potentially act as antioxidants,
playing an important role in the protective mechanisms against cardiovascular diseases
(Middleton Jr and Kandaswami, 1994). Further, as flavonoids are reported to inhibit the
release of thromboxane, their higher concentration in plasma than serum is potentially
related to the clotting process (Vita, 2005).
The last lipid found to be highly enhanced in plasma is an isoprenoid, categorized
into the main class of sesquiterpenes. While not much is known concerning this lipid
specifically, sesquiterpenes have already been investigated regarding their interactions
with plasma and serum in other studies. The results indicate a different protein binding
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activity of various sesquiterpenes to plasma or serum albumin (Wagner et al., 2004). Thus,
a possible high bondage of the lipid found here with albumin is assumed, and possibly
associated with a lower amount of this sesquiterpene in serum after the clotting process.
In summary, our study showed that if the same analytical procedures are used, plasma
and serum only differ slightly in the amount of lipids measured in both matrices. However,
as no multiple measurements were performed, the reproducibility of these results cannot be
commented. Further, when targeting a special category or individual lipids, the choice of
matrix is crucial, as many lipids are only found in either plasma or serum. Additionally,
serum results should be viewed with caution, as they are altered due to the clotting
process. Plasma on the other hand represents the original properties of the blood, only
potentially modified by added lithium heparin.
Regarding the different anticoagulants, no general consensus exists in the lipidomic
community. The difference between anticoagulants lies in their mechanisms to prevent
the clotting formation with citrate and EDTA chelating Ca2+, while heparin binds to en-
zymes responsible for the coagulation cascade (Gonzalez-Covarrubias et al., 2013). Since
lipid extraction should eliminate most of the anticoagulant salts before LC–MS analysis
(Gonzalez-Covarrubias et al., 2013), possible interactions with lipids must occur during
initial contact. As the use of lithium heparin has been shown to result in slightly more
identified lipid species than with EDTA or sodium citrate, some authors recommend
lithium heparin as a suitable anticoagulant (Vuckovic, 2012; Pereira et al., 2010).
4.2.3 Prednisolone Treatment
The effect of hyperadrenocorticism and enhanced levels of glucocorticoids (GCs) upon
lipoprotein compositions in dogs has been studied by various research teams (Barrie et al.,
1993b; Mahley et al., 1974; Ling et al., 1979; Bauer, 2004; Xenoulis and Steiner, 2010).
Regarding the effects of GCs on the lipid metabolism, increased lipolysis, lipid oxidation
and insulin–antagonistic effects have already been mentioned, resulting in enhanced free
fatty acids with enhanced levels of TGs and eventually TG–rich lipoproteins such as
VLDLs (Barrie et al., 1993b). Increased plasma cholesterol concentrations and partly
increased LDL–cholesterol concentrations or enhanced levels of LDLs and VLDLs are also
known to occur after GC treatment (Barrie et al., 1993b; Bauer, 2004). As in the present
study, prednisolone treatment was only short term, so no long–term consequences as seen
with hyperadrenocorticism were expected. However, as we used a high dose prednisolone
treatment, some differences were still assumed to be observed afterwards.
Beside the immediate effect of GCs on the lipid metabolism by lipolysis, a rapid
anti–inflammatory response is promoted by arachidonic acid derivates. This may occur
through an altered membrane lipid metabolism caused by GCs. Further, as the enzyme
COX–2 is inhibited by GCs, synthesis of pro–inflammatory prostaglandins is suppressed
(Malcher-Lopes et al., 2008).
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Canine Plasma
Ten lipids were significantly altered after prednisolone treatment in plasma. However,
as a false discovery rate was used as mentioned above, log2 ratios of mean abundances
were taken into consideration. If the log2 ratio was >2 or <–2, lipids were assumed to be
greatly altered after prednisolone treatment. Therefore only six of the ten significantly
altered lipids are discussed here at length.
All of these six lipids are fatty acids, which seems plausible, as FAs represent ≈ 45%
of all lipids identified in canine plasma. Further, five of the six FAs discussed here were
increased after prednisolone treatment, possibly through lipolysis, whereas only one FA
was significantly decreased after prednisolone.
The lipid most increased after prednisolone treatment was Docosatriynoic acid, an
unsaturated fatty acid with a log2 ratio of 3.9. Docosatriynoic acid (22:3 δ10 ω6) is
an acetylenic acid, where δ designates the position of the first double bond, counted
from the carboxyl end of the fatty acid, and ω designates the position of the last double
bond, counted from the terminal carbon of the fatty acid (Sams, 1981). A possible
explanation for the high amount of this lipid after prednisolone treatment could be the
inhibition of prostaglandin synthesis through COX–2 inhibition achieved by GCs. This
may be due to prostaglandins being formed by enzymatic oxygenation of certain essential
polyunsaturated fatty acids (PUFAs) (Sams, 1981). As the lipid discussed here is also a
PUFA, it may be enhanced because it was not synthesized into prostaglandin. However,
many lipids are PUFAs and only some of them are included in the prostaglandin pathway.
Another study revealed acetylenic acids to inhibit the prostaglandin synthesis from certain
unsaturated fatty acids in cows. The most potent inhibitors were octadeca–6,9,12–triynoic
acid and eicosa–8,11,14–triynoic acid, however docosa–10,13,16–triynoic acid was also
mentioned as being inhibitory, although less potent (Goetz et al., 1976). Hence, release
of 10,13,16–docosatriynoic acid could be triggered by prednisolone treatment to further
inhibit prostaglandin synthesis.
Likewise, DPA (docosapentaenoic acid, 22:5n–3) was threefold increased after treat-
ment, an ω3 PUFA with a log2 ratio of 3.2 after prednisolone treatment. This n–3 DPA
has been mentioned several times in studies, mostly as a fish–derived fatty acid. It is a
metabolite of eicosapentaenoic acid (EPA, 20:5n–3) and an intermediary product between
EPA and docosahexaenoic acid (DHA, 22:6n–3), the end product of the essential fatty
acid metabolism. It has been suggested that n–3 DPA has beneficial effects regarding car-
diovascular diseases (Kaur et al., 2011; Rissanen et al., 2000). Further it is metabolized
by lipoxygenase in platelets and also inhibits aggregation of platelets, at least in rabbits.
Furthermore, n–3 DPA has been shown to possess a tenfold greater endothelial cell migra-
tion ability than EPA, important in wound healing processes (Kaur et al., 2011). In regard
to inflammatory processes, both n–6 PUFA such as arachidonic acids, the precursors of
inflammatory eicosanoids, and n–3 PUFAs EPA and DHA are interesting. EPA and DHA
inhibit the arachidonic acid metabolism and act, in the end, anti–inflammatorily or give
rise to mediators that are less inflammatory. Furthermore, they have anti–inflammatory
effects on leukocyte chemotaxis and cytokine production (Calder, 2008; Groeger et al.,
2010). n–3 DPA was also described to be responsible for cholesterol–lowering activity
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together with DHA, therefore lowering the risk of developing atherosclerosis (Chen et al.,
2012). To summarize, the reason for the high occurrence of DPA after prednisolone treat-
ment may be explained by its being an intermediate product between EPA and DHA,
involved in the anti–inflammatory response.
Another lipid is 3–hydroxy–hexadecanoic acid with a log2 ratio after prednisolone
treatment of 2.3. Not much is known of this hydroxy fatty acid, a derivate of palmitic
acid, but it has been associated with a certain antioxidant activity, together with 3–
hydroxytetradecanoic acid and palmitic acid (Tel et al., 2010).
Having the same log2 ratio of 2.3 after prednisolone treatment, 9R–hydroxy–octa–
decanoic (9–HODE) is an oxidation product of linoleic acid and regulated through the
LOX pathway, whilst HETEs are derived from arachidonic acids. HODEs, more specif-
ically 9– and 13–HODE, have been detected as the most abundant oxidation prod-
ucts in atherosclerotic plaques, together with 15– and 11–HETEs, although in smaller
amounts. Further, they have also been identified in increased amounts in the LDLs of
these atherosclerotic plaques (Kuhn et al., 1992). In humans, almost 50% of the PUFAs in
LDLs are made of linoleic acid, which is susceptible to oxidation. Therefore, HODEs and
specific HETEs may account for biomarkers in plasma representing the degree of oxidative
damage (Jira et al., 1998). Some of the HETEs also activate chemotaxis of neutrophils
(Goetzl et al., 1980), whilst HODEs stimulate foam cell formation through upregula-
tion of peroxisome proliferator activated receptors and resulting monocyte–macrophage
differentiation (Tontonoz et al., 1998).
3R–hydroxyoctadecanoic acid (3–HODE) has a slightly lower log2 ratio of 2.1 after
prednisolone treatment and has also been associated but not specifically identified within
atherosclerotic plaques. However, the occurrence of HODEs may be triggered in some way
by prednisolone, as glucocorticoids enhance the stress level within the body, potentially
stimulating oxidative stress processes.
The only lipid found to be drastically decreased after prednisolone treatment was
hydroxyphthioceranic acid (C39), a long–chain branched fatty acid with a log2 ratio of
–3.2. This lipid has so far mostly been associated with Mycobacterium tuberculosis as a
key component of its cell–wall (Sirakova et al., 2001). Reasons for the occurrence of such
a lipid in the blood of dogs can only be speculated upon. However, as it was found in all
dogs, it potentially has further functions than being a cell component of M. tuberculosis.
Four other lipids were also found to be significantly altered after prednisolone treat-
ment in plasma but displayed ratios of <2 or >–2, therefore the relevance of these lipids
may be decreased as potentially false positive results. 8,11–eicosadiynoic acid is one of
them, an unsaturated fatty acid with a log2 ratio of 1.7 after prednisolone treatment and
known to inhibit the eicosanoid biosynthesis at several stages (Laposata et al., 1987). An
upregulation under prednisolone treatment seems therefore plausible as eicosanoids are
associated with inflammation in the body.
PE(P–16:0/22:4), a glycerophosphoethanolamine with a log2 ratio of 0.6 after pred-
nisolone treatment is reported to consist of two parts: one plasmalogen chain 16:0 and
one adrenic acid. Plasmalogen 16:0 is derived from animal fat, liver and kidney, whereas
adrenic acid is mostly derived from animal fats (Wishart et al., 2013). Previous studies
reported plasmalogen to function as an antioxidant, also for LDLs to prevent oxidation
70 Chapter 4. Discussion
(Vance, 1990).
The last two significantly altered lipids are decreased after prednisolone treatment,
MG(18:1(11E)/0:0/0:0) with a log2 ratio of –0.6 and 11Z–octadecen–9–ynoic with a log2
ratio of –0.8. As MGs are derived from DGs and TGs due to lipolysis, the decreased levels
after prednisolone are surprising. Similarly 11Z–octadecen–9–ynoic, a PUFA, could not
be directly linked to glucocorticoids.
Canine Serum
Of the three lipids tested to be significantly altered in serum after prednisolone treatment,
none of them showed log2 ratios of >2 or <–2. Hence, they will not be thoroughly
discussed here, with the exception of 9R–hydroxy–octadecanoic acid. This lipid was found
to be enhanced in plasma as well as serum after prednisolone treatment, however the log2
ratio in serum was only 0.9 compared to plasma with 2.3 As both serum and plasma were
drawn at the same time and matrices underwent the same analytical steps, prednisolone
treatment seems to show a greater impact on the relative abundances of this lipid in plasma
than in serum. This may be either due to matrix–associated differences affected by the
clotting process, or due to inaccuracy during lipid measurements. Generally, as plasma
produced a wider range of statistically significant results and is assumed to represent the
conditions unaltered as in vivo without the clotting process, plasma seems more suitable
for further lipidomic studies.
The other two lipids found in canine serum to be significantly altered after prednisolone
treatment were adrenic acid and PE(20:4/20:0). Adrenic acid, a PUFA, was enhanced
after prednisolone treatment and can be found in the adrenal gland, brain, kidney, and
vasculature (Mann et al., 1986). Similar to arachidonic acid, it is metabolized by COX,
LOX and CYP450 enzymes to dihomo eicosanoids (Kopf et al., 2010). Therefore, it seems
possible that prednisolone enhances its amount in the blood due to inhibiting further
enzyme reactions.
The decrease of PE(20:4/20:0) on the other hand cannot be readily explained; however
it consists of one chain of arachidonic acid and one chain of arachidic acid (?), which may
associate it with the effects of GCs.
4.3 Limitations of the Study
4.3.1 Lipoprotein Separation
Both protocols A and B were made of blood from the same dog, therefore no comparison
with other dogs or mean values of different dogs were possible and the power of the study
is low. Nevertheless, our results are sufficient to demonstrate the altering density ranges of
canine to human lipoproteins and verify published studies. Due to the overlapping density
ranges in the dog, no further investigations were performed using ultracentrifugation.
A possible limitation of protocol B could be the usage of lithium heparin instead
of EDTA plasma, as was used in previous protocols, potentially enhancing the heparin
concentration during precipitation. However, other studies with differing compositions of
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heparin manganese chloride did not achieve an accurate separation either (Asuka et al.,
2013). Further, we only estimated molecular weights based on manual measurements
on SDS–PAGEs. Apoproteins were assumed based on estimated molecular weights and
not identified by further techniques such as GP–HPLC. However, as major apoproteins
of canine LDL and HDL differ greatly in their molecular weights, our protocols seemed
sufficient for our goals.
4.3.2 Lipidomics
This study was a pilot study to investigate the lipidome of healthy and prednisolone
treated dogs. As no other studies on the lipidome of dogs are known so far, comparisons
could not be made.
Further, using LC–MS/MS as done in this study, a tighter spectrum of lipids can
be detected and identified, although potentially missing others. But even in this study,
using LC prior to MS analyses, several lipids with overlapping mass to charge (m/z)
ratios were detected, enhancing the difficulty of accurate lipid identification. Moreover,
as only one lipid extraction protocol was used in this study, not all lipids are equally
extracted into the organic phase due to differing polarities. With MTBE–based lipid
extraction by Matyash et al. (2008), the main lipid classes were believed to be extracted
with similar high recoveries as achieved by the classic lipid extraction (Folch et al., 1957).
However, semipolar and especially polar compounds (e.g. phospholipids) are probably
retrieved in lower amounts than they actually occur due to the biphasic nature of lipid–
lipid extractions. Finally, only non–polar lipid species are presented at a high level through
our LC–MS approach, whereas for polar lipids a GC–MS system probably would have been
more suitable (Teo et al., 2015).
Regarding quantitative measurements, this study was only semiquantitative, as lipid
extracts were not spiked with internal standards. These standards would typically com-
promise isotopically labeled or non–endogenous odd–chain lipids, possessing similar char-
acteristics as the lipid species wished to target (Teo et al., 2015). However, as the same
procedure was used on all samples and plasma and serum were taken from the same dogs
at the same time, comparison between samples still results in reliable semiquantitative
findings.
Also, no repeated measurements of the same samples were done, which would en-
hance reliable lipid identification and quantification. Correction for multiple testing was
performed using a false discovery rate (fdr); therefore if results were <5%, false positive
results may have occurred as discussed above. Hence log2 ratios should be taken into
consideration. Further, statistical statements including p–values from semiquantitative
mean abundances can be deceptive due to the low number of dogs compared, the effect of
age and gender of the animals and the high sensitivity of mass spectrometric measurement
techniques to minor differences in sample handling or analytical procedures.
Looking at the identified and statistically significant lipids gives us points of interests,
however our biological knowledge of these lipids is small and mostly related to the lipid
class rather than the individual identified lipids. After detecting significantly altered
lipids, the next challenge is to discern whether they represent actual alterations caused
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by the given treatment.
Although great advances in the field of mass spectrometric researches have been
achieved and it has proved to be a valuable tool for lipid analysis, there is always potential
for development. Minor components or oxidized lipids often still remain undetected due
to ion suppression of low–abundance species by high–abundance species, although detec-
tion is better with chromatographic separation in advance (Hu et al., 2009; Teo et al.,
2015). In this study, no oxidized lipids were included in the lipid identification process
but should be focused on in a future study due to their role in atherosclerotic plaques.
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AppendixA
Supplemental Material
A.1 Canine Lipidome
Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
Fatty
Acyls
(FAs)
1 FA00 Other
Fatty Acyls
Serratamic acid N–(3S–hydroxydecanoyl)–L–
serine
276 P
2 FA01 Fatty Acids
and Conju-
gates
Branched
fatty acids
18:1(12E)(11Me) 11–methyl–12E–octadecenoic
acid
314 P
3 FA01 ” ” ” ” 18:1(7Z)(17Me) 17–methyl–7Z–octadecenoic
acid
314 P / S
4 FA01 ” ” ” ” Hydroxyphthioceranic
acid (C31)
2S,4S,6S,8R,10R–
pentamethyl–11–hydroxy–
hexacosanoic acid
483 S
5 FA01 ” ” ” ” Hydroxyphthioceranic
acid (C34)
2S,4S,6S,8R,10R,12R–
hexamethyl–13–hydroxy–
octacosanoic acid
526 P / S
6 FA01 ” ” ” ” Hydroxyphthioceranic
acid (C36)
2S,4S,6S,8R,10R,12R–
hexamethyl–13–hydroxy–
triacontanoic acid
571 P / S
7 FA01 ” ” ” ” Hydroxyphthioceranic
acid (C39)
2S,4S,6S,8S,10R,12R,14R–
heptamethyl–15–hydroxy–
dotriacontanoic acid
613 P / S
8 FA01 ” ” ” ” Hydroxyphthioceranic
acid (C40)
2S,4S,6S,8S,10R,12R,14R,16R–
octamethyl–17–hydroxy–
dotriacontanoic acid
627 /
610
P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
9 FA01 ” ” ” ” Hydroxyphthioceranic
acid (C42)
2S,4S,6S,8S,10R,12R,14R,16R–
octamethyl–17–hydroxy–
tetratriacontanoic acid
655 P / S
10 FA01 ” ” ” ” Hydroxyphthioceranic
acid (C37)
2S,4S,6S,8S,10R,12R,14R–
heptamethyl–15–hydroxy–
triacontanoic acid
585 S
11 FA01 ” ” ” ” Mycocerosic acid
(C28)
2R,4R,6R–trimethyl–
pentacosanoicacid
442 P / S
12 FA01 ” ” ” ” Mycolipenic acid
(C29)
2,4S,6S–trimethyl–2E–
hexacosenoicacid
454 S
13 FA01 ” ” ” ” 22–methyl–tricosanoic acid 386 P / S
14 FA01 ” ” ” ” 2–methyl–hexadecanoic acid 253 /
303
P / S
15 FA01 ” ” ” ” 2–methyl–tetradecanoic acid 225 /
260
P / S
16 FA01 ” ” ” ” 2oxo–3R–methyl–pentanoic
acid
113 P
17 FA01 ” ” ” ” - 4–methyl–octadecanoic acid 316 P / S
18 FA01 Fatty Acids
and Conju-
gates
Unsaturated
fatty acids
– 10,13,16–Docosatriynoic acid 351 P
19 FA01 ” ” ” ” – 10E–heptadecen–8–ynoic acid 282 /
297
P / S
20 FA01 ” ” ” ” – 10–hydroxy–2Z,8Z–
Decadiene–4,6–diynoic acid
163 /
213
P / S
21 FA01 ” ” ” ” – 10–Hydroxy–3,7–dimethyl–
2E,6E–decadienoic acid
195 P / S
22 FA01 ” ” ” ” – 11Z–octadecen–9–ynoic acid 296 /
279
P / S
23 FA01 ” ” ” ” – 12,14–Pentacosadiynoic acid 407 P
24 FA01 ” ” ” ” – 13–hexadecenoic acid 272 /
277
P / S
25 FA01 ” ” ” ” – 14Z–tricosenoic acid 370 P / S
26 FA01 ” ” ” ” – 15Z–eicosenoic acid 328 P / S
27 FA01 ” ” ” ” – 18–nonadecynoic acid 312 P
28 FA01 ” ” ” ” – 19Z–octacosenoic acid 440 P / S
29 FA01 ” ” ” ” – 3E–tetradecenoic acid 227 P
30 FA01 ” ” ” ” – 3–heptadecenoic acid 269 P
31 FA01 ” ” ” ” – 4,9–octadecadiynoic acid 277 P
32 FA01 ” ” ” ” – 4E–Undecene–6,8,10–triynoic
acid
205 S
33 FA01 ” ” ” ” – 4–tridecynoic acid 193 /
228
P / S
34 FA01 ” ” ” ” – 4–undecynoic acid 183 P
35 FA01 ” ” ” ” – 6,9–heptadecadiynoic acid 280 S
36 FA01 ” ” ” ” – 8,11–Eicosadiynoic acid 287 P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
37 FA01 ” ” ” ” – 9,12,15–Eicosatriynoic acid 301 P
38 FA01 ” ” ” ” – 9–heptadecynoic acid 267 /
284
P / S
39 FA01 ” ” ” ” – 9–hexacosenoic acid 412 P / S
40 FA01 ” ” ” ” – 9–hydroxy–7Z–Nonene–3,5–
diynoic acid
165 P
41 FA01 ” ” ” ” 17:1(11Z) 11Z–heptadecenoic acid 269 P / S
42 FA01 ” ” ” ” 21:1(7Z) 7Z–heneicosenoic acid 342 P / S
43 FA01 ” ” ” ” 21:3(5Z,14Z,17Z) 5Z,14Z,17Z–heneicosatrienoic
acid
338 P / S
44 FA01 ” ” ” ” 29:2(5Z,9Z) 5Z,9Z–nonacosadienoic acid 452 P / S
45 FA01 ” ” ” ” 34:6(16Z,19Z,22Z,25Z,
28Z,31Z)
16Z,19Z,22Z,25Z,28Z,31Z–
tetratriacontahexaenoic acid
529 P
46 FA01 ” ” ” ” cis,trans–hepta–
2,4,6–trienoic acid
2Z,4E,6–heptatrienoic acid 157 S
47 FA01 ” ” ” ” Linoelaidic acid 9E,12E–octadecadienoic acid 281 /
298
P / S
48 FA01 ” ” ” ” Oleic acid(d2) 9Z–octadecenoic acid(d2) 267 P
49 FA01 ” ” ” ” TrHA 5Z,8Z,11Z,14Z,17Z,20Z–
tricosahexaenoic acid
360 P / S
50 FA01 ” ” ” ” δ2–THA 2E,6Z,9Z,12Z,15Z,18Z,21Z–
tetracosaheptaenoic acid
372 P / S
51 FA01 Fatty Acids
and Conju-
gates
Hydroperoxy
fatty acids
– 5–hydroperoxy–7–[3,5–
epidioxy–2–(2–octenyl)–
cyclopentyl]–6–heptenoic
acid
355 S
52 FA01 ” ” ” ” – methyl 15–hydroperoxy–
9Z,12Z,16E–octadecatrienoate
307 P / S
53 FA01 Fatty Acids
and Conju-
gates
Hydroxy
fatty acids
– 11S–hydroxy–tetradecanoic
acid
245 /
267
P / S
54 FA01 ” ” ” ” – 12–hydroxy–5,8,10–
heptadecatrienoic acid
263 S
55 FA01 ” ” ” ” – 13,14–dihydroxy–docosanoic
acid
373 P / S
56 FA01 ” ” ” ” – 16–hydroxy–9E–hexadecenoic
acid
288 P
57 FA01 ” ” ” ” – 17–hydroxy–heptadecanoic
acid
304 P / S
58 FA01 ” ” ” ” – 19–hydroxy–nonadecanoic acid 297 P / S
59 FA01 ” ” ” ” – 21–hydroxy–heneicosanoic
acid
360 P / S
60 FA01 ” ” ” ” – 24–hydroxy–tetracosanoic acid 402 P
61 FA01 ” ” ” ” – 2–hydroxy–10–undecenoic acid 201 P
62 FA01 ” ” ” ” – 3–hydroxy–hexadecanoic acid 290 P / S
63 FA01 ” ” ” ” – 3R–hydroxy–eicosanoic acid 311 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
64 FA01 ” ” ” ” – 3R–hydroxy–pentadecanoic
acid
259 /
241
P / S
65 FA01 ” ” ” ” – 7–hydroxy–10–heptadecen–8–
ynoic acid
300 P / S
66 FA01 ” ” ” ” – methyl 8–[2–(2–formyl–
vinyl)–3–hydroxy–5–oxo–
cyclopentyl]–octanoate
311 S
67 FA01 ” ” ” ” – methyl 9,12–dihydroxy–13–
oxo–10–octadecenoate
360 S
68 FA01 ” ” ” ” 11,12–dihydroxy
arachidic acid
11,12–dihydroxy–eicosanoic
acid
362 S
69 FA01 ” ” ” ” 2,15–dihydroxy–
pentadecylicacid
2,15–dihydroxy–pentadecanoic
acid
292 P / S
70 FA01 ” ” ” ” 2–hydroxy behenic 2–hydroxy–docosanoic acid 357 /
374
P / S
71 FA01 ” ” ” ” 2–hydroxy–3–
methylhexadecanoic–
acid
2–hydroxy–3–
methylhexadecanoicacid
304 P / S
72 FA01 ” ” ” ” 2R–hydroxylauric
acid
2R–hydroxydodecanoic acid 217 P
73 FA01 ” ” ” ” 3–hydroxy–
isoheptanoic acid
3–hydroxy–6–methyl–hexanoic
acid
183 P / S
74 FA01 ” ” ” ” 9,16–dihydroxy–
palmitic acid
9,16–dihydroxy–hexadecanoic
acid
311 /
306
P / S
75 FA01 ” ” ” ” Axillarenic acid 11,13–dihydroxy–9E–
tetracosenoic acid
399 P
76 FA01 ” ” ” ” Hydroxynervonic
acid
2–hydroxy–15Z–tetracosenoic
acid
400 P / S
77 FA01 Fatty Acids
and Conju-
gates
Oxo fatty
acids
– 12–oxo–5E,8E,10Z–
dodecatrienoic acid
247 P
78 FA01 ” ” ” ” – 18–oxo–nonadecanoic acid 330 S
79 FA01 ” ” ” ” – 2–oxo–docosanoic acid 372 P / S
80 FA01 ” ” ” ” – 3–oxo–eicosanoic acid 344 /
309
P / S
81 FA01 ” ” ” ” – 3–oxo–nonadecanoic acid 330 P
82 FA01 ” ” ” ” – 4,7–dioxo–octanoic acid 173 P
83 FA01 ” ” ” ” – 5–oxo–7–octenoic acid 139 /
157
P / S
84 FA01 ” ” ” ” – 7–oxo–11Z–Tetradecenoic acid 258 S
85 FA01 ” ” ” ” 14–keto pentade-
canoic acid
14–oxo–pentadecanoic acid 279 /
257
P / S
86 FA01 ” ” ” ” 3–oxohexacosanoic
acid
3–oxohexacosanoic acid 428 S
87 FA01 ” ” ” ” 4–keto pentadecanoic
acid
4–oxo–pentadecanoic acid 257 S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
88 FA01 ” ” ” ” 7–methyl–3–
oxooctanoic acid
7–methyl–3–oxooctanoic acid 190 P
89 FA01 ” ” ” ” 9–Keto heptadecylic
acid
9–oxo–heptadecanoic acid 267 P / S
90 FA01 Fatty Acids
and Conju-
gates
Epoxy fatty
acids
– methyl 12,13–epoxy–9,15–
octadecadienoate
309 P / S
91 FA01 Fatty Acids
and Conju-
gates
Methoxy
fatty acids
– 12,13–dihydroxy–11–
methoxy–9–octadecenoic
acid
362 P / S
92 FA01 Fatty Acids
and Conju-
gates
Halogenated
fatty acids
– 9–hydroxy–10–chloro–
octadecanoic acid
352 P
93 FA01 ” ” ” ” 14–fluoro–myristic
acid
14–fluoro–tetradecanoic acid 279 P
94 FA01 Fatty Acids
and Conju-
gates
Amino
fatty acids
– 11–amino–undecanoic acid 184 S
95 FA01 ” ” ” ” – 2E,4E,8E,10E–
Dodecatetraenedioic acid
223 P / S
96 FA01 ” ” ” ” – 4–methyl–tridecanedioic acid 259 P / S
97 FA01 ” ” ” ” – 5–methyl–tetradecanedioic
acid
273 P / S
98 FA01 ” ” ” ” – 9–hydroxy–hexadecan–1,16–
dioic acid
320 S
99 FA01 ” ” ” ” 3–hydroxy–sebacic
acid
3–hydroxy–decanedioic acid 236 P
100FA01 ” ” ” ” Docosanedioic acid Docosanedioic acid 388 P / S
101FA01 ” ” ” ” Hexacosanedioic acid Hexacosanedioic acid 444 /
427
P / S
102FA01 ” ” ” ” Tridecanedioic acid Tridecanedioic acid 245 P
103FA01 Fatty Acids
and Conju-
gates
Carbocyclic
fatty acids
Majusculoic acid 4S,5S–methylene–11–bromo–
8E,10E–tetradecadienoic acid
297 P / S
104FA01 ” ” ” ” Oncobic acid 15–(2–cyclopenten–1–yl)–8–
pentadecenoic acid
289 P
105FA01 ” ” ” ” Sterculynic acid 7–(2–non–8–yn–1–
ylcycloprop–1–en–1–
yl)heptanoic acid
323 S
106FA01 Fatty Acids
and Conju-
gates
Dicarboxylic
acids
– 10–hydroxy–16–oxo–
hexadecanoic acid
304 P / S
107FA01 ” ” ” ” – 2E–Decenedioic acid 218 P
108FA01 ” ” ” ” – 5–methyl–hexadecanedioic
acid
323 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
109FA01 ” ” ” ” 2,2–dimethyl–
succinic acid
2,2–dimethyl–
butanedioicAˆ acid
129 P / S
110FA01 ” ” ” ” 3–hydroxy–
tetradecanedioic
acid
3–hydroxy–tetradecanedioic
acid
292 /
297
P / S
111FA01 ” ” ” ” Ceriporic acid C 1,10Z–heptadecadiene–2,3R–
dicarboxylic acid
370 P / S
112FA01 ” ” ” ” Eicosanedioic acid Eicosanedioic acid 360 P
113FA01 ” ” ” ” Suberic acid 1,8–octanedioic acid 157 P
114FA02 Octadeca–
noids
12–
oxophytodienoic
acid
metabo-
lites
– (1R,2R)–3–oxo–2–pentyl–
cyclopentanehexanoic acid
269 S
115FA02 ” ” ” ” (9R,13R)–10–oxo–
11–phytoenoic acid
(9R,13R)–2–oxo–5–pentyl–
3–cyclopentene–1–octanoic
acid
312 S
116FA02 Octadeca–
noids
Jasmonic
acids
methyl (+)–7–
isojasmonate
methyl (1R,2S)–3–oxo–
2–[(2Z)–pent–2–en–1–
yl]cyclopentylacetate
225 P
117FA02 Octadeca–
noids
Other Oc-
tadecanoids
– 14–oxo–octadecanoic acid 316 P / S
118FA02 ” ” ” ” – 3R–hydroxy–octadecanoic acid 318 P
119FA02 ” ” ” ” – 8–hydroxy–17–octadecene–
9,11–diynoic acid
308 P
120FA02 ” ” ” ” – 9–hydroxy–10E,14Z–
octadecadien–12–ynoic acid
293 P
121FA02 ” ” ” ” – 9R–hydroxy–octadecanoic acid 318 P / S
122FA02 ” ” ” ” 12–HpOTrE 12–hydroperoxy–9Z,13E,15–
octadecatrienoic acid
293 /
311
P / S
123FA02 ” ” ” ” 18–hydroxy–9R,10S–
epoxy–stearicacid
18–hydroxy–9R,10S–epoxy–
octadecanoic acid
332 /
337
P / S
124FA02 ” ” ” ” 18–hydroxy–9S,10R–
dihydroxy–stearic
acid
18–hydroxy–9S,10R–
dihydroxy–octadecanoic
acid
350 P / S
125FA02 ” ” ” ” 2R–hydroxy–oleic
acid
2R–hydroxy–9Z–octadecenoic
acid
331 P
126FA02 ” ” ” ” 5,8,12–TriHOME(9) 5,8,12–trihydroxy–9–
octadecenoic acid
313 S
127FA02 ” ” ” ” 5S,8R–DiHODE 5S,8R–dihydroxy–9Z,12Z–
octadecadienoic acid
313 S
128FA02 ” ” ” ” 6,7–dihydroxy stearic
acid
6,7–dihydroxy–octadecanoic
acid
334 P
129FA02 ” ” ” ” 7,8–dihydroxy stearic
acid
7,8–dihydroxy–octadecanoic
acid
334 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
130FA02 ” ” ” ” 7S,8S–DiHOTrE 7S,8S–dihydroxy–9Z,12Z,15Z–
octadecatrienoic acid
328 S
131FA02 ” ” ” ” 9,10,18–
TriHOME(12)
9,10,18–trihydroxy–12–
octadecenoic acid
331 P / S
132FA02 ” ” ” ” 9,12,13,TriHODE 9,12,13–trihydroxy–10,15–
octadecadienoic acid
346 /
351
P / S
133FA02 ” ” ” ” 9–HODE 9–hydroxy–10E,12Z–
octadecadienoic acid
314 /
279
P / S
134FA02 ” ” ” ” 9R,10S–dihydroxy–
stearic acid
9R,10S–dihydroxy–
octadecanoic acid
334 P / S
135FA02 ” ” ” ” 9S–HODE–d4 9S–hydroxy–10E,12Z–
octadecadienoic acid–d4
301 P / S
136FA02 ” ” ” ” Avenoleic acid 15R–hydroxy–9Z,12Z–
octadecadienoic acid
314 P
137FA02 ” ” ” ” α–9,10–DiHODE (+/–)–9,10–dihydroxy–
12Z,15Z–octadecadienoic
acid
295 P
138FA02 ” ” ” ” γ– 6(7)–EpODE 6(7)–epoxy–9Z,12Z–
octadecadienoic acid
295 S
139FA03 Eicosanoids Other
Eicosanoids
Dichotellate A Methyl 12R–(3–
methylbutanoyloxy)–
5Z,8E,10E,14Z–
eicosatetraenoate
436 P / S
140FA03 Eicosanoids Prostaglan–
dins
15–deoxy–δ–12,14–
PGJ2–d4
11–oxo–5Z,9,12E,14Z–
prostatetraenoic acid–d4
303 /
353
P / S
141FA03 ” ” ” ” 15–methyl–15R–
PGD2
9S,15R–dihydroxy–11–
oxo–15–methyl–5Z,13E–
prostadienoic acid
367 S
142FA03 ” ” ” ” 2,3–dinor–PGE1 9–oxo–11R,15S–dihydroxy–
2,3–dinor–13E–prostenoic
acid
344 P
143FA03 ” ” ” ” PGD2–d4 9S,15S–dihydroxy–11–oxo–
5Z,13E–prostadienoic acid
(3,3,4,4–d4)
379 S
144FA03 ” ” ” ” PGF2α isopropyl es-
ter
isopropyl 9S,11R,15S–
trihydroxy–5Z,13E–
prostadienoate
414 S
145FA03 ” ” ” ” PGF2α methyl ester methyl 9S,11R,15S–
trihydroxy–5Z,13E–
prostadienoate
386 P / S
146FA03 ” ” ” ” PGH2–EA N–(9S,11R–epidioxy–
15S–hydroxy–5Z,13E–
prostadienoyl)–ethanolamine
394 S
147FA03 ” ” ” ” PGI2–EA N–(6,9S–epoxy–11R,15S–
dihydoxy–5Z,13E–
prostadienoyl)–ethanolamine
396 S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
148FA03 ” ” ” ” Tetranor–PGEM–d6 11R–hydroxy–9,15–dioxo–
2,3,4,5–tetranor–prostan–
1,20–dioic acid–d6
725 P
149FA03 Eicosanoids Leukotrienes12–keto–10,11,14,15–
tetrahydro–LTB4
5S–hydroxy–12–keto–6Z,8E–
eicosadienoic acid
339 S
150FA03 Eicosanoids Thrombo–
xanes
2,3–Dinor–TXB1 9S,11,15S–trihydroxy–2,3–
dinor–thrombox–13E–en–1–
oic acid
360 P / S
151FA03 Eicosanoids Hydroxy/
hydrope–
roxyeico–
satetra–
enoic acids
8R–HETE 8R–hydroxy–5Z,9E,11Z,14Z–
eicosatetraenoic acid
303 S
152FA03 ” ” ” ” 10,11–dihydro–12–
oxo–Resolvin E1
12–oxo–5S,18S–dihydroxy–
6Z,8E,14Z,16E–
eicosatetraenoic acid
368 S
153FA03 Eicosanoids Hydroxy/
hydrope–
roxyeic–
osapenta–
enoicacids
12–oxo–Resolvin E1 12–oxo–5S,18S–dihydroxy–
6Z,8E,10E,14Z,16E–
eicosapentaenoic acid
366 P
154FA03 Eicosanoids Hepoxilins 14,15–HxA3–D(11S) 11S,15S–dihydroxy–14R–(S–
cysteinyl–glycyl)–5Z,8Z,12E–
eicosatrienoic acid
497 S
155FA03 Eicosanoids Isoprostanes 7–F2–dihomo–IsoP 1a,1b–dihomo–5,9,11–
trihydroxy–6E,14Z–
prostadienoic acid–cyclo[8,12]
400 P
156FA03 ” ” ” ” 8–epi–15–D2c–IsoP 11–oxo–9S,15S–dihydroxy–
5Z,13E–prostadienoic acid–
cyclo[8S,12S]
335 S
157FA03 ” ” ” ” ent–5–epi–5–J2–IsoP 5S–hydroxy–11–oxo–
6E,14Z,12–prostatrienoic
acid–cyclo[8S,12R]
352 S
158FA04 Docosanoids– 4S–hydroperoxy–
17S–HDHA
4S–hydroperoxy–
17S–hydroxy–
5E,7Z,10Z,13Z,15E,19Z–
docosahexaenoic acid
394 S
159FA04 ” ” – 7S,8S–epoxy–17R–
HDHA
7S,8S–epoxy–17R–hydroxy–
4Z,9E,11E,13Z,15E,19Z–
docosahexaenoic acid
376 P / S
160FA04 ” ” Adrenic acid 7,10,13,16–docosatetraenoic
acid oder 7Z,10Z,13Z,16Z–
docosatetraenoic acid
350 P / S
161FA04 ” ” – DPA 7Z,10Z,13Z,16Z,19Z–
docosapentaenoic acid
353 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
162FA05 Fatty alco-
hols
– – 1,3–Hexadecadien–1–ol 239 S
163FA05 ” ” – – 10,11–Difluoro–8E,10E–
dodecadien–1–ol
201 P / S
164FA05 ” ” – – 11Z–heptadecen–1–ol 255 /
272
P / S
165FA05 ” ” – – 2,2,9,9–tetramethyl–undecan–
1,10–diol
248 P
166FA05 ” ” – – 2Z,13Z–Octadecadien–1–ol 267 S
167FA05 ” ” – – 6Z,11Z–hexadecadien–1–ol 239 P
168FA05 ” ” – – 8Z,10E–Dodecadien–1–ol 183 P
169FA05 ” ” – – 9,12,15–Octadecatrien–1–ol 282 S
170FA05 ” ” – anteiso–1,2–
octadecanediol
3–methylheptadecane–1,2–diol 309 /
304
P / S
171FA05 ” ” – Falcarindiol 1,9–heptadecadien–4,6–diyn–
3,8–diol oder Heptadeca–1,9E–
dien–4,6–diyne–3R,8S– diol
oder (3R,8S,9Z)–heptadeca–
1,9–dien–4,6– diyne–3,8–diol
243 /
278
P / S
172FA05 ” ” – iso–1,2–
heptadecanediol
2–methylhexadecane–1,2–diol 290 S
173FA05 ” ” – Persin 1–acetoxy–2–hydroxy–
12Z,15Z–heneicosadien–4–one
381 S
174FA06 Fatty alde-
hydes
– – 11Z,13–Tetradecadienal 209 S
175FA06 ” ” – – 13Z–Hexadecen–11–ynal 252 S
176FA06 ” ” – – 2,4,6,8–decatetraenal 181 P
177FA06 ” ” – – 3,7–Dimethyl–8,11–dioxo–
2E,6E,9E–dodecatrienal
252 /
217
P / S
178FA06 ” ” – – 4,10–undecadiynal 163 P / S
179FA06 ” ” – – 8Z,10Z–Tetradecadienal 209 S
180FA06 ” ” – – 9Z,12Z,15Z–Octadecatrienal 263 S
181FA06 ” ” – 2–
hydroxyhexadecanal
2–hydroxyhexadecanal 257 P / S
182FA06 ” ” – Muconic dialdehyde 2,4–hexadienedial 111 S
183FA06 ” ” 7Z,11Z–Hexadecadienal 237 P
184FA07 Fatty esters Wax mono–
esters
– (E)–3,7–Dimethyl–2,6–
octadienyl nonanoate
312 S
185FA07 ” ” ” ” – (Z)–3–Hexenyl 3–
methylbutanoate
167 S
186FA07 ” ” ” ” – 11Z–octadecenyl hexade-
canoate
525 S
187FA07 ” ” ” ” – 12–methyl–tridecanyl 10–
methyl–hexadecanoate
485 S
188FA07 ” ” ” ” – 14,14,14–Trifluoro–11E–
tetradecenyl acetate
326 /
309.
P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
189FA07 ” ” ” ” – 16–methyl–heptadecanyl
tetradecanoate
499 P / S
190FA07 ” ” ” ” – 1–Methylbutyl 3–
methylbutanoate
181 P
191FA07 ” ” ” ” – 3E,13E–Octadecadienyl ac-
etate
326 P
192FA07 ” ” ” ” – 3E,8Z,11Z–Tetradecatrienyl
acetate
273 P / S
193FA07 ” ” ” ” – 4E,9Z–Tetradecadienyl acetate 235 /
285
P / S
194FA07 ” ” ” ” – 4E–Tridecenyl acetate 273 P / S
195FA07 ” ” ” ” – 5E–Dodecenyl acetate 244 P
196FA07 ” ” ” ” – 9E–Hexadecenyl acetate 305 /
300
P / S
197FA07 ” ” ” ” – decyl octanoate 302 P / S
198FA07 ” ” ” ” – formyl 7–oxo–11E–
tetradecenoate
255 P / S
199FA07 ” ” ” ” – hexadecyl butyrate 295 P
200FA07 ” ” ” ” – Methyl (E)–2,6,10–trimethyl–
5,9–undecadienoate
221 S
201FA07 ” ” ” ” – octadecyl 11E–hexadecenoate 525 P
202FA07 ” ” ” ” Arachidyl linoleate eicosanyl 9Z,12Z–
octadecadienoate
577 S
203FA07 ” ” ” ” Behenyl linoleate docosanyl 9Z,12Z–
octadecadienoate
607 S
204FA07 ” ” ” ” Behenyl linolenate docosanyl 9Z,12Z,15Z–
octadecatrienoate
605 S
205FA07 ” ” ” ” Behenyl palmitoleate docosanyl 9Z–hexadecenoate 581 S
206FA07 ” ” ” ” Heptadecyl palmi-
toleate
Heptadecyl 9Z–hexadecenoate 511 P / S
207FA07 ” ” ” ” Heptadecyl–
palmitate
heptadecyl hexadecanoate 513 S
208FA07 ” ” ” ” Lauryl oleate dodecanyl 9Z–octadecenoate 468 P / S
209FA07 ” ” ” ” Linoleyl arachidate 9Z,12Z–octadecadienyl
eicosanoate
579 S
210FA07 ” ” ” ” Linoleyl myristate 9Z,12Z–octadecadienyl
tetradecanoate
494 S
211FA07 ” ” ” ” Myristoleyl behenate 9Z–tetradecenyl docosanoate 553 P
212FA07 ” ” ” ” Myristyl laurate tetradecanyl dodecanoate 414 P / S
213FA07 ” ” ” ” Myristyl oleate tetradecanyl 9Z–octadecenoate 497 P / S
214FA07 ” ” ” ” Nonadecyl palmi-
toleate
Nonadecyl 9Z–hexadecenoate 539 S
215FA07 ” ” ” ” Oleyl oleate 9Z–octadecenyl 9Z–
octadecenoate
551 P / S
216FA07 ” ” ” ” Palmityl linoleate hexadecanyl 9Z,12Z–
octadecadienoate
523 S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
217FA07 ” ” ” ” Palmityl myristate hexadecanyl tetradecanoate 470 P / S
218FA07 ” ” ” ” Palmityl stearate hexadecanyl octadecanoate 527 P / S
219FA07 ” ” ” ” Stearyl linolenate octadecanyl 9Z,12Z,15Z–
octadecatrienoate
564 S
220FA07 Fatty esters Lactones – 3–acetyl–3–
methyldihydrofuran–2(3H)–
one
175 /
125
P / S
221FA07 ” ” ” ” – Dihydro–3–hydroxy–3–(1–
hydroxyethyl)–4–methylfuran–
2(3H)–one
143 /
178
P / S
222FA07 Fatty esters Fatty acyl
carnitines
– O–butanoyl–carnitine 232 P
223FA07 ” ” ” ” – O–octanoyl–R–carnitine 310 /
288
P / S
224FA07 ” ” ” ” hexadecanedioic acid
mono–L–carnitine es-
ter
– 447 S
225FA08 Fatty
amides
Primary
amides
– dodecanamide 200 P
226FA08 ” ” ” ” – pentanamide 84 P / S
227FA08 ” ” ” ” decanamide decanamide 172 S
228FA08 ” ” ” ” Linoleamide 9Z,12Z–octadecadienamide 280 S
229FA08 ” ” ” ” Palmitamide Hexadecanamide 256 /
273
P / S
230FA08 ” ” ” ” Palmitoleamide 9Z–hexadecenamide 276 P / S
231FA08 ” ” ” ” Stearamide Octadecanamide 284 P / S
232FA08 Fatty
amides
N–acyl
amines
– N–propyl–16,16–
dimethyl–5Z,8Z,11Z,14Z–
docosatetraenoyl amine
402 S
233FA08 ” ” ” ” N–(2–phenoxy–ethyl)
arachidonoyl amine
N–(2–phenoxy–ethyl)–
5Z,8Z,11Z,14Z–
eicosatetraenoyl amine
446 S
234FA08 ” ” ” ” N–palmitoyl glycine N–hexadecanoyl–glycine 296 /
314
P / S
235FA08 ” ” ” ” N–palmitoyl pheny-
lalanine
N–hexadecanoyl–
phenylalanine
436 P
236FA08 ” ” ” ” N–stearoyl serine N–octadecanoyl–serine 404 P
237FA08 ” ” ” ” N–stearoyl alanine N–octadecanoyl–alanine 356 S
238FA08 Fatty
amides
Fatty acyl
homoserine
lactones
– N–heptanoyl–homoserine lac-
tone
246 S
239FA08 Fatty
amides
N–acyl
ethanol–
amines (en-
docannabi-
noids)
Anandamide (18:2,
n–6)
N–(9Z,12Z–octadecadienoyl)–
ethanolamine
324 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
240FA08 ” ” ” ” Anandamide (20:2,
n–6)
N–(11Z,14Z–eicosadienoyl)–
ethanolamine
352 S
241FA08 ” ” ” ” Arachidonoyl–
EA(d8)
N–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–
ethanolamine(d8)
394 P
242FA08 ” ” ” ” Dihomo–γ–
linolenoyl–EA
N–(8Z,11Z,14Z–
eicosatrienoyl)–ethanolamine
367 P
243FA08 ” ” ” ” Lauroyl–EA N–(Dodecanoyl)–
ethanolamine
244 P
244FA11 Hydrocarbons– – 1–Octacosene 415 S
245FA11 ” ” – – 4,6–Dimethyl–2E,4E,6E–
nonatriene
151 P
246FA11 ” ” – – 6,10–Dimethyl–5(E),9–
undecadien–2–one
227 /
195
P / S
247FA11 ” ” – – 7–Heptacosene 401 S
248FA12 Oxygenated
hydrocar-
bons
– – (3S,4R)–(6S,7R)–Diepoxy–
9Z–heneicosene
340 P
249FA12 ” ” – – 10–Heptadecen–2–one 235 /
270
P / S
250FA12 ” ” – – 2–methyl–7R,8S–Epoxy–
octadecane
300 P / S
251FA12 ” ” – – 2S–Hydroxyhexan–3–one 99 S
252FA12 ” ” – – 3E–Nonen–2–one 141 S
253FA12 ” ” – – 5–Ethylundecane–2,4–dione 195 P / S
254FA12 ” ” – – 6S,7R–Epoxy–3Z,9Z–
octadecadiene
282 /
265
P / S
255FA12 ” ” – – 7–Ethyl–4E–undecen–6–one 219 S
256FA12 ” ” – hentriacontane–
14,16–dione
hentriacontane–14,16–dione 482 P / S
257FA13 Fatty acyl
glycosides
Fatty acyl
glycosides
of mono–
and disac-
charides
– 1–O–α–D–glucopyranosyl–
1,2–eicosandiol
494 S
Glycerophospholipids
(GPs)
1 GP00 Other
Glyc-
erophos-
pholipids
– – 1,2–diacyl–3–O–(phospho–
2’–O–(1’–amino)–2’,3’,4’,5’–
pentanetetrol)–sn–glycerol
390 P
2 GP01 Glycero–
phospho–
cholines
(PCs)
Diacylgly–
cerophos-
phocholines
PC(14:0/21:0) 1–tetradecanoyl–2–
heneicosanoyl–glycero–3–
phosphocholine
809 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
3 GP01 ” ” ” ” PC(14:1(9Z)/18:1
(9Z))
1–(9Z–tetradecenoyl)–2–(9Z–
octadecenoyl)–glycero–3–
phosphocholine
753 S
4 GP01 ” ” ” ” PC(18:0/18:0) 1,2–dioctadecanoyl–sn–
glycero–3–phosphocholine
823 P / S
5 GP01 ” ” ” ” PC(18:0/20:5(9Z,11Z,
13Z,15Z,17Z))
1–octadecanoyl–2–
(9Z,11Z,13Z,15Z,17Z–
eicosapentaenoyl)–sn–glycero–
3–phosphocholine
791 S
6 GP01 ” ” ” ” PC(18:3(9Z,12Z,15Z)/
17:0)
1–(9Z,12Z,15Z–
octadecatrienoyl)–2–
heptadecanoyl–glycero–3–
phosphocholine
771 S
7 GP01 ” ” ” ” PC(18:4(6Z,9Z,12Z,
15Z)/18:0)
1–(6Z,9Z,12Z,15Z–
octadecatetraenoyl)–2–
octadecanoyl–glycero–3–
phosphocholine
805 S
8 GP01 ” ” ” ” PC(20:2(11Z,14Z)/
17:0)
1–(11Z,14Z–eicosadienoyl)–
2–heptadecanoyl–glycero–3–
phosphocholine
783 S
9 GP01 ” ” ” ” PC(20:3(8Z,11Z,14Z)/
12:0)
1–(8Z,11Z,14Z–
eicosatrienoyl)–2–dodecanoyl–
glycero–3–phosphocholine
729 P / S
10 GP01 ” ” ” ” PC(20:4(5Z,8Z,11Z,
14Z)/17:0)
1–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–2–
heptadecanoyl–glycero–3–
phosphocholine
797 P
11 GP01 ” ” ” ” PC(20:5(5Z,8Z,11Z,
14Z,17Z)/14:0)
1–(5Z,8Z,11Z,14Z,17Z–
eicosapentaenoyl)–2–
tetradecanoyl–glycero–3–
phosphocholine
785 S
12 GP01 ” ” ” ” PC(20:5(5Z,8Z,11Z,
14Z,17Z)/15:0)
1–(5Z,8Z,11Z,14Z,17Z–
eicosapentaenoyl)–2–
pentadecanoyl–glycero–3–
phosphocholine
749 P
13 GP01 ” ” ” ” PC(20:5(5Z,8Z,11Z,
14Z,17Z)/17:0)
1–(5Z,8Z,11Z,14Z,17Z–
eicosapentaenoyl)–2–
heptadecanoyl–glycero–3–
phosphocholine
777 S
14 GP01 ” ” ” ” PC(22:6(4E,7E,10E,
13E,16E,19E)/16:0)
1–(4E,7E,10E,13E,16E,19E–
docosahexaenoyl)–2–
hexadecanoyl–sn–glycero–
3–phosphocholine
829 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
15 GP01 ” ” ” ” PC(22:6(4Z,7Z,10Z,
13Z,16Z,19Z)/16:1
(9Z))
1–(4Z,7Z,10Z,13Z,16Z,19Z–
docosahexaenoyl)–2–(9Z–
hexadecenoyl)–glycero–3–
phosphocholine
805 P / S
16 GP01 Glycero–
phospho–
cholines
(PCs)
1–(1Z–
alkenyl),2–
acylglycero–
phospho-
cholines
PC(O–16:0/1:0) 1–hexadecyl–2–formyl–sn–
glycero–3–phosphocholine
510 /
532
P / S
17 GP01 ” ” ” ” PC(O–16:0/19:0) 1–hexadecyl–2–nonadecanoyl–
sn–glycero–3–phosphocholine
763 P
18 GP01 ” ” ” ” PC(O–
16:0/22:5(7Z,10Z,13Z,
16Z,19Z))
1–hexadecyl–2–
(7Z,10Z,13Z,16Z,19Z–
docosapentaenoyl)–sn–
glycero–3–phosphocholine
795 P / S
19 GP01 ” ” ” ” PC(O–18:0/1:0) 1–octadecyl–2–formyl–sn–
glycero–3–phosphocholine
538 S
20 GP01 ” ” ” ” PC(O–18:0/19:0) 1–octadecyl–2–nonadecanoyl–
glycero–3–phosphocholine
823 P
21 GP01 ” ” ” ” PC(P–14:0/18:1(9Z)) 1–O–(1Z–tetradecenyl)–
2–(9Z–octadecenoyl)–sn–
glycero–3–disaccharides
[FA1301]
749 /
755
P / S
22 GP01 ” ” ” ” PC(P–
16:0/22:6(4Z,7Z,10Z,
13Z,16Z,19Z))
1–(1Z–hexadecenyl)–2–
(4Z,7Z,10Z,13Z,16Z,19Z–
docosahexaenoyl)–sn–glycero–
3–phosphocholine
791 P
23 GP01 ” ” ” ” PC(P–18:0/2:0) 1–(1Z–octadecenyl)–2–acetyl–
sn–glycero–3–phosphocholine
550 P
24 GP01 ” ” ” ” PC(P–
20:0/20:4(5Z,8Z,11Z,
14Z))
1–(1Z–eicosenyl)–
2–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–glycero–
3–phosphocholine
845 P
25 GP01 Glycero–
phospho–
cholines
(PCs)
Monoacyl–
glycero–
phospho-
cholines
PC(0:0/16:0) 2–hexadecanoyl–sn–glycero–3–
phosphocholine
496 P / S
26 GP01 ” ” ” ” PC(0:0/20:4(5Z,8Z,
11Z,14Z))
2–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–sn–glycero–
3–phosphocholine
544 P / S
27 GP01 ” ” ” ” PC(13:0/0:0) 1–tridecanoyl–sn–glycero–3–
phosphocholine
454 P
28 GP01 ” ” ” ” PC(15:0/0:0) 1–pentadecanoyl–sn–glycero–
3–phosphocholine
482 P
29 GP01 ” ” ” ” PC(15:1(9Z)/0:0) 1–(9Z–pentadecenoyl)–
glycero–3–phosphocholine
480 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
30 GP01 ” ” ” ” PC(16:1(9Z)/0:0) 1–(9Z–hexadecenoyl)–sn–
glycero–3–phosphocholine
494 S
31 GP01 ” ” ” ” PC(18:0/0:0) 1–octadecanoyl–sn–glycero–3–
phosphocholine
546 /
524
P / S
32 GP01 ” ” ” ” PC(18:1(9Z)/0:0)[rac] 1–(9Z–octadecenoyl)–sn–
glycero–3–phosphocholine
522 P
33 GP01 ” ” ” ” PC(18:2(9Z,12Z)/0:0) 1–(9Z,12Z–octadecadienoyl)–
sn–glycero–3–phosphocholine
520 P / S
34 GP01 ” ” ” ” PC(18:4(6Z,9Z,12Z,
15Z)/0:0)
1–(6Z,9Z,12Z,15Z–
octadecatetraenoyl)–glycero–
3–phosphocholine
548 S
35 GP01 ” ” ” ” PC(20:0/0:0) 1–eicosanoyl–sn–glycero–3–
phosphocholine
552 S
36 GP01 ” ” ” ” PC(20:3(8Z,11Z,14Z)
/0:0)
1–(8Z,11Z,14Z–
eicosatrienoyl)–glycero–3–
phosphocholine
578 P / S
37 GP01 ” ” ” ” PC(20:5(5Z,8Z,11Z,
14Z,17Z)/0:0)
1–(5Z,8Z,11Z,14Z,17Z–
eicosapentaenoyl)–sn–glycero–
3–phosphocholine
542 P / S
38 GP01 ” ” ” ” PC(22:1(11Z)/0:0) 1–(11Z–docosenoyl)–glycero–
3–phosphocholine
578 S
39 GP01 ” ” ” ” PC(22:4(7Z,10Z,13Z,
16Z)/0:0)
1–(7Z,10Z,13Z,16Z–
docosatetraenoyl)–glycero–
3–phosphocholine
572 P / S
40 GP01 ” ” ” ” PC(22:6(4Z,7Z,10Z,
13Z,16Z,19Z)/0:0)
1–(4Z,7Z,10Z,13Z,16Z,19Z–
docosahexaenoyl)–sn–glycero–
3–phosphocholine
568 P
41 GP01 ” ” ” ” PC(O–16:0/0:0) 1–hexadecyl–sn–glycero–3–
phosphocholine
482 P / S
42 GP01 ” ” ” ” PC(O–
16:1(11Z)/0:0)
1–(11Z–hexadecenyl)–sn–
glycero–3–phosphocholine
480 P
43 GP02 Glycero–
phospho–
ethanol–
amines
(PEs)
Diacylgly–
cerophospho–
ethanolamines
PE(15:0/12:0) 1–pentadecanoyl–2–
dodecanoyl–glycero–3–
phosphoethanolamine
604 P / S
44 GP02 ” ” ” ” PE(15:1(9Z)/21:0) 1–(9Z–pentadecenoyl)–2–
heneicosanoyl–glycero–3–
phosphoethanolamine
729 P / S
45 GP02 ” ” ” ” PE(16:1(9Z)/22:0) 1–(9Z–hexadecenoyl)–2–
docosanoyl–glycero–3–
phosphoethanolamine
775 S
46 GP02 ” ” ” ” PE(18:0(10(R)Me)/
16:0)
1–((R)–10–
methyloctadecanoyl)–2–
hexadecanoyl–sn–glycero–3–
phosphoethanolamine
735 P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
47 GP02 ” ” ” ” PE(18:0/15:0) 1–octadecanoyl–2–
pentadecanoyl–glycero–3–
phosphoethanolamine
729 P
48 GP02 ” ” ” ” PE(18:1(9Z)/21:0) 1–(9Z–octadecenoyl)–2–
heneicosanoyl–glycero–3–
phosphoethanolamine
821 P / S
49 GP02 ” ” ” ” PE(18:2(9Z,12Z)/
18:0)
1–(9Z,12Z–octadecadienoyl)–
2–octadecanoyl–glycero–3–
phosphoethanolamine
745 S
50 GP02 ” ” ” ” PE(18:2(9Z,12Z)/
21:0)
1–(9Z,12Z–octadecadienoyl)–
2–heneicosanoyl–glycero–3–
phosphoethanolamine
769 P / S
51 GP02 ” ” ” ” PE(18:3(9Z,12Z,15Z)/
19:0)
1–(9Z,12Z,15Z–
octadecatrienoyl)–2–
nonadecanoyl–glycero–3–
phosphoethanolamine
739 P
52 GP02 ” ” ” ” PE(18:4(6Z,9Z,12Z,
15Z)/22:0)
1–(6Z,9Z,12Z,15Z–
octadecatetraenoyl)–2–
docosanoyl–glycero–3–
phosphoethanolamine
779 P
53 GP02 ” ” ” ” PE(20:3(8Z,11Z,14Z)
/18:0)
1–(8Z,11Z,14Z–
eicosatrienoyl)–2–
octadecanoyl–glycero–3–
phosphoethanolamine
771 P
54 GP02 ” ” ” ” PE(20:4(5Z,8Z,11Z,
14Z)/20:0)
1–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–2–
eicosanoyl–glycero–3–
phosphoethanolamine
797 S
55 GP02 ” ” ” ” PE(20:5(5Z,8Z,11Z,
14Z,17Z)/19:1(9Z))
1–(5Z,8Z,11Z,14Z,17Z–
eicosapentaenoyl)–2–(9Z–
nonadecenoyl)–glycero–3–
phosphoethanolamine
779 S
56 GP02 ” ” ” ” PE(20:5(5Z,8Z,11Z,
14Z,17Z)/20:0)
1–(5Z,8Z,11Z,14Z,17Z–
eicosapentaenoyl)–2–
eicosanoyl–glycero–3–
phosphoethanolamine
777 P
57 GP02 ” ” ” ” PE(21:0/16:0) 1–heneicosanoyl–2–
hexadecanoyl–glycero–3–
phosphoethanolamine
801 S
58 GP02 ” ” ” ” PE(22:6(4Z,7Z,10Z,
13Z,16Z,19Z)/18:3
(6Z,9Z,12Z))
1–(4Z,7Z,10Z,13Z,16Z,19Z–
docosahexaenoyl)–
2–(6Z,9Z,12Z–
octadecatrienoyl)–glycero–
3–phosphoethanolamine
804 S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
59 GP02 ” ” ” ” PE(22:6(4Z,7Z,10Z,
13Z,16Z,19Z)/21:0)
1–(4Z,7Z,10Z,13Z,16Z,19Z–
docosahexaenoyl)–2–
heneicosanoyl–glycero–3–
phosphoethanolamine
835 P
60 GP02 Glycero–
phospho–
ethanol–
amines
(PEs)
1–alkyl,2–
acylglycero–
phosphoetha–
nolamines
PE(O–16:0/13:0) 1–hexadecyl–2–
tridecanoyl–glycero–3–
phosphoethanolamine
654 S
61 GP02 Glycero–
phospho–
ethanol–
amines
(PEs)
1–(1Z–
alkenyl),2–
acylglycero–
phosphoetha–
nolamines
PE(P–
16:0/22:4(7Z,10Z,13Z,
16Z))
1–(1Z–hexadecenyl)–
2–(7Z,10Z,13Z,16Z–
docosatetraenoyl)–glycero–
3–phosphoethanolamine
753 P / S
62 GP02 ” ” ” ” PE(P–
20:0/22:1(11Z))
1–(1Z–eicosenyl)–2–(11Z–
docosenoyl)–glycero–3–
phosphoethanolamine
832 P
63 GP02 Glycero–
phospho–
ethanol–
amines
(PEs)
Monoacyl–
glycerophos–
phoethanol–
amines
PE(16:0/0:0) 1–hexadecanoyl–sn–glycero–3–
phosphoethanolamine
454 S
64 GP02 ” ” ” ” PE(17:0/0:0) 1–heptadecanoyl–glycero–3–
phosphoethanolamine
468 P / S
65 GP02 ” ” ” ” PE(18:0/0:0) 1–octadecanoyl–sn–glycero–3–
phosphoethanolamine
482 S
66 GP02 ” ” ” ” PE(18:1(9Z)/0:0) 1–(9Z–octadecenoyl)–
sn–glycero–3–
phosphoethanolamine
480 S
67 GP02 ” ” ” ” PE(20:4(5Z,8Z,11Z,
14Z)/0:0)
1–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–sn–glycero–
3–phosphoethanolamine
502 P
68 GP02 ” ” ” ” PE(22:0/0:0) 1–docosanoyl–glycero–3–
phosphoethanolamine
538 P
69 GP02 Glycero–
phospho–
ethanol–
amines
(PEs)
Monoalkyl–
glycerophos–
phoetha–
nolamines
PE(O–18:1(9Z)/0:0) 1–(9Z–octadecenyl)–
sn–glycero–3–
phosphoethanolamine
466 S
70 GP02 Glycero–
phospho–
ethanol–
amines
(PEs)
1Z–
alkenylgly–
cerophos–
phoetha–
nolamines
PE(P–18:0/0:0) 1–(1Z–octadecenyl)–
sn–glycero–3–
phosphoethanolamine
466 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
71 GP03 Glycero–
phospho-
serines
(PSs)
Diacylgly–
cerophos–
phoserines
PS(17:2(9Z,12Z)/
21:0)
1–(9Z,12Z–heptadecadienoyl)–
2–heneicosanoyl–glycero–3–
phosphoserine
799 S
72 GP03 ” ” ” ” PS(18:2(9Z,12Z)/
13:0)
1–(9Z,12Z–octadecadienoyl)–
2–tridecanoyl–glycero–3–
phosphoserine
718 S
73 GP03 ” ” ” ” PS(18:3(6Z,9Z,12Z)
/22:0)
1–(6Z,9Z,12Z–
octadecatrienoyl)–2–
docosanoyl–glycero–3–
phosphoserine
825 P
74 GP03 ” ” ” ” PS(20:1(11Z)/16:0) 1–(11Z–eicosenoyl)–2–
hexadecanoyl–glycero–3–
phosphoserine
791 S
75 GP03 ” ” ” ” PS(20:3(8Z,11Z,14Z)
/20:0)
1–(8Z,11Z,14Z–
eicosatrienoyl)–2–eicosanoyl–
glycero–3–phosphoserine
825 S
76 GP03 Glycero–
phospho-
serines
(PSs)
1–alkyl,2–
acylglycero–
phospho-
serines
PS(O–18:0/15:0) 1–octadecyl–2–pentadecanoyl–
glycero–3–phosphoserine
737 P
77 GP03 ” ” ” ” PS(O–20:0/19:0) 1–eicosyl–2–nonadecanoyl–
glycero–3–phosphoserine
803 P / S
78 GP03 ” ” ” ” PS(O–
20:0/22:1(11Z))
1–eicosyl–2–(11Z–
docosenoyl)–glycero–3–
phosphoserine
843 S
79 GP03 Glycero–
phospho-
serines
(PSs)
1–(1Z–
alkenyl),2–
acylglycero–
phospho-
serines
PS(P–16:0/13:0) 1–(1Z–hexadecenyl)–2–
tridecanoyl–glycero–3–
phosphoserine
678 S
80 GP03 ” ” ” ” PS(P–16:0/18:0) 1–(1Z–hexadecenyl)–2–
octadecanoyl–glycero–3–
phosphoserine
781 /
749
P / S
81 GP03 ” ” ” ” PS(P–16:0/19:1(9Z)) 1–(1Z–hexadecenyl)–2–(9Z–
nonadecenoyl)–glycero–3–
phosphoserine
761 S
82 GP03 ” ” ” ” PS(P–16:0/20:0) 1–(1Z–hexadecenyl)–2–
eicosanoyl–glycero–3–
phosphoserine
759 S
83 GP03 ” ” ” ” PS(P–
16:0/20:1(11Z))
1–(1Z–hexadecenyl)–2–
(11Z–eicosenoyl)–glycero–
3–phosphoserine
813 P
84 GP03 ” ” ” ” PS(P–
16:0/22:1(11Z))
1–(1Z–hexadecenyl)–2–
(11Z–docosenoyl)–glycero–
3–phosphoserine
785 S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
85 GP03 ” ” ” ” PS(P–18:0/14:1(9Z)) 1–(1Z–octadecenyl)–2–(9Z–
tetradecenoyl)–glycero–3–
phosphoserine
751 P
86 GP03 ” ” ” ” PS(P–18:0/20:0) 1–(1Z–octadecenyl)–2–
eicosanoyl–glycero–3–
phosphoserine
827 P / S
87 GP03 ” ” ” ” PS(P–20:0/19:1(9Z)) 1–(1Z–eicosenyl)–2–(9Z–
nonadecenoyl)–glycero–3–
phosphoserine
799 P
88 GP03 ” ” ” ” PS(P–20:0/22:0) 1–(1Z–eicosenyl)–2–
docosanoyl–glycero–3–
phosphoserine
843 P
89 GP03 Glycero–
phospho-
serines
(PSs)
Monoacyl–
glycerophos–
phoserines
PS(13:0/0:0) 1–tridecanoyl–sn–glycero–3–
phosphoserine
473 S
90 GP03 ” ” ” ” PS(O–18:0/0:0) 1–octadecyl–glycero–3–
phosphoserine
494 P
91 GP03 ” ” ” ” PS(O–20:0/0:0) 1–eicosyl–glycero–3–
phosphoserine
522 S
92 GP04 Glycero–
phospho–
glycerols
(PGs)
Diacyl–
glycerophos–
phoglyc-
erols
PG(18:4(6Z,9Z,12Z,
15Z)/12:0)
1–(6Z,9Z,12Z,15Z–
octadecatetraenoyl)–2–
dodecanoyl–glycero–3–
phospho–(1’–sn–glycerol)
704 S
93 GP04 Glycero–
phospho–
glycerols
(PGs)
Monoacyl–
glycerophos–
phoglyc-
erols
PG(15:0/0:0) 1–pentadecanoyl–glycero–3–
phospho–(1’–sn–glycerol)
488 P
94 GP06 Glycero–
phospho–
inositols
(PIs)
Diacyl–
glycerophos–
phoinosi-
tols
PI(12:0/22:1(11Z)) 1–dodecanoyl–2–(11Z–
docosenoyl)–glycero–3–
phospho–(1’–myo–inositol)
855 S
95 GP06 ” ” ” ” PI(14:1(9Z)/22:1
(11Z))
1–(9Z–tetradecenoyl)–2–
(11Z–docosenoyl)–glycero–3–
phospho–(1’–myo–inositol)
881 P / S
96 GP06 ” ” ” ” PI(17:2(9Z,12Z)/17:0)1–(9Z,12Z–heptadecadienoyl)–
2–heptadecanoyl–glycero–3–
phospho–(1’–myo–inositol)
853 P / S
97 GP06 ” ” ” ” PI(18:3(6Z,9Z,12Z)/
20:2(11Z,14Z))
1–(6Z,9Z,12Z–
octadecatrienoyl)–2–
(11Z,14Z–eicosadienoyl)–
glycero–3–phospho–(1’–myo–
inositol)
903 P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
98 GP06 ” ” ” ” PI(18:4(6Z,9Z,12Z,
15Z)/20:0)
1–(6Z,9Z,12Z,15Z–
octadecatetraenoyl)–2–
eicosanoyl–glycero–3–
phospho–(1’–myo–inositol)
905 P / S
99 GP06 ” ” ” ” PI(19:1(9Z)/15:0) 1–(9Z–nonadecenoyl)–2–
pentadecanoyl–glycero–3–
phospho–(1’–myo–inositol)
855 P
100GP06 ” ” ” ” PI(20:4(5Z,8Z,11Z
,14Z)/16:0)
1–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–2–
hexadecanoyl–glycero–3–
phospho–(1’–myo–inositol)
877 P / S
101GP06 Glycero–
phospho–
inositols
(PIs)
1–alkyl,2–
acylgly–
cerophos-
phoinosi-
tols
PI(O–16:0/16:0) 1–hexadecyl–2–hexadecanoyl–
glycero–3–phospho–(1’–myo–
inositol)
815 S
102GP06 Glycero–
phospho–
inositols
(PIs)
Monoacyl–
glycerophos–
phoinosi-
tols
PI(18:0/0:0) 1–octadecanoyl–sn–glycero–3–
phospho–(1’–myo–inositol)
601 P / S
103GP06 ” ” ” ” PI(20:4(5Z,8Z,11Z,
14Z)/0:0)
1–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–sn–glycero–
3–phospho–(1’–myo–inositol)
638 P
104GP10 Glycero–
phosphates
(PAs)
Diacylgly–
cerophos–
phates
PA(16:1(9Z)/16:0) 1–(9Z–hexadecenoyl)–2–
hexadecanoyl–glycero–3–
phosphate
647 P / S
105GP10 ” ” ” ” PA(18:4(6Z,9Z,12Z,
15Z)/17:2(9Z,12Z))
1–(6Z,9Z,12Z,15Z–
octadecatetraenoyl)–2–
(9Z,12Z–heptadecadienoyl)–
glycero–3–phosphate
679 P / S
106GP10 ” ” ” ” PA(22:6(4Z,7Z,10Z,
13Z,16Z,19Z)/17:0)
1–(4Z,7Z,10Z,13Z,16Z,19Z–
docosahexaenoyl)–2–
heptadecanoyl–glycero–3–
phosphate
717 P
107GP10 Glycero–
phosphates
(PAs)
1–alkyl,2–
acylglycero–
phosphates
PA(O–20:0/17:0) 1–eicosyl–2–heptadecanoyl–
glycero–3–phosphate
738 P
108GP10 ” ” ” ” PA(P–20:0/0:0) 1–(1Z–eicosenyl)–glycero–3–
phosphate
451 P / S
109GP10 Glycero–
phosphates
(PAs)
Monoacyl–
glycero–
phosphates
PA(0:0/18:1(9Z)) 2–(9Z–octadecenoyl)–sn–
glycero–3–phosphate
454 P / S
110GP10 ” ” ” ” PA(16:0/0:0) 1–hexadecanoyl–sn–glycero–3–
phosphate
428 P / S
111GP10 ” ” ” ” PA(18:0/0:0) 1–octadecanoyl–sn–glycero–3–
phosphate
456 P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
112GP10 ” ” ” ” PA(18:2(9Z,12Z)/0:0) 1–(9Z,12Z–octadecadienoyl)–
glycero–3–phosphate
452 P / S
113GP10 ” ” ” ” PA(20:4(5Z,8Z,11Z,
14Z)/0:0)
1–(5Z,8Z,11Z,14Z–
eicosatetraenoyl)–sn–glycero–
3–phosphate
476 P / S
114GP20 Oxidized
glycero–
phospho-
lipids
Oxidized
glycero–
phospho-
cholines
PC(16:0/9:0(CHO)) 1–hexadecanoyl–2–(9–oxo–
nonanoyl)–sn–glycero–3–
phosphocholine
650 P
115GP20 Oxidized
glycero–
phospho-
lipids
Oxidized
glycero–
phospho–
ethanol–
amines
PE(P–
16:0/20:4(5Z,8Z,10E,
14Z)(12OH[S]))
1–O–(1Z–hexadecenyl)–2–
(12S–hydroxy–5Z,8Z,10E,14Z–
eicosatetraenoyl)–sn–glycero–
3–phosphoethanolamine
741 P / S
116GP20 ” ” ” ” PE(P–
18:0/20:4(5Z,8Z,10E,
14Z)(12OH[S]))
1–O–(1Z–octadecenyl)–2–
(12S–hydroxy–5Z,8Z,10E,14Z–
eicosatetraenoyl)–sn–glycero–
3–phosphoethanolamine
769 P / S
Sterol
Lipids
(STs)
1 ST01 Sterols Cholesterol
and deriva-
tives
– (25S)–5α–cholestan–
3β,6α,7β,8β,15α,16β,26–
heptol
502 P / S
2 ST01 ” ” ” ” 15α–
hydroxycholestene
5α–cholest–8(14)–en–3β,15α–
diol
385 P / S
3 ST01 ” ” ” ” 4β–
(hydroxymethyl)–
4α–methyl–5α–
cholest–7–en–3β–ol
4β–(hydroxymethyl)–4–
methyl–5α–cholest–7–en–3β–
ol 4β–(hydroxymethyl)–4α–
methyl–5α–cholest–7–en–3β–
ol
448 P / S
4 ST01 ” ” ” ” Cholestan eskeleton – 373 S
5 ST01 ” ” ” ” Cucurbitacin E – 574 P / S
6 ST01 ” ” ” ” Cucurbitacin O – 536 P
7 ST01 ” ” ” ” DHCEO 3β,5α–dihydroxycholest–7–
en–6–one
417 P
8 ST01 Sterols Steryl
esters
14:1 Cholesteryl ester cholest–5–en–3b–yl (9Z–
tetradecenoate)
618 P
9 ST01 ” ” ” ” 18:1 Cholesteryl ester cholest–5–en–3b–yl (9Z–
octadecenoate)
669 P / S
10 ST01 ” ” ” ” 18:2 Cholesteryl ester cholest–5–en–3β–yl (9Z,12Z–
octadecadienoate)
667 S
11 ST01 ” ” ” ” 18:3 Cholesteryl ester cholest–5–en–3β–
yl (9Z,12Z,15Z–
octadecatrienoate)
665 P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
12 ST01 ” ” ” ” 20:4 Cholesteryl ester cholest–5–en–3β–
yl (5Z,8Z,11Z,14Z–
eicosatetraenoate)
691 P / S
13 ST01 ” ” ” ” 20:5 Cholesteryl ester cholest–5–en–3β–yl
(5Z,8Z,11Z,14Z,17Z–
eicosapentaenoate)
689 P / S
14 ST01 ” ” ” ” 22:6 Cholesteryl ester cholest–5–en–3β–yl
(4Z,7Z,10Z,13Z,16Z,19Z–
docosahexaenoate)
715 P
15 ST01 ” ” ” ” zymosteryl oleate 5α–cholesta–8,24–dien–3β–yl
(9Z)–octadec–9–enoate
667 P
16 ST01 Sterols Ergosterols
and C24–
methyl
derivatives
– 4α,14α–dimethyl–24–
methylene–cholest–7,9(11)–
dien–3β–ol
442 S
17 ST01 ” ” ” ” Nebrosteroid L 3β–hydroxy–6β–acetoxy–24–
methylene–cholest–5–en–19–al
488 S
18 ST01 ” ” ” ” Nebrosteroid M 4α–methyl–24–methylene–
cholestan–3β,8β,11β–triol
464 S
19 ST01 ” ” ” ” Xestosterol 24–methylene,26,27–
dimethylcholest–5–en–3β–ol
444 /
427
P / S
20 ST01 Sterols Stigmasterols
and C24–
ethyl
derivatives
– 24–ethyl–5α–cholest–25–en–
3α,12α,16α–triol
464 /
429
P / S
21 ST01 Sterols Cycloarta–
nols and
derivatives
cimicifoetiside A 15α,25–dihydroxy–
16β,23R:16α,24S–diepoxy–
9β,19–cyclolanostan–
3β–yl 2–O–acetyl–α–L–
arabinopyranoside
680 P / S
22 ST01 Sterols Cardanoli–
des and
derivatives
Digitoxigenin 3–β,14β–dihydroxy–5–β–
card–20(22)–enolide
375 P
23 ST01 ” ” ” ” gitoxigenin 3β,14,16β–trihydroxy–5β–
card–20(22)–enolide
391 P / S
24 ST02 Steroids C19
steroids
(andro-
gens) and
derivatives
5α–androstane–
3β,17α–diol
5α–androstane–3β,17α–diol 310 /
325
P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
25 ST02 Steroids C21
steroids
(gluco/mi–
neralocor-
ticoids,
progesto-
gens) and
derivatives
(20R)–20–
hydroxypregn–4–
en–3–one
20R–hydroxypregn–4–en–3–
one
334 P / S
26 ST02 ” ” ” ” 17,20–
dihydroxypregn–
4–en–3–one
17,20–dihydroxypregn–4–en–
3–one
350 S
27 ST02 ” ” ” ” 3–hydroxy–5β–
pregnan–20–one
3–hydroxy–5β–pregnan–20–
one
336 P / S
28 ST02 ” ” ” ” megestrol 17–hydroxypregna–4,6–diene–
3,20–dione
329 S
29 ST03 Secosteroids Vitamin D3
and deriva-
tives
(24S)–1α,24–
dihydroxy–22–
oxavitamin D3
/ (24S)–1α,24–
dihydroxy–22–
oxacholecalciferol
(5Z,7E)–(1S,3R,24S)–22–
oxa–9,10–seco–5,7,10(19)–
cholestatriene–1,3,24–triol
441 S
30 ST03 ” ” ” ” (25R)–1α,25,26–
trihydroxy–22–
oxavitamin D3 /
(25R)–1α,25,26–
trihydroxy–22–
oxacholecalciferol
(5Z,7E)–(1S,3R,25R)–22–
oxa–9,10–seco–5,7,10(19)–
cholestatriene–1,3,25,26–tetrol
473 P
31 ST03 ” ” ” ” 1α,25–dihydroxy–
11β–methoxyvitamin
D3 / 1α,25–
dihydroxy–11β–
methoxycholecalciferol
(5Z,7E)–(1S,3R,11R)–
11–methoxy–9,10–seco–
5,7,10(19)–cholestatriene–
1,3,25–triol
447 S
32 ST03 ” ” ” ” 1α,25–dihydroxy–19–
nor–22–oxavitamin
D3 1α,25–dihydroxy–
19–nor–22–
oxacholecalciferol
(7E)–(1R,3R)–19–nor–
22–oxa–9,10–seco–5,7–
cholestadiene–1,3,25–triol
424 P / S
33 ST03 ” ” ” ” 1α,25–dihydroxy–21–
nor–20–oxavitamin
D3 / 1α,25–
dihydroxy–21–nor–
20–oxacholecalciferol
(5Z,7E)–(1S,3R)–21–nor–20–
oxa–9,10–seco–5,7,10(19)–
cholestatriene–1,3,25–triol
427 /
422
P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
34 ST03 ” ” ” ” 1α,25–dihydroxy–
26,27–dimethyl–
22,22,23,23–
tetradehydro–
24a,24b,24c–
trihomo–20–
epivitamin D3 /
1α,25–dihydroxy–
26,27–dimethyl–
22,22,23,23–
tetradehydro–
24a,24b,24c–
trihomo–20–
epicholecalciferol
(5Z,7E)–(1S,3R,20R)–26,27–
dimethyl–24a,24b,24c–
trihomo–9,10–seco–5,7,10(19)–
cholestatrien–22–yne–1,3,25–
triol
500 P / S
35 ST03 ” ” ” ” 1α,25–dihydroxy–
26,27–dimethyl–
22,22,23,23–
tetradehydro–24a–
homovitamin D3 /
1α,25–dihydroxy–
26,27–dimethyl–
22,22,23,23–
tetradehydro–24a–
homocholecalciferol
(5Z,7E)–(1S,3R)–26,27–
dimethyl–24a–homo–9,10–
seco–5,7,10(19)–cholestatrien–
22–yne–1,3,25–triol
472 P / S
36 ST03 ” ” ” ” 1α,25–dihydroxy–
26,27–dimethyl–
24a,24b–
dihomovitamin
D3 / 1α,25–
dihydroxy–26,27–
dimethyl–24a,24b–
dihomocholecalciferol
(5Z,7E)–(1S,3R)–26,27–
dimethyl–24a,24b–dihomo–
9,10–seco–5,7,10(19)–
cholestatrien–1,3,25–triol
490 P / S
37 ST03 ” ” ” ” 1α,25–
dihydroxy–6,7–
didehydroprevitamin
D3 / 1α,25–
dihydroxy–6,7–
didehydroprechole–
calciferol
(1S,3R)–9,10–seco–5(10),8–
cholestadien–6–yne–1,3,25–
triol
447 S
38 ST03 ” ” ” ” 2α–(3–
Hydroxypropyl)–
1α,25–dihydroxy–19–
norvitamin D3
(5Z,7E)–(1R,2R,3R)–3–
(hydroxy–propyl)–19–nor–
9,10–seco–5,7–cholestadien–
1,3,25–triol
445 P / S
39 ST03 ” ” ” ” 3–Fluoro–9,10–
secocholesta–
5,7,10(19)–triene
(5Z,7E)–(3S)–3–fluoro–9,10–
seco–5,7,10(19)–cholestatriene
404 S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
40 ST03 ” ” ” ” ZK 168281 (5Z,7E,22E)–(1S,3R,24R)–25–
(carboethoxy–methylene)–
26,26–cyclo–9,10–seco–
5,7,10(19),22–1,3,24–
triolcholestatetraene–1,3,24–
triol
528 P
41 ST04 Bile acids
and deriva-
tives
C24 bile
acids, alco-
hols, and
derivatives
– (20S,22E)–3β–Hydroxy–5α–
chol–22–en–24–oic Acid
357 P
42 ST04 ” ” ” ” – (22E)–3β–Hydroxy–5α–chola–
7,22–dien–24–oic Acid
373 P / S
43 ST04 ” ” ” ” – 12–Oxo–5β–cholan–24–oic
Acid
357 P
44 ST04 ” ” ” ” – 2β,3β–Dihydroxy–6–oxo–5α–
chol–7–en–24–oic Acid
422 P / S
45 ST04 ” ” ” ” – 3α–Hydroxy–1,7–dioxo–5β–
cholan–24–oic Acid
422 P
46 ST04 ” ” ” ” – 3β,12β–Dihydroxy–5β–
cholan–24–oic Acid
410 P / S
47 ST04 ” ” ” ” – 3β,6α,7α–Trihydroxy–5β–
cholan–24–oic Acid
426 P
48 ST04 ” ” ” ” – 3β,9α–Dihydroxy–11–oxo–5β–
cholan–24–oic Acid
424 P / S
49 ST04 ” ” ” ” – 3β–Hydroxy–7–oxo–5α–
cholan–24–oic Acid
391 P / S
50 ST04 ” ” ” ” – 3β–Hydroxy–chol–5–en–24–oic
Acid
357 P / S
51 ST04 Bile acids
and deriva-
tives
C27 bile
acids, alco-
hols, and
derivatives
– 5β–Cholest–25–ene–
3α,7α,12α,23–tetrol
452 P
52 ST04 Bile acids
and deriva-
tives
C23 bile
acids, alco-
hols, and
derivatives
– 24–Nor–5β–chol–22–ene–
3α,6α–diol
364 P / S
53 ST05 Steroid
conjugates
Taurine
conjugates
Taurochenodeoxy–
cholic acid
N–(3α,7α–dihydroxy–5β–
cholan–24–oyl)–taurine
517 P / S
54 ST05 ” ” ” ” Taurodeoxycholic
acid
N–(3α,12α–dihydroxy–5β–
cholan–24–oyl)–taurine
350 P
55 ST05 ” ” ” ” Taurohyocholic acid N–(3α,6α,7α–Trihydroxy–5β–
cholan–24–oyl)–taurine
533 S
Glycerolipids
(GLs)
1 GL01 Monoradyl–
glycerols
Monoacyl–
glycerols
MG(0:0/18:1(9Z)/
0:0)
2–(9Z–octadecenoyl)–sn–
glycerol
374 S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
2 GL01 ” ” ” ” MG(16:0/0:0/0:0) 1–hexadecanoyl–sn–glycerol 348 /
353
P / S
3 GL01 ” ” ” ” MG(17:0/0:0/0:0)[rac]1–heptadecanoyl–rac–glycerol 362 P
4 GL01 ” ” ” ” MG(18:0/0:0/0:0)[rac]1–octadecanoyl–rac–glycerol 376 P / S
5 GL01 ” ” ” ” MG(18:1(11E)/
0:0/0:0)[rac]
1–(11E–octadecenoyl)–rac–
glycerol
357 P
6 GL01 ” ” ” ” MG(18:2(9Z,12Z)
/0:0/0:0)[rac]
1–(9Z,12Z–octadecadienoyl)–
rac–glycerol
372 P / S
7 GL01 ” ” ” ” MG(20:0/0:0/0:0)[rac]1–eicosanoyl–rac–glycerol 387 P / S
8 GL02 Diradyl–
glycerols
Diacyl–
glycerols
DG(12:0/17:2(9Z,12Z)
/0:0)[iso2]
1–dodecanoyl–2–(9Z,12Z–
heptadecadienoyl)–sn–glycerol
505 P
9 GL02 ” ” ” ” DG(12:0/21:0/0:0)
[iso2]
1–dodecanoyl–2–
heneicosanoyl–sn–glycerol
601 P / S
10 GL02 ” ” ” ” DG(12:0/22:2
(13Z,16Z)/0:0)[iso2]
1–dodecanoyl–2–(13Z,16Z–
docosadienoyl)–sn–glycerol
576 /
611
P / S
11 GL02 ” ” ” ” DG(13:0/16:0/0:0)
[iso2]
1–tridecanoyl–2–
hexadecanoyl–sn–glycerol
544 P
12 GL02 ” ” ” ” DG(14:0/16:0/0:0)
[iso2]
1–tetradecanoyl–2–
hexadecanoyl–sn–glycerol
559 P / S
13 GL02 ” ” ” ” DG(14:0/20:0/0:0)
[iso2]
1–tetradecanoyl–2–eicosanoyl–
sn–glycerol
615 P / S
14 GL02 ” ” ” ” DG(14:1(9Z)/
19:0/0:0)[iso2]
1–(9Z–tetradecenoyl)–2–
nonadecanoyl–sn–glycerol
599 S
15 GL02 ” ” ” ” DG(14:1(9Z)/22:2
(13Z,16Z)/0:0)[iso2]
1–(9Z–tetradecenoyl)–2–
(13Z,16Z–docosadienoyl)–sn–
glycerol
637 P
16 GL02 ” ” ” ” DG(15:0/16:0/0:0)
[iso2]
1–pentadecanoyl–2–
hexadecanoyl–sn–glycerol
573 P / S
17 GL02 ” ” ” ” DG(15:0/18:1(9Z)
/0:0)[iso2]
1–pentadecanoyl–2–(9Z–
octadecenoyl)–sn–glycerol
582 P
18 GL02 ” ” ” ” DG(15:1(9Z)/19:0/
0:0)[iso2]
1–(9Z–pentadecenoyl)–2–
nonadecanoyl–sn–glycerol
613 P / S
19 GL02 ” ” ” ” DG(15:1(9Z)/21:0/
0:0)[iso2]
1–(9Z–pentadecenoyl)–2–
heneicosanoyl–sn–glycerol
641 P / S
20 GL02 ” ” ” ” DG(16:0/0:0/16:0)
(d5)
1,3–dihexadecanoyl–2–
hydroxy–glycerolAˆ (d5)
597 P
21 GL02 ” ” ” ” DG(16:0/16:0/0:0)
[rac]
1,2–dihexadecanoyl–rac–
glycerol
587 P / S
22 GL02 ” ” ” ” DG(16:0/16:1(9Z)/
0:0)[iso2]
1–hexadecanoyl–2–(9Z–
hexadecenoyl)–sn–glycerol
585 P / S
23 GL02 ” ” ” ” DG(16:0/19:0/0:0)
[iso2]
1–hexadecanoyl–2–
nonadecanoyl–sn–glycerol
629 P / S
24 GL02 ” ” ” ” DG(16:0/22:0/0:0)
[iso2]
1–hexadecanoyl–2–
docosanoyl–sn–glycerol
671 P / S
25 GL02 ” ” ” ” DG(16:1(9Z)/0:0/
16:1(9Z)) (d5)
1,3–di–(9Z–hexadecenoyl)–2–
hydroxy–glycerol (d5)
552 S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
26 GL02 ” ” ” ” DG(17:0/0:0/17:0)
(d5)
1,3–diheptadecanoyl–2–
hydroxy–glycerolAˆ (d5)
625 S
27 GL02 ” ” ” ” DG(17:2(9Z,12Z)/
19:0/0:0)[iso2]
1–(9Z,12Z–heptadecadienoyl)–
2–nonadecanoyl–sn–glycerol
604 P / S
28 GL02 ” ” ” ” DG(17:2(9Z,12Z)/
21:0/0:0)[iso2]
1–(9Z,12Z–heptadecadienoyl)–
2–heneicosanoyl–sn–glycerol
667 P
29 GL02 ” ” ” ” DG(18:0/18:0/0:0) 1,2–dioctadecanoyl–sn–
glycerol
643 P / S
30 GL02 ” ” ” ” DG(18:1(9Z)/22:1
(13Z)/0:0)[iso2]
1–(9Z–octadecenoyl)–2–(13Z–
docosenoyl)–sn–glycerol
700 P
31 GL02 ” ” ” ” DG(18:2(9Z,12Z)/
22:0/0:0)[iso2]
1–(9Z,12Z–octadecadienoyl)–
2–docosanoyl–sn–glycerol
700 S
32 GL02 ” ” ” ” DG(18:3(6Z,9Z,12Z)/
18:0/0:0)[iso2]
1–(6Z,9Z,12Z–
octadecatrienoyl)–2–
octadecanoyl–sn–glycerol
637 S
33 GL02 ” ” ” ” DG(18:3(9Z,12Z,15Z)
/20:2(11Z,14Z)/0:0)
[iso2]
1–(9Z,12Z,15Z–
octadecatrienoyl)–2–
(11Z,14Z–eicosadienoyl)–
sn–glycerol
661 P
34 GL02 ” ” ” ” DG(18:4(6Z,9Z,
12Z,15Z)/18:0/0:0)
[iso2]
1–(6Z,9Z,12Z,15Z–
octadecatetraenoyl)–2–
octadecanoyl–sn–glycerol
600 P / S
35 GL02 ” ” ” ” DG(18:4(6Z,9Z,12Z,
15Z)/20:0/0:0) [iso2]
1–(6Z,9Z,12Z,15Z–
octadecatetraenoyl)–2–
eicosanoyl–sn–glycerol
663 S
36 GL03 Triradyl–
glycerols
Triacyl–
glycerols
TG(13:0/14:0/14:1
(9Z))[iso6]
1–tridecanoyl–2–
tetradecanoyl–3–(9Z–
tetradecenoyl)–sn–glycerol
894 P
37 GL03 ” ” ” ” TG(13:0/20:0/22:6
(4Z,7Z,10Z,13Z,16Z,
19Z))[iso6]
1–tridecanoyl–2–eicosanoyl–
3–(4Z,7Z,10Z,13Z,16Z, 19Z–
docosahexaenoyl)–sn–glycerol
875 /
894
P / S
38 GL03 ” ” ” ” TG(14:1(9Z)/18:0/
20:2(11Z,14Z)) [iso6]
1–(9Z–tetradecenoyl)–2–
octadecanoyl–3–(11Z,14Z–
eicosadienoyl)–sn–glycerol
933 P
39 GL03 ” ” ” ” TG(14:1(9Z)/18:0/
22:3(10Z,13Z,16Z))
[iso6]
1–(9Z–tetradecenoyl)–
2–octadecanoyl–
3–(10Z,13Z,16Z–
docosatrienoyl)–sn–glycerol
901 S
40 GL03 ” ” ” ” TG(16:0/18:0/22:2
(13Z,16Z))[iso6]
1–hexadecanoyl–2–
octadecanoyl–3–(13Z,16Z–
docosadienoyl)–sn–glycerol
871 P
41 GL03 ” ” ” ” TG(16:1(9Z)/18:0/
18:4(6Z,9Z,12Z,15Z))
[iso6]
1–(9Z–hexadecenoyl)–
2–octadecanoyl–3–
(6Z,9Z,12Z,15Z–
octadecatetraenoyl)–sn–
glycerol
942 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
42 GL03 ” ” ” ” TG(18:0/18:0/20:5
(5Z,8Z,11Z,14Z,17Z))
[iso3]
1,2–dioctadecanoyl–3–
(5Z,8Z,11Z,14Z,17Z–
eicosapentaenoyl)–sn–glycerol
1022 P
43 GL03 ” ” ” ” TG(18:1(9Z)/22:0/
22:6(4Z,7Z,10Z,13Z,
16Z, 19Z))[iso6]
1–(9Z–octadecenoyl)–
2–docosanoyl–3–
(4Z,7Z,10Z,13Z,16Z,19Z–
docosahexaenoyl)–sn–glycerol
965 P
44 GL03 ” ” ” ” Trilauroyl–glycerol 1,2,3–tridodecanoyl–sn–sn–
glycerol
657 P / S
Sphingolipids
(SPs)
1 SP01 Sphingoid
bases
Sphingoid
base homo–
logs and
variants
C16 Sphingosine Hexadecasphing–4E–enine 254 /
272
P / S
2 SP01 Sphingoid
bases
Sphingoid
base
analogs
– 2–amino–14,16–
dimethyloctadecan–3–ol
336 S
3 SP01 ” ” ” ” (4E,8E,10E–d18:3)
sphingosine
sphinga–4E,8E,10E–trienine 296 /
278
P / S
4 SP01 ” ” ” ” (4E,8E,9Me–d19:2)
sphingosine
9–methyl–sphinga–4E,8E–
dienine
294 S
5 SP01 ” ” ” ” (4E,8E,d18:2) sphin-
gosine
sphinga–4E,8E–dienine 280 S
6 SP01 ” ” ” ” 6–
hydroxysphingosine
6–hydroxysphing–4E–enine 338 P
7 SP01 ” ” ” ” Clavepictine B (9aS)–6S–(deca–1,3E–dienyl)–
4S–methyloctahydro–1H–
quinolizin–3R–ol
288 S
8 SP01 ” ” ” ” Lepadin D 5S–(5S–hydroxyoctyl)–2S–
methyldecahydroquinolin–3R–
ol
280 P
9 SP01 ” ” ” ” N,N–dimethyl–
Safingol
2S–
dimethylaminooctadecane–
1,3R–diol
330 S
10 SP01 ” ” ” ” Obscuraminol A 1–deoxy–sphinga–
6Z,9Z,12Z,15Z–tetraenine
278 P / S
11 SP01 ” ” ” ” Prosopinine 6R–(8–hydroxydecyl)–2R–
(hydroxymethyl)–piperidin–
3R–ol
288 S
12 SP02 Ceramides N–acyl–
sphingo–
sines (cera–
mides)
Cer(d18:1/17:0) N–(heptadecanoyl)–sphing–4–
enine
585 P / S
13 SP02 ” ” ” ” Cer(d18:1/18:0) N–(octadecanoyl)–sphing–4–
enine
567 P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
14 SP02 ” ” ” ” Cer(d18:1/22:0) N–(docosanoyl)–sphing–4–
enine
623 P / S
15 SP02 ” ” ” ” Cer(d18:1/23:0) N–(tricosanoyl)–sphing–4–
enine
637 P / S
16 SP02 ” ” ” ” Cer(d18:1/24:0) N–(tetracosanoyl)–sphing–4–
enine
651 P / S
17 SP02 ” ” ” ” Cer(d18:1/24:1(15Z)) N–(15Z–tetracosenoyl)–
sphing–4–enine
649 P / S
18 SP02 ” ” ” ” Cer(d18:1/25:0) N–(pentacosanoyl)–sphing–4–
enine
665 P / S
19 SP02 ” ” ” ” Cer(d18:2/23:0) N–(tricosanoyl)–4E,14Z–
sphingadienine
635 P / S
20 SP02 Ceramides N–acyl–
sphin-
ganines
(dihydroce-
ramides)
Cer(d18:0/14:0) N–(tetradecanoyl)–
sphinganine
513 S
21 SP02 Ceramides N–acyl–4–
hydroxy–
sphin-
ganines
(phytoce-
ramides)
Cer(t18:0/24:0(2OH)) N–(2–hydroxytetracosanoyl)–
4R–hydroxy– sphinganine
723 /
685
P / S
22 SP02 Ceramides Ceramide
1–
phosphates
CerP(d18:1/24:0) N–(tetracosanoyl)–sphing–4–
enine–1–phosphate
763 S
23 SP03 Phospho–
sphin-
golipids
Ceramide
phospho-
cholines
(sphin-
gomyelins)
SM(d18:2/24:1) N–(15Z–tetracosenoyl)–
4E,14Z–sphingadienine–1–
phosphocholine
812 P / S
24 SP03 ” ” ” ” SM(d16:1/18:1) N–(9Z–octadecenoyl)–
hexadecasphing–4–enine–
1–phosphocholine
702 P / S
25 SP03 ” ” ” ” SM(d16:1/22:0) N–(docosanoyl)–
hexadecasphing–4–enine–
1–phosphocholine
782 P
26 SP03 ” ” ” ” SM(d18:0/16:0) N–(hexadecanoyl)–
sphinganine–1–phosphocholine
706 P
27 SP03 ” ” ” ” SM(d18:2/18:0) N–(octadecanoyl)–
4E,14Z–sphingadienine–1–
phosphocholine
730 P / S
28 SP03 ” ” ” ” SM(d16:1/18:0) N–(octadecanoyl)–
hexadecasphing–4–enine–
1–phosphocholine
704 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
29 SP03 ” ” ” ” SM(d18:1/18:0) N–(octadecanoyl)–sphing–4–
enine–1–phosphocholine
732 P / S
30 SP03 ” ” ” ” SM(d18:1/24:0) N–(tetracosanoyl)–sphing–4–
enine–1–phosphocholine
816 P / S
31 SP03 ” ” ” ” SM(d18:1/23:0) N–(tricosanoyl)–sphing–4–
enine–1–phosphocholine
802 S
32 SP05 Neutral
glycosphin-
golipids
GalNAcβ1–
3Galα1–
4Galβ1–
4Glc–
(Globo
series)
Galα1–4Galβ1–4Glcβ–
Cer(d18:1/24:0)
975 P / S
33 SP05 Neutral
glycosphin-
golipids
Etn–1–P–
Cer(d14:1/18:0)
690 P
34 SP05 ” ” GalCer(d18:1/16:0) 718 P / S
35 SP05 ” ” GalCer(d18:1/20:0) 779 P
36 SP06 Acidic
glycosphin-
golipids
Ganglio–
sides
– Galβ1–3GalNAcβ1–
4(NeuAcα2–3)Galβ1–4Glcβ–
Cer(d18:1/16:0)
1154 P / S
37 SP06 ” ” ” ” – Galβ1–3GalNAcβ1–
4(NeuAcα2–3)Galβ1–4Glcβ–
Cer(d18:1/18:0)
1182 P / S
38 SP06 Acidic
glycosphin-
golipids
Sulfoglyco–
sphin-
golipids
(sulfatides)
(3’–sulfo)Galβ–
Cer(d18:1/16:0)
N–hexadecanoyl–1–β–(3’–
sulfo)–glucosyl–sphing–4–
enine
803 P
39 SP06 Acidic
glycosphin-
golipids
Phospho–
glycosphin-
golipids
GlcNα1–6Ins–1–P–
Cer(t18:0/26:0)
N–(hexacosanoyl)–4R–
hydroxysphinganine–1–
phospho–(1’–[2–amino–2–
deoxy–D–glucopyranosyl–α1–
6–D–myo–inositol])
971 S
Prenol
Lipids
(PRs)
1 PR01 Isoprenoids C10 iso–
prenoids
(monoter-
penes)
(+)–trans–allethrin 2–methyl–4–oxo–3–(prop–2–
en–1–yl)cyclopent–2–en–1–yl
(1R,3R)–2,2–dimethyl–3–
(2–methylprop–1–en–1–
yl)cyclopropanecarboxylate
285 P
2 PR01 ” ” ” ” (+)–β–Phellandrene – 159 P
3 PR01 ” ” ” ” (4R,6R)–cis–Carveol – 153 P / S
4 PR01 ” ” ” ” Iridotrial – 183 S
5 PR01 ” ” ” ” β–Dolabrin – 180 P
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
6 PR01 Isoprenoids C15 iso–
prenoids
(sesquiter-
penes)
(–)–Solavetivone – 219 P
7 PR01 ” ” ” ” (+)–Blennin D – 284 /
267
P / S
8 PR01 ” ” ” ” 5–(1–hydroxybutan–
2–yl)isolongifol–4–
ene
– 309 S
9 PR01 ” ” ” ” 5–(2–
methoxyethyl)iso–
longifol–5–ene
(1R,8S)–5–(2–
methoxyethyl)–2,2,7,7–
tetramethyltricyclo[6.2.1.0(1,6)]
undec–5–ene
263 /
280
P / S
10 PR01 ” ” ” ” Acutifolane A – 295 S
11 PR01 ” ” ” ” alantolactone (3aR,5S,8aR,9aR)–5,8a–
dimethyl–3–methylidene–
3a,5,6,7,8,8a,9,9a–
octahydronaphtho[2,3–
b]furan–2(3H)–one
265 P
12 PR01 ” ” ” ” Botrydial – 293 P
13 PR01 ” ” ” ” Dendrobane A – 253 S
14 PR01 ” ” ” ” Emmotin A – 279 P / S
15 PR01 ” ” ” ” Juvenile hormone III – 249 /
284
P / S
16 PR01 ” ” ” ” Latia luciferin (1E)–2–methyl–4–(2,6,6–
trimethylcyclohex–1–en–1–
yl)but–1–enylAˆ formate
237 P
17 PR01 ” ” ” ” Sugeonol 8S–hydroxy–1,4R,9,9–
tetramethyl–3,4,5,6,7,8–
hexahydro–3a(R),7–
methanoazulen–2–one
235 P / S
18 PR01 ” ” ” ” Sugeonyl acetate 8S–acetoxy–1,4R,9,9–
tetramethyl–3,4,5,6,7,8–
hexahydro–3a(R),7–
methanoazulen–2–one
294 P / S
19 PR01 Isoprenoids C20 iso–
prenoids
(diter-
penes)
(–)–Asbestinine 2 – 494 P
20 PR01 ” ” ” ” Eremolactone – 321 /
316
P / S
21 PR01 ” ” ” ” gibberellin A17 – 396 P
22 PR01 ” ” ” ” Neoabietic acid – 303 P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
23 PR01 Isoprenoids C25 iso–
prenoids
(sesterter-
penes)
(–)–Ceriferol 1 – 374 P
24 PR01 Isoprenoids C30 iso–
prenoids
(triter-
penes)
gypsogenin 3β–hydroxy–23–oxoolean–12–
en–28–oic acid
488 P
25 PR01 Isoprenoids C40 iso–
prenoids
(tetrater-
penes)
4,4’–Diapolycopene – 383 P / S
26 PR01 ” ” ” ” 4,4’–Diapophytoene/
Dehydrosqualene
– 409 S
27 PR01 ” ” ” ” 4’–Apo–3,4–
didehydrolycopene/
(4–Apo–3’,4’–
didehydrolycopene)
– 484 P
28 PR01 ” ” ” ” 7,8–
Didehydroastaxanthin
– 612 P
29 PR01 ” ” ” ” Spheroidene – 587 S
30 PR01 Isoprenoids Retinoids 11–cis–retinal – 302 S
31 PR01 ” ” ” ” 13–cis–retinoic acid,
Isotretinoin
– 318 /
301
P / S
32 PR01 ” ” ” ” 19–Oxo–9–cis–
retinoic acid
– 315 P
33 PR01 ” ” ” ” 9–cis–retinol 9Z–retinol 304 P / S
34 PR01 ” ” ” ” All–Trans–3,4–
Didehydro–Retinoic
acid
– 316 S
35 PR02 Quinones
and hydro-
quinones
UbiquinonesPlastoquinol–1 2,3–dimethyl–5–(3–
methylbut–2–enyl)–benzene–
1,4–diol
362 /
345
P / S
36 PR02 Quinones
and hydro-
quinones
Vitamin E alhpa–
tocopheronolactone
– 279 P / S
37 PR04 Hopanoids – Diploptene Hop–22(29)–ene 428 S
Polyketides
(PKs)
1 PK01 Linear
polyketides
– Trichostatin – 325 S
2 PK04 Macrolides
and lactone
polyketides
– 6–deoxyerythronolide
B
– 387 /
404
P / S
3 PK04 ” ” – Zearalenone – 319 P / S
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Table A.1: Complete canine plasma (P) and serum (S) lipidome using untargeted LC/MS, no
internal standards, lipid extraction by Matyash et al. (2008) and lipid identification by LipidMaps.
Nr. Main
Cat.
Main Class Sub Class Common Name Systematic Name m/z
mea-
sured
Plasma
(P) /
Serum
(S)
4 PK12 Flavonoids Isoflavans Machaerol C 6,8,2’–Trihydroxy–7,3’,4’–
trimethoxyisoflavan
331 P / S
5 PK12 Flavonoids Chalcones
and dihy-
drochal-
cones
– 1–(2,5–dihydro–6,8–
dihydroxy–3–methyl–1–
benzoxepin–7–yl)–3–phenyl–
1–propanone
325 P / S
6 PK12 ” ” ” ” Crotaoprostrin 2’–Hydroxy–3,4,5–
methoxychalcone
332 P
7 PK12 ” ” ” ” Desmosdumotin C – 313 P / S
8 PK12 ” ” ” ” Pongagallone A – 353 P
9 PK12 ” ” ” ” Prorepensin 5,3’–Digeranyl–3,4,2’,4’–
tetrahydroxychalcone
562 P / S
10 PK12 ” ” ” ” Syzygiol – 517 /
332
P / S
11 PK12 Flavonoids Flavanones Brosimacutin C – 360 P / S
12 PK13 Aromatic
polyketides
Diphenyl
ethers,
biphenyls,
diben-
zyls and
stilbenes
Glepidotin C – 331 P
Saccharolipids
(SLs)
1 SL05 Other acyl
sugars
– – 6–O–(3R,4–dihydroxy–2–
methylene–butanoyl)–β–D–
glucopyranose
312 S
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A.2 Plasma vs. Serum: QQ–Plots
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Figure A.1: QQ–Plots of canine lithium heparin plasma before treatment with prednisolone, indi-
cating normal distribution of lipids (for biological samples) within the six dogs.
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Figure A.2: QQ–Plots of canine serum before treatment with prednisolone, indicating normal
distribution of lipids (for biological samples) within the six dogs.
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A.3 Prednisolone Treatment: QQ-Plots
Six healthy Beagles were treated with prednisolone and blood was taken before (A) and
after (B) treatment. Using logarithmic transformation, results were presumed to be nor-
mally distributed regarding slight biological variations.
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Figure A.3: QQ–Plot using plasma from dog 1–6. A = before treatment. B = after
treatment. Results can be presumed as normally distributed after log 2 transformation.
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Figure A.4: QQ–Plot using serum from dog 1–6. A = before treatment. B = after treat-
ment. Results can be presumed as normally distributed after log 2 transformation.
